U.S. patent application number 13/552795 was filed with the patent office on 2012-11-08 for imidazopyridazinecarbonitriles useful as kinase inhibitors.
This patent application is currently assigned to Bristol-Myers Squibb Company. Invention is credited to Libing Chen, Brian E. Fink, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Andrew James Nation, Litai H. Zhang, Yufen Zhao.
Application Number | 20120283241 13/552795 |
Document ID | / |
Family ID | 41718919 |
Filed Date | 2012-11-08 |
United States Patent
Application |
20120283241 |
Kind Code |
A1 |
Fink; Brian E. ; et
al. |
November 8, 2012 |
IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
Abstract
The invention provides compounds of Formula (I) ##STR00001## and
pharmaceutically acceptable salts thereof. The Formula (I)
imidazopyridazines inhibit protein kinase activity thereby making
them useful as anticancer agents.
Inventors: |
Fink; Brian E.; (Yardley,
PA) ; Chen; Libing; (Newtown, PA) ; Gavai;
Ashvinikumar V.; (Princeton Junction, NJ) ; He;
Liqi; (Furlong, PA) ; Kim; Soong-Hoon;
(Titusville, NJ) ; Nation; Andrew James; (Scotch
Plains, NJ) ; Zhao; Yufen; (Pennington, NJ) ;
Zhang; Litai H.; (Lawrenceville, NJ) |
Assignee: |
Bristol-Myers Squibb
Company
|
Family ID: |
41718919 |
Appl. No.: |
13/552795 |
Filed: |
July 19, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12575589 |
Oct 8, 2009 |
8252795 |
|
|
13552795 |
|
|
|
|
61104045 |
Oct 9, 2008 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
514/230.5; 514/233.2; 514/248; 544/105; 544/117; 544/236 |
Current CPC
Class: |
C07D 498/04 20130101;
A61P 15/00 20180101; A61P 43/00 20180101; A61P 5/14 20180101; A61P
35/02 20180101; A61P 1/04 20180101; A61P 13/08 20180101; A61P 29/00
20180101; C07D 487/04 20130101; A61P 11/00 20180101; A61P 19/02
20180101; A61P 17/06 20180101; A61P 25/00 20180101; A61P 1/18
20180101; A61P 9/00 20180101; A61P 35/00 20180101 |
Class at
Publication: |
514/210.21 ;
544/236; 514/248; 544/117; 514/233.2; 544/105; 514/230.5 |
International
Class: |
A61K 31/5025 20060101
A61K031/5025; A61P 35/00 20060101 A61P035/00; A61P 17/06 20060101
A61P017/06; A61K 31/538 20060101 A61K031/538; A61P 35/02 20060101
A61P035/02; A61K 31/5377 20060101 A61K031/5377; C07D 498/04
20060101 C07D498/04; C07D 487/04 20060101 C07D487/04; A61P 29/00
20060101 A61P029/00 |
Claims
1. A compound according to Formula (I): ##STR00468## or a
pharmaceutically acceptable salt thereof, wherein R.sub.1 is
selected from H, F, Cl, Br, CN, and C.sub.1-6alkyl; R.sub.2 is
selected from aryl substituted with 0-5 R.sub.2a and heteroaryl
substituted with 0-5 R.sub.2a; R.sub.2a, at each occurrence, is
independently selected from H, F, Cl, Br, .dbd.O, CN, NO.sub.2,
--OR.sub.b, --S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d,
--NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, C.sub.1-6 alkyl substituted with 0-5
R.sub.e, --(CR.sub.2bR.sub.2c).sub.r--C.sub.3-6carbocyclyl
substituted with 0-5 R.sub.e, and
--(CR.sub.2bR.sub.2c).sub.r-heterocyclyl substituted with 0-5
R.sub.e; R.sub.2b, at each occurrence, is independently selected
from H and C.sub.1-6alkyl substituted with 0-5 R.sub.e; R.sub.2c,
at each occurrence, is independently selected from H and
C.sub.1-6alkyl substituted with 0-5 R.sub.e; R.sub.3 is selected
from H, F, Cl, Br, CN, --OR.sub.b, --NR.sub.aR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2R.sub.c,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b, and
C.sub.1-6alkyl substituted with 0-5 R.sub.e; R.sub.4 is selected
from H, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
--(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.pR.sub.c,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.2NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6carbocyclyl substituted with
0-5 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-5 R.sub.4a; R.sub.4a, at each occurrence, is independently
selected from F, Cl, Br, C.sub.1-6alkyl substituted with 0-5
R.sub.e, C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, .dbd.O, CN,
--SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a;
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl; R.sub.4b, at each occurrence, is independently selected from
H and C.sub.1-6alkyl substituted with 0-5 R.sub.e; R.sub.4c, at
each occurrence, is independently selected from H and
C.sub.1-6alkyl substituted with 0-5 R.sub.e; R.sub.5 is selected
from hydrogen and C.sub.1-6alkyl substituted with 0-5 R.sub.e;
R.sub.6 is selected from hydrogen and C.sub.1-6alkyl substituted
with 0-5 R.sub.e; R.sub.a, at each occurrence, is independently
selected from H, CN, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
C.sub.2-6 alkenyl substituted with 0-5 R.sub.e, C.sub.2-6 alkynyl
substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; or R.sub.a and R.sub.a together with the nitrogen atom to
which they are both attached form a heterocyclic ring substituted
with 0-5 R.sub.e; R.sub.b, at each occurrence, is independently
selected from H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
C.sub.2-6 alkenyl substituted with 0-5 R.sub.e, C.sub.2-6 alkynyl
substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; R.sub.c, at each occurrence, is independently selected
from C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.2-6alkenyl
substituted with 0-5 R.sub.e, C.sub.2-6alkynyl substituted with 0-5
R.sub.e, C.sub.3-6carbocyclyl, and heterocyclyl; R.sub.d, at each
occurrence, is independently selected from H, C.sub.1-6 alkyl
substituted with 0-5 R.sub.e, C.sub.2-6alkenyl substituted with 0-5
R.sub.e, C.sub.2-6alkynyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; R.sub.e, at each occurrence, is independently selected
from C.sub.1-6 alkyl substituted with 0-5 R.sub.f, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, --(CH.sub.2).sub.r--C.sub.3-6
cycloalkyl, F, Cl, Br, CN, NO.sub.2, .dbd.O, CO.sub.2H,
--(CH.sub.2).sub.rOC.sub.1-5 alkyl, --(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f; R.sub.f, at each occurrence, is
independently selected from H, C.sub.1-5 alkyl, C.sub.3-6
cycloalkyl, and phenyl, or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring; p, at each occurrence, is independently selected from zero,
1, and 2; and r, at each occurrence, is independently selected from
zero, 1, 2, 3, and 4.
2. The compound according to claim 1 of the Formula (II) or salt
thereof, ##STR00469## wherein R.sub.2 is selected from aryl
substituted with 0-4 R.sub.2a and heteroaryl substituted with 0-4
R.sub.2a, wherein said heteroaryl comprises carbon atoms and 1-4
heteroatoms selected from N, O, and S(O).sub.p; R.sub.2a, at each
occurrence, is independently selected from H, F, Cl, Br, .dbd.O,
CN, --OR.sub.b, --S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d,
--NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--NR.sub.2S(O).sub.2R.sub.c, C.sub.1-4 alkyl substituted with 0-3
R.sub.e, --(CR.sub.2bR.sub.2c).sub.r--C.sub.3-6carbocyclyl
substituted with 0-3 R.sub.e, and
--(CR.sub.2bR.sub.2c).sub.r-heterocyclyl substituted with 0-3
R.sub.e; R.sub.2b, at each occurrence, is independently selected
from H and C.sub.1-4alkyl; R.sub.2c, at each occurrence, is
independently selected from H and C.sub.1-4alkyl; R.sub.4 is
selected from H, C.sub.1-4alkyl substituted with 0-5 R.sub.e,
--(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.pR.sub.c,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6carbocyclyl substituted with
0-4 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-4 R.sub.4a; R.sub.4a, at each occurrence, is independently
selected from F, Cl, Br, C.sub.1-6alkyl substituted with 0-3
R.sub.e, C.sub.2-6alkynyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2R.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl; R.sub.4b, at each occurrence, is independently selected from
H and C.sub.1-4alkyl; R.sub.4c, at each occurrence, is
independently selected from H and C.sub.1-4alkyl; and r, at each
occurrence, is independently selected from zero, 1, 2, and 3.
3. The compound according to claim 2, wherein R.sub.2 is selected
from 4- to 7-membered monocyclic or 8- to 12-membered bicyclic aryl
substituted with 1-4 R.sub.2a and 4- to 7-membered monocyclic or 7-
to 12-membered bicyclic heteroaryl substituted with 0-4 R.sub.2a;
R.sub.2a, at each occurrence, is independently selected from H, F,
Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --OC(.dbd.O)NR.sub.aR.sub.a,
--NHC(.dbd.O)NR.sub.aR.sub.a, --(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, or C.sub.1-6 alkyl substituted with 0-3
R.sub.e, --(CH.sub.2).sub.r--C.sub.3-6 carbocyclyl substituted with
0-3 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with
0-3 R.sub.e; R.sub.4 is selected from H, C.sub.1-4alkyl substituted
with 0-5 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rS(O).sub.pR.sub.c,
--(CH.sub.2).sub.rC(.dbd.O)R.sub.d,
--(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CH.sub.2c).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--(CH.sub.2).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CH.sub.2).sub.r--C.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e;
R.sub.4a, at each occurrence, is independently selected from
C.sub.1-6alkyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2R.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NHC(.dbd.O)R.sub.d, --NHC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl.
4. The compound according to claim 3 of the Formula (III) or salt
thereof, ##STR00470## wherein R.sub.2a, at each occurrence, is
independently selected from H, F, Cl, Br, .dbd.O, CN, --OR.sub.b,
--S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --OC(.dbd.O)NR.sub.aR.sub.a,
--NHC(.dbd.O)NR.sub.aR.sub.a, --(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, or C.sub.1-4 alkyl substituted with 0-3
R.sub.e, --(CH.sub.2).sub.r--C.sub.3-6 carbocyclyl substituted with
0-3 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with
0-3 R.sub.e; R.sub.4 is selected from H, C.sub.1-6alkyl substituted
with 0-5 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.r--C.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.4a;
R.sub.4a, at each occurrence, is independently selected from
C.sub.1-6alkyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c, --OR.sub.b,
--NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)NR.sub.aR.sub.a, --C(.dbd.O)OR.sub.b,
--C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl R.sub.a, at each occurrence, is independently selected from H,
CN, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; or R.sub.a and R.sub.a together with the nitrogen atom to
which they are both attached form a heterocyclic ring substituted
with 0-5 R.sub.e; R.sub.b, at each occurrence, is independently
selected from H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; R.sub.c, at each occurrence, is independently selected
from C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
C.sub.3-6carbocyclyl, and heterocyclyl; R.sub.d, at each
occurrence, is independently selected from H, C.sub.1-6 alkyl
substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; R.sub.e, at each occurrence, is independently selected
from C.sub.1-6 alkyl substituted with 0-5 R.sub.f,
--(CH.sub.2).sub.r--C.sub.3-6 cycloalkyl, F, Cl, Br, CN, NO.sub.2,
.dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5alkyl,
--(CH.sub.2).sub.rOH, SH, and --(CH.sub.2).sub.rNR.sub.fR.sub.f;
R.sub.f, at each occurrence, is independently selected from H,
C.sub.1-5 alkyl, and phenyl, or R.sub.f and R.sub.f together with
the nitrogen atom to which they are both attached form a
heterocyclic ring; and n, at each occurrence, is independently
selected from zero, 1, 2, 3, and 4.
5. The compound according to claim 4, wherein R.sub.4 is selected
from H, C.sub.1-6alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.rOR.sub.b; --(CH.sub.2).sub.rNR.sub.aR.sub.a,
--C.sub.3-6cycloalkyl substituted with 0-3 R.sub.4a, aryl
substituted with 0-3 R.sub.4a, 4-, 5-, or 6-membered non-aromatic
monocyclic heterocyclyl substituted with 0-3 R.sub.4a; and 5- to
6-membered heteroaryl substituted with 0-3 R.sub.4a; R.sub.4a, at
each occurrence, is independently selected from C.sub.1-6alkyl
substituted with 0-3 R.sub.e, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NHC(.dbd.O)R.sub.d; --NHC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl; R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a monocyclic heterocyclic ring substituted
with 0-3 R.sub.e; R.sub.b, at each occurrence, is independently
selected from H and C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
and heterocyclyl; R.sub.c, at each occurrence, is independently
selected from C.sub.1-4 alkyl substituted with 0-3 R.sub.e and
heterocyclyl; R.sub.d, at each occurrence, is independently
selected from H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-3
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e; R.sub.e, at each occurrence, is independently selected
from C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, CN,
NO.sub.2, .dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5 alkyl,
--(CH.sub.2).sub.rOH, SH, and --(CH.sub.2).sub.rNR.sub.fR.sub.f;
R.sub.f, at each occurrence, is independently selected from H and
C.sub.1-4alkyl or R.sub.f and R.sub.f together with the nitrogen
atom to which they are both attached form a heterocyclic ring.
6. The compound according to claim 4, wherein R.sub.2a, at each
occurrence, is independently selected from H, F, Cl, Br, CN,
.dbd.O, O--C.sub.1-4alkyl substituted with 0-3 R.sub.e,
--O(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl
--O--(CH.sub.2).sub.rOC.sub.1-4alkyl,
--O(CH.sub.2).sub.r-heterocyclyl, --S(O).sub.2C.sub.1-4alkyl,
--C(.dbd.O)C.sub.1-4alkyl, --NH.sub.2, --N(C.sub.1-4alkyl).sub.2,
--NHCN, --NR.sub.a(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl,
--NR.sub.a(CH.sub.2).sub.rOC.sub.1-4alkyl,
--NH(CH.sub.2).sub.r-heterocyclyl,
--(CH.sub.2).sub.rC(.dbd.O)NH.sub.2, --C(.dbd.O)NH-heterocyclyl,
--C(.dbd.O)NH(CH.sub.2).sub.rN(C.sub.1-4alkyl).sub.2,
--C(.dbd.O)-heterocyclyl, --NHC(.dbd.O)C.sub.1-4alkyl,
--NHC(.dbd.O)OC.sub.1-4alkyl, --NHC(.dbd.O)NHC.sub.1-4alkyl,
C(.dbd.O)OC.sub.1-4alkyl, --(CH.sub.2).sub.rC(.dbd.O)OH,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH-heterocyclyl,
--S(O).sub.2NHC.sub.1-4alkyl, --S(O).sub.2-heterocyclyl substituted
with 0-3 R.sub.e, --NH.sub.2S(O).sub.2NH.sub.2,
--NHS(O).sub.2C.sub.1-4alkyl, C.sub.1-4alkyl, CF.sub.3,
--(CH.sub.2).sub.rOH, C.sub.3-6carbocyclyl substituted with 0-3
R.sub.e, non-aromatic heterocyclyl substituted with 0-3 R.sub.e,
and 5- or 6-membered heteroaryl substituted with 0-3 R.sub.e.
7. The compound according to claim 3, wherein R.sub.2 is selected
from ##STR00471## represents an optional bond; R.sub.2ab, at each
occurrence, is independently selected from C.sub.1-4 alkyl
substituted with 0-3 R.sub.e, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, C(.dbd.O)OR.sub.b; and m, at each occurrence,
is independently selected from zero, 1, 2, and 3.
8. The compound according to claim 7, wherein R.sub.4 is selected
from H, C.sub.1-4alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.rOR.sub.b, --(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.rC.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.4a.
9. The compound according to claim 2, wherein R.sub.2 is selected
from phenyl substituted with 1-3 R.sub.2a and heteroaryl
substituted with 0-3 R.sub.2a; R.sub.2a, at each occurrence, is
independently selected from H, F, Cl, Br, .dbd.O, CN, --OR.sub.b,
--S(O).sub.2R.sub.c, --C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --NHC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c,
C.sub.1-4alkyl substituted with 0-3 R.sub.e, non-aromatic
heterocyclyl substituted with 0-3 R.sub.e, and heteroaryl
substituted with 0-3 R.sub.e; R.sub.4 is selected from H,
C.sub.1-6alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.rOR.sub.b, --C.sub.3-6cycloalkyl substituted with
0-3 R.sub.4a, aryl substituted with 0-3 R.sub.4a,
--(CH.sub.2).sub.r-4, 5-, or 6-membered saturated monocyclic
heterocyclyl substituted with 0-3 R.sub.4a, and
--(CH.sub.2).sub.r-5- to 6-membered heteroaryl substituted with 0-3
R.sub.4a; R.sub.4a, at each occurrence, is independently selected
from C.sub.1-4alkyl substituted with 0-3 R.sub.e, --OR.sub.b, and
C(.dbd.O)NR.sub.aR.sub.a; R.sub.a, at each occurrence, is
independently selected from H, CN, C.sub.1-4 alkyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e; or R.sub.a and R.sub.a together with the nitrogen atom to
which they are both attached form a heterocyclic ring, having 1 to
3 heteroatoms selected from N, O, S, and substituted with 0-3
R.sub.e; R.sub.b, at each occurrence, is independently selected
from H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl; R.sub.c, at each occurrence, is independently
C.sub.1-4 alkyl substituted with 0-3 R.sub.e; R.sub.d, at each
occurrence, is independently selected from H and C.sub.1-4 alkyl
substituted with 0-3 R.sub.e; R.sub.e, at each occurrence, is
independently selected from C.sub.1-4 alkyl substituted with 0-4
R.sub.f, F, Cl, Br, .dbd.O, --(CH.sub.2).sub.rOC.sub.1-5 alkyl,
--(CH.sub.2).sub.rOH, and --(CH.sub.2).sub.rNR.sub.fR.sub.f; and
R.sub.f, at each occurrence, is independently selected from H and
C.sub.1-3alkyl or R.sub.f and R.sub.f together with the nitrogen
atom to which they are both attached form a heterocyclic ring; r,
at each occurrence, is independently selected from zero, 1, 2, and
3; and m, at each occurrence, is independently selected from zero,
1, 2, and 3.
10. A pharmaceutical composition comprising one or more compounds
of claim 1 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising one or more compounds
according to claim 1 in combination with a pharmaceutically
acceptable carrier and one or more other anti-cancer or cytotoxic
agents.
12. A method of inhibiting angiogenesis comprising administering to
a mammalian species in need thereof, a therapeutically effective
amount of one or more compounds according to claim 1.
13. A method for treating cancer, psoriasis and rheumatoid
arthritis, comprising administering to a mammalian species in need
thereof, a therapeutically effective amount of one or more
compounds according to claim 1.
14. The method of claim 13 wherein the cancer is carcinoma of the
prostate, pancreatic ductal adenocarcinoma, breast, colon, lung,
ovary, pancreas and thyroid, neuroblastoma, glioblastoma,
medulloblastoma, melanoma, multiple myeloma, and/or acute
myelogenous leukemia (AML).
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 12/575,589, filed Oct. 8, 2009, and claims priority
benefit of U.S. provisional application Ser. No. 61/104,045, filed
on Oct. 9, 2008, the disclosure of which is hereby incorporated by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The invention relates to novel substituted imidazopyridazine
compounds useful as protein kinase inhibitors. The invention also
relates to methods of using the compounds in the treatment of
proliferative and other types of diseases and to pharmaceutical
compositions containing the compounds.
BACKGROUND OF THE INVENTION
[0003] The invention relates to fused heterocyclic compounds which
inhibit protein kinase enzymes, compositions which contain protein
kinase inhibiting compounds and methods of using inhibitors of
protein kinase enzymes to treat diseases which are characterized by
an overexpression or upregulation of protein kinases. Protein
kinases mediate intracellular signal transduction. They do this by
effecting a phosphoryl transfer from a nucleoside triphosphate to a
protein acceptor that is involved in a signaling pathway. There are
a number of kinases and pathways through which extracellular and
other stimuli cause a variety of cellular responses to occur inside
the cell. An extracellular stimulus may effect one or more cellular
responses related to cell growth, migration, differentiation,
secretion of hormones, activation of transcription factors, muscle
contraction, glucose metabolism, control of protein synthesis and
regulation of cell cycle.
[0004] Many diseases are associated with abnormal cellular
responses triggered by protein kinase-mediated events. These
diseases include autoimmune diseases, inflammatory diseases,
neurological and neurodegenerative diseases, cancer, cardiovascular
diseases, allergies and asthma, Alzheimer's disease or
hormone-related diseases. Accordingly, there has been a substantial
effort in medicinal chemistry to find protein kinase inhibitors
that are effective as therapeutic agents.
[0005] Serine/threonine kinases are a class of protein kinases that
are among the most promising drug targets for future small molecule
inhibitors. Inhibition of serine/threonine kinases is likely to
have relevance to the treatment of cancer, diabetes and a variety
of inflammatory disorders. The successful development of
GLEEVEC.RTM. as a Bcr/Abl protein kinase inhibitor has provided
further evidence that protein kinases including protein kinase CK2
are valid drug targets for potential cancer therapies.
[0006] Protein kinase CK2 (formerly known as casein kinase II) is a
highly conserved serine/threonine kinase. Protein kinase CK2 is
ubiquitously distributed and constitutively active in eukaryotes.
In mammals, the enzyme exists in two isozymic forms due to
variations in the catalytic subunits of the enzyme. The CK2
holoenzyme is a heterotetrameric complex composed of two catalytic
.alpha. (CK2A1) subunits or .alpha.' (CK2A2) subunits and two
regulatory .beta.-subunits. The formation of CK2 complexes
containing the catalytic subunits requires dimerization of the
regulatory .beta.-subunits. CK2 interacts with a variety of
cellular proteins and has been implicated in cell replication such
as cell proliferation and differentiation, cellular survival, and
tumorigenesis. With respect to tumorigenesis, protein kinase CK2
has been implicated in kidney tumors (Stalter et al., "Asymmetric
expression of protein kinase CK2 subunits in human kidney tumors",
Biochem. Biophys. Res. Commun., 202:141-147 (1994)), mammary gland
tumors (Landesman-Bollag et al., "Protein kinase CK2 in mammary
gland tumorigenesis", Oncology, 20:3247-3257 (2001)), lung
carcinoma (Daya-Makin et al., "Activation of a tumor-associated
protein kinase (p40TAK) and casein kinase II in human squamous cell
carcinomas and adenocarcinomas of the lung", Cancer Res.,
54:2262-2268 (1994)), head and neck carcinoma (Faust et al.,
"Antisense oligonucleotides against protein kinase CK2-.alpha.
inhibit growth of squamous cell carcinoma of the head and neck in
vitro", Head Neck, 22:341-346 (2000)), and prostate cancer (Wang et
al., "Role of protein kinase CK2 in the regulation of tumor
necrosis factor-related apoptosis inducing ligand-induced apoptosis
in prostate cancer cells", Cancer Res., 66:2242-2249 (2006)).
[0007] Inhibitors of protein kinases are widely sought and small
molecule compounds capable of modulating protein kinases have been
reported. For example, pyrazolotriazines as CK2 kinase inhibitors
were reported in Nie et al. (Bioorganic & Medicinal Chemistry
Letters, 17:4191-4195 (2007); 18:619-623 (2008)) and
imidazopyridazines as IRAK kinase modulators were reported in PCT
Publication WO 2008/030579. In addition, certain imidazopyridazine
compounds were disclosed in WO 2007/038314, published Apr. 5, 2007,
WO 2008/0045536, published Feb. 21, 2008, both assigned to the
present assignee. The present invention relates to a new class of
imidazopyridazine-carbonitriles found to be effective inhibitors of
protein kinases, particularly the CK2 kinase. These novel compounds
are provided to be useful as pharmaceuticals with desirable
stability, bioavailability, therapeutic index and toxicity values
that are important to their drugability.
SUMMARY OF THE INVENTION
[0008] The invention is directed to fused heterocyclic compounds of
Formulae (I)-(X) or stereoisomers, tautomers, pharmaceutically
acceptable salts, solvates or prodrugs thereof, which inhibit
protein kinase enzymes, especially protein kinase CK2 for the
treatment of cancer.
[0009] The present invention also provides processes and
intermediates for making the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrugs thereof.
[0010] The present invention also provides pharmaceutical
compositions comprising a pharmaceutically acceptable carrier and
at least one of the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrugs thereof.
[0011] The present invention also provides methods for inhibiting
the activity of protein kinase CK2 comprising administering to a
host in need of such treatment a therapeutically effective amount
of at least one of the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrugs thereof.
[0012] The present invention also provides methods for inhibiting
angiogenesis or treating cancers comprising administering to a host
in need of such treatment a therapeutically effective amount of at
least one of the compounds of the present invention or
stereoisomers, tautomers, pharmaceutically acceptable salts,
solvates, or prodrugs thereof.
[0013] The present invention also provides the compounds of the
present invention or stereoisomers, tautomers, pharmaceutically
acceptable salts, solvates, or prodrugs thereof, for use in
therapy.
[0014] The present invention also provides the use of the compounds
of the present invention or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
in preparing a medicament for the treatment of cancer in a human
patient, particularly a cancer receptive to treatment via
inhibition of the CK2 enzyme.
[0015] These and other features of the invention will be set forth
in the expanded form as the disclosure continues.
DETAILED DESCRIPTION OF THE INVENTION
[0016] The invention provides for novel imidazopyridazine compounds
useful as therapeutic agents, pharmaceutical compositions employing
such novel compounds and for methods of using such compounds.
[0017] In accordance with the invention, there are disclosed
compounds of Formula (I) including enantiomers, diastereomers,
tautomers, pharmaceutically-acceptable salts, prodrugs, hydrates,
or solvates thereof,
##STR00002##
wherein
[0018] R.sub.1 is selected from H, F, Cl, Br, CN, and
C.sub.1-6alkyl;
[0019] R.sub.2 is selected from aryl substituted with 0-5 R.sub.2a
and heteroaryl substituted with 0-5 R.sub.2a;
[0020] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, NO.sub.2, --OR.sub.b,
--S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, C.sub.1-6 alkyl substituted with 0-5
R.sub.e, --(CR.sub.2bR.sub.2c).sub.r--C.sub.3-6carbocyclyl
substituted with 0-5 R.sub.e, and
--(CR.sub.2bR.sub.2c).sub.r-heterocyclyl substituted with 0-5
R.sub.e;
[0021] R.sub.2b, at each occurrence, is independently selected from
H and C.sub.1-6alkyl substituted with 0-5 R.sub.e;
[0022] R.sub.2c, at each occurrence, is independently selected from
H and C.sub.1-6alkyl substituted with 0-5 R.sub.e;
[0023] R.sub.3 is selected from H, F, Cl, Br, CN, --OR.sub.b,
--NR.sub.aR.sub.a, --C(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --NR.sub.aC(.dbd.O)R.sub.d,
--NR.sub.aC(.dbd.O)OR.sub.b, and C.sub.1-6alkyl substituted with
0-5 R.sub.e;
[0024] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-5 R.sub.e, --(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.pR.sub.c,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.2NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6carbocyclyl substituted with
0-5 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-5 R.sub.4a;
[0025] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, .dbd.O, CN,
--SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0026] R.sub.4b, at each occurrence, is independently selected from
H and C.sub.1-6alkyl substituted with 0-5 R.sub.e;
[0027] R.sub.4c, at each occurrence, is independently selected from
H and C.sub.1-6alkyl substituted with 0-5 R.sub.e;
[0028] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0029] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0030] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.2-6
alkenyl substituted with 0-5 R.sub.e, C.sub.2-6 alkynyl substituted
with 0-5 R.sub.e, --(CH.sub.2).sub.r--C.sub.3-10carbocyclyl
substituted with 0-5 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl
substituted with 0-5 R.sub.e; or R.sub.a and R.sub.a together with
the nitrogen atom to which they are both attached form a
heterocyclic ring substituted with 0-5 R.sub.e;
[0031] R.sub.b, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.2-6 alkenyl
substituted with 0-5 R.sub.e, C.sub.2-6 alkynyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted
with 0-5 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted
with 0-5 R.sub.e;
[0032] R.sub.c, at each occurrence, is independently selected from
C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.2-6alkenyl
substituted with 0-5 R.sub.e, C.sub.2-6alkynyl substituted with 0-5
R.sub.e, C.sub.3-6carbocyclyl, and heterocyclyl;
[0033] R.sub.d, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.2-6alkenyl
substituted with 0-5 R.sub.e, C.sub.2-6alkynyl substituted with 0-5
R.sub.e, --(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with
0-5 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with
0-5 R.sub.e;
[0034] R.sub.e, at each occurrence, is independently selected from
C.sub.1-6 alkyl substituted with 0-5 R.sub.f, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, --(CH.sub.2).sub.r--C.sub.3-6 cycloalkyl, F, Cl,
Br, CN, NO.sub.2, .dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5
alkyl, --(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f;
[0035] R.sub.f, at each occurrence, is independently selected from
H, C.sub.1-5 alkyl, C.sub.3-6 cycloalkyl, and phenyl, or R.sub.f
and R.sub.f together with the nitrogen atom to which they are both
attached form a heterocyclic ring;
[0036] p, at each occurrence, is independently selected from zero,
1, and 2; and
[0037] r, at each occurrence, is independently selected from zero,
1, 2, 3, and 4.
[0038] In another aspect, there are disclosed compounds of Formula
(II) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof
##STR00003##
wherein
[0039] R.sub.2 is selected from aryl substituted with 0-4 R.sub.2a
and heteroaryl substituted with 0-4 R.sub.2a, wherein said
heteroaryl comprises carbon atoms and 1-4 heteroatoms selected from
N, O, and S(O).sub.p;
[0040] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.2bR.sub.2c).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2NR.sub.aR.sub.a,
--NR.sub.2S(O).sub.2R.sub.c, C.sub.1-4 alkyl substituted with 0-3
R.sub.e, --(CR.sub.2bR.sub.2c).sub.r--C.sub.3-6carbocyclyl
substituted with 0-3 R.sub.e, and
--(CR.sub.2bR.sub.2c).sub.r-heterocyclyl substituted with 0-3
R.sub.e;
[0041] R.sub.2b, at each occurrence, is independently selected from
H and C.sub.1-4alkyl;
[0042] R.sub.2c, at each occurrence, is independently selected from
H and C.sub.1-4alkyl;
[0043] R.sub.4 is selected from H, C.sub.1-4alkyl substituted with
0-5 R.sub.e, --(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rS(O).sub.pR.sub.c,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.rC(.dbd.O)OR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6carbocyclyl substituted with
0-4 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-4 R.sub.4a;
[0044] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-3 R.sub.e,
C.sub.2-6alkynyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2R.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0045] R.sub.4b, at each occurrence, is independently selected from
H and C.sub.1-4alkyl;
[0046] R.sub.4c, at each occurrence, is independently selected from
H and C.sub.1-4alkyl; and
[0047] r, at each occurrence, is independently selected from zero,
1, 2, and 3.
[0048] In another embodiment, there are disclosed compounds
including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0049] R.sub.2 is selected from 4- to 7-membered monocyclic or 8-
to 12-membered bicyclic aryl substituted with 1-4 R.sub.2a and 4-
to 7-membered monocyclic or 7- to 12-membered bicyclic heteroaryl
substituted with 0-4 R.sub.2a;
[0050] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --OC(.dbd.O)NR.sub.aR.sub.a,
--NHC(.dbd.O)NR.sub.aR.sub.a, --(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, or C.sub.1-6 alkyl substituted with 0-3
R.sub.e, --(CH.sub.2).sub.r--C.sub.3-6 carbocyclyl substituted with
0-3 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with
0-3 R.sub.e;
[0051] R.sub.4 is selected from H, C.sub.1-4alkyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rS(O).sub.pR.sub.c,
--(CH.sub.2).sub.rC(.dbd.O)R.sub.d,
--(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)R.sub.d,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)OR.sub.b,
--(CH.sub.2e).sub.rOC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rNR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--(CH.sub.2).sub.rNR.sub.aS(O).sub.2R.sub.c,
--(CH.sub.2).sub.r--C.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e;
[0052] R.sub.4a, at each occurrence, is independently selected from
C.sub.1-6alkyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2R.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NHC(.dbd.O)R.sub.d, --NHC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl.
[0053] In another embodiment, there are disclosed compounds of
formula (III) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof,
##STR00004##
wherein
[0054] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --OC(.dbd.O)NR.sub.aR.sub.a,
--NHC(.dbd.O)NR.sub.aR.sub.a, --(CH.sub.2).sub.rC(.dbd.O)OR.sub.b,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2R.sub.c, or C.sub.1-4 alkyl substituted with 0-3
R.sub.e, --(CH.sub.2).sub.r--C.sub.3-6 carbocyclyl substituted with
0-3 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with
0-3 R.sub.e;
[0055] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.r--C.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.4a;
[0056] R.sub.4a, at each occurrence, is independently selected from
C.sub.1-6alkyl substituted with 0-3 R.sub.e, --SR.sub.c,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c, --OR.sub.b,
--NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)NR.sub.aR.sub.a, --C(.dbd.O)OR.sub.b,
--C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0057] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e; or R.sub.a and R.sub.a together with the nitrogen atom to
which they are both attached form a heterocyclic ring substituted
with 0-5 R.sub.e;
[0058] R.sub.b, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e;
[0059] R.sub.c, at each occurrence, is independently selected from
C.sub.1-6 alkyl substituted with 0-5 R.sub.e, C.sub.3-6carbocyclyl,
and heterocyclyl;
[0060] R.sub.d, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-5
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-5
R.sub.e;
[0061] R.sub.e, at each occurrence, is independently selected from
C.sub.1-6 alkyl substituted with 0-5 R.sub.f,
--(CH.sub.2).sub.r--C.sub.3-6 cycloalkyl, F, Cl, Br, CN, NO.sub.2,
.dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5alkyl,
--(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f;
[0062] R.sub.f, at each occurrence, is independently selected from
H, C.sub.1-5 alkyl, and phenyl, or R.sub.f and R.sub.f together
with the nitrogen atom to which they are both attached form a
heterocyclic ring; and
[0063] n, at each occurrence, is independently selected from zero,
1, 2, 3, and 4.
[0064] In another embodiment, there are disclosed compounds of
Formula (III) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0065] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-3 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rNR.sub.aR.sub.a, --C.sub.3-6cycloalkyl
substituted with 0-3 R.sub.4a, aryl substituted with 0-3 R.sub.4a,
4-, 5-, or 6-membered non-aromatic monocyclic heterocyclyl
substituted with 0-3 R.sub.4a, and 5- or 6-membered heteroaryl
substituted with 0-3 R.sub.4a;
[0066] R.sub.4a, at each occurrence, is independently selected from
C.sub.1-6alkyl substituted with 0-3 R.sub.e,
--S(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c, --OR.sub.b,
--NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d;
--NHC(.dbd.O)NR.sub.aR.sub.a, --C(.dbd.O)OR.sub.b,
--C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0067] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a monocyclic heterocyclic ring substituted
with 0-3 R.sub.e;
[0068] R.sub.b, at each occurrence, is independently selected from
H and C.sub.1-4 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl;
[0069] R.sub.c, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-3 R.sub.e and heterocyclyl;
[0070] R.sub.d, at each occurrence, is independently selected from
H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-3
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e;
[0071] R.sub.e, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, CN,
NO.sub.2, .dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5 alkyl,
--(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f;
[0072] R.sub.f, at each occurrence, is independently selected from
H and C.sub.1-4alkyl or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring.
[0073] In another embodiment, there are disclosed compounds of
Formula (III) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0074] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, CN, .dbd.O, O--C.sub.1-4alkyl substituted with 0-3
R.sub.e,
--O(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl-O--(CH.sub.2).sub.rOC.sub.1-4al-
kyl, --O(CH.sub.2).sub.r-heterocyclyl, --S(O).sub.2C.sub.1-4alkyl,
--C(.dbd.O)C.sub.1-4alkyl, --NH.sub.2, --N(C.sub.1-4alkyl).sub.2,
--NHCN, --NR.sub.a(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl,
--NR.sub.a(CH.sub.2).sub.rOC.sub.1-4alkyl,
--NH(CH.sub.2).sub.r-heterocyclyl,
--(CH.sub.2).sub.rC(.dbd.O)NH.sub.2, --C(.dbd.O)NH-heterocyclyl,
--C(.dbd.O)NH(CH.sub.2).sub.rN(C.sub.1-4alkyl).sub.2,
--C(.dbd.O)-heterocyclyl, --NHC(.dbd.O)C.sub.1-4alkyl,
--NHC(.dbd.O)OC.sub.1-4alkyl, --NHC(.dbd.O)NHC.sub.1-4alkyl,
C(.dbd.O)OC.sub.1-4alkyl, --(CH.sub.2).sub.rC(.dbd.O)OH,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH-heterocyclyl,
--S(O).sub.2NHC.sub.1-4alkyl, --S(O).sub.2-heterocyclyl substituted
with 0-3 R.sub.e, --NH.sub.2S(O).sub.2NH.sub.2,
--NHS(O).sub.2C.sub.1-4alkyl, C.sub.1-4alkyl, CF.sub.3,
--(CH.sub.2).sub.rOH, C.sub.3-6carbocyclyl substituted with 0-3
R.sub.e, non-aromatic heterocyclyl substituted with 0-3 R.sub.e,
and 5- or 6-membered heteroaryl substituted with 0-3 R.sub.e.
[0075] In another embodiment, there are disclosed compounds of
Formula (II) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0076] R.sub.2 is selected from
##STR00005##
[0077] represents an optional bond;
[0078] R.sub.2ab, at each occurrence, is independently selected
from C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d, C(.dbd.O)OR.sub.b; and
[0079] m, at each occurrence, is independently selected from zero,
1, 2, and 3.
[0080] In another embodiment, there are disclosed compounds of
Formula (II) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0081] R.sub.4 is selected from H, C.sub.1-4alkyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.rOR.sub.b,
--(CH.sub.2).sub.rNR.sub.aR.sub.a,
--(CH.sub.2).sub.rC.sub.3-6cycloalkyl substituted with 0-3
R.sub.4a, --(CH.sub.2).sub.r-aryl substituted with 0-3 R.sub.4a,
and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.4a.
[0082] In another embodiment, there are disclosed compounds of
Formula (II) including enantiomers, diastereomers, tautomers,
pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates
thereof, wherein
[0083] R.sub.2 is selected from phenyl substituted with 1-3
R.sub.2a and heteroaryl substituted with 0-3 R.sub.2a;
[0084] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.2R.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d,
--NHC(.dbd.O)OR.sub.b, --NHC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c,
C.sub.1-4alkyl substituted with 0-3 R.sub.e, non-aromatic
heterocyclyl substituted with 0-3 R.sub.e, and heteroaryl
substituted with 0-3 R.sub.e;
[0085] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-3 R.sub.e, --(CH.sub.2).sub.rOR.sub.b, --C.sub.3-6cycloalkyl
substituted with 0-3 R.sub.4a, aryl substituted with 0-3 R.sub.4a,
--(CH.sub.2).sub.r-4- to 6-membered saturated monocyclic
heterocyclyl substituted with 0-3 R.sub.4a, and
--(CH.sub.2).sub.r-5- to 6-membered heteroaryl substituted with 0-3
R.sub.4a;
[0086] R.sub.4a, at each occurrence, is independently selected from
C.sub.1-4alkyl substituted with 0-3 R.sub.e, --OR.sub.b, and
C(.dbd.O)NR.sub.aR.sub.a;
[0087] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-4 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a heterocyclic ring, having 1 to 3
heteroatoms selected from N, O, S, and substituted with 0-3
R.sub.e;
[0088] R.sub.b, at each occurrence, is independently selected from
H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl;
[0089] R.sub.c, at each occurrence, is independently C.sub.1-4
alkyl substituted with 0-3 R.sub.e;
[0090] R.sub.d, at each occurrence, is independently selected from
H and C.sub.1-4 alkyl substituted with 0-3 R.sub.e;
[0091] R.sub.e, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, .dbd.O,
--(CH.sub.2).sub.rOC.sub.1-5 alkyl, --(CH.sub.2).sub.rOH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f; and
[0092] R.sub.f, at each occurrence, is independently selected from
H and C.sub.1-3alkyl or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring;
[0093] r, at each occurrence, is independently selected from zero,
1, 2, and 3; and
[0094] m, at each occurrence, is independently selected from zero,
1, 2, and 3.
[0095] In another embodiment, there are disclosed compounds of
Formulae (IV) and (V) including enantiomers, diastereomers,
tautomers, pharmaceutically-acceptable salts, prodrugs, hydrates,
or solvates thereof,
##STR00006##
[0096] In another embodiment of the compounds of Formulae (I) and
(II), R.sub.2 is heteroaryl selected from pyridyl, pyrimidinyl,
pyrazinyl, pyridazinyl, triazinyl, furyl, quinolinyl,
dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, thienyl,
imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuryl,
benzothienyl, benzthiazolyl, benzoxazinyl, isoxazolyl, pyrazolyl,
triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl,
purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl,
and benzodioxane, each of which is substituted with 0-4
R.sub.2a.
[0097] In another embodiment, there are disclosed compounds of
Formula (VI) or (VII), including enantiomers, diastereomers,
tautomers, pharmaceutically-acceptable salts, prodrugs, hydrates,
or solvates thereof,
##STR00007##
wherein
[0098] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2NR.sub.aR.sub.a, --NR.sub.aS(O).sub.2R.sub.c,
or C.sub.1-6 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-6 carbocyclyl substituted with 0-3
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e;
[0099] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a monocyclic heterocyclic ring substituted
with 0-3 R.sub.e;
[0100] R.sub.b, at each occurrence, is independently selected from
H and C.sub.1-4 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl;
[0101] R.sub.c, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-3 R.sub.e, C.sub.2-4 alkenyl
substituted with 0-3 R.sub.e, and C.sub.2-4 alkynyl substituted
with 0-3 R.sub.e;
[0102] R.sub.d, at each occurrence, is independently selected from
H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted with 0-3
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e;
[0103] R.sub.e, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, CN,
NO.sub.2, .dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5 alkyl,
--(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f;
[0104] R.sub.f, at each occurrence, is independently selected from
H and C.sub.1-4alkyl or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring;
[0105] n, at each occurrence, is independently selected from zero,
1, 2, 3, and 4; and
[0106] r, at each occurrence is independently selected from zero,
1, 2, and 3.
[0107] In another embodiment of the compounds of Formulae (VI) and
(VII), R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, CN, .dbd.O, O--C.sub.1-4alkyl substituted with 0-3
R.sub.e, --O(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl
--O--(CH.sub.2).sub.rOC.sub.1-4alkyl,
--O(CH.sub.2).sub.r-heterocyclyl, --S(O).sub.2C.sub.1-4alkyl,
--C(.dbd.O)C.sub.1-4alkyl, --NH.sub.2, --N(C.sub.1-4alkyl).sub.2,
--NHCN, --NR.sub.a(CH.sub.2).sub.rNR.sub.aC.sub.1-4alkyl,
--NR.sub.a(CH.sub.2).sub.rOC.sub.1-4alkyl,
--NH(CH.sub.2).sub.r-heterocyclyl,
--(CH.sub.2).sub.rC(.dbd.O)NH.sub.2, --C(.dbd.O)NH-heterocyclyl,
--C(.dbd.O)NH(CH.sub.2).sub.rN(C.sub.1-4alkyl).sub.2,
--C(.dbd.O)-heterocyclyl, --NHC(.dbd.O)C.sub.1-4alkyl,
--NHC(.dbd.O)OC.sub.1-4alkyl, --NHC(.dbd.O)NHC.sub.1-4alkyl,
C(.dbd.O)OC.sub.1-4alkyl, --(CH.sub.2).sub.rC(.dbd.O)OH,
--S(O).sub.2NH.sub.2, --S(O).sub.2NH-heterocyclyl,
--S(O).sub.2NHC.sub.1-4alkyl, --S(O).sub.2-heterocyclyl substituted
with 0-3 R.sub.e, --NH.sub.2S(O).sub.2NH.sub.2,
--NHS(O).sub.2C.sub.1-4alkyl, C.sub.1-4alkyl, CF.sub.3,
--(CH.sub.2).sub.rOH, C.sub.3-6carbocyclyl substituted with 0-3
R.sub.e, non-aromatic heterocyclyl substituted with 0-3 R.sub.e,
and 5- or 6-membered heteroaryl substituted with 0-3 R.sub.e.
[0108] In another embodiment of the compounds of Formula (I),
[0109] R.sub.1 is H;
[0110] R.sub.2 is selected from phenyl substituted with 1-4
R.sub.2a and heteroaryl substituted with 0-4 R.sub.2a,
[0111] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.pR.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)OR.sub.b,
--OC(.dbd.O)NR.sub.aR.sub.a, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2NR.sub.aR.sub.a, --NR.sub.2S(O).sub.2R.sub.c,
C.sub.1-6 alkyl substituted with 0-3 R.sub.e,
--(CH.sub.2).sub.r--C.sub.3-6carbocyclyl substituted with 0-3
R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted with 0-3
R.sub.e;
[0112] R.sub.3 is selected from H and C.sub.1-4alkyl;
[0113] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-5 R.sub.e, --(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6cycloalkyl substituted with
0-3 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-aryl substituted with 0-3
R.sub.4a, and --(CR.sub.4bR.sup.4c).sub.r-heterocyclyl substituted
with 0-3 R.sub.4a;
[0114] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, CN, C.sub.1-6alkyl substituted with 0-3 R.sub.e,
--OR.sub.b, and C(.dbd.O)NR.sub.aR.sub.a;
[0115] R.sub.4b, at each occurrence, is independently selected from
H and C.sub.1-4alkyl;
[0116] R.sub.4c, at each occurrence, is independently selected from
H and C.sub.1-4alkyl;
[0117] R.sub.5 is H;
[0118] R.sub.6 is H;
[0119] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-6 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a heterocyclic ring, having 1 to 3
heteroatoms selected from N, O, S, and substituted with 0-3
R.sub.e;
[0120] R.sub.b, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl;
[0121] R.sub.c, at each occurrence, is independently selected from
C.sub.1-6 alkyl substituted with 0-3 R.sub.e, C.sub.2-6 alkenyl
substituted with 0-3 R.sub.e, and C.sub.2-6 alkynyl substituted
with 0-3 R.sub.e;
[0122] R.sub.d, at each occurrence, is independently selected from
H, C.sub.1-6 alkyl substituted with 0-3 R.sub.e, C.sub.2-6 alkenyl
substituted with 0-3 R.sub.e, C.sub.2-6 alkynyl substituted with
0-3 R.sub.e, --(CH.sub.2).sub.r--C.sub.3-10carbocyclyl substituted
with 0-3 R.sub.e, and --(CH.sub.2).sub.r-heterocyclyl substituted
with 0-3 R.sub.e;
[0123] R.sub.e, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, CN,
NO.sub.2, .dbd.O, CO.sub.2H, --(CH.sub.2).sub.rOC.sub.1-5 alkyl,
--(CH.sub.2).sub.rOH, SH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f;
[0124] R.sub.f, at each occurrence, is independently selected from
H and C.sub.1-4alkyl or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring;
[0125] p, at each occurrence, is independently selected from zero,
1, and 2; and
[0126] r, at each occurrence, is independently selected from zero,
1, 2, and 3.
[0127] In another embodiment of the compounds of Formula (I),
[0128] R.sub.2 is selected from phenyl substituted with 1-3
R.sub.2a and
##STR00008##
[0129] represents an optional bond;
[0130] R.sub.2a, at each occurrence, is independently selected from
H, F, Cl, Br, .dbd.O, CN, --OR.sub.b, --S(O).sub.2R.sub.c,
--C(.dbd.O)R.sub.d, --NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)NR.sub.aR.sub.a, --NHC(.dbd.O)R.sub.d;
--NHC(.dbd.O)OR.sub.b, --NHC(.dbd.O)NR.sub.aR.sub.a,
--(CH.sub.2).sub.rC(.dbd.O)OR.sub.b, --S(O).sub.2NR.sub.aR.sub.a,
--NHS(O).sub.2NR.sub.aR.sub.a; --NHS(O).sub.2R.sub.c,
C.sub.1-4alkyl substituted with 0-3 R.sub.e, non-aromatic
heterocyclyl substituted with 0-3 R.sub.e, and heteroaryl
substituted with 0-3 R.sub.e;
[0131] R.sub.2ab, at each occurrence, is independently selected
from C.sub.1-4 alkyl substituted with 0-3 R.sub.e,
--S(O).sub.pR.sub.c, --C(.dbd.O)R.sub.d, C(.dbd.O)OR.sub.b;
[0132] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-3 R.sub.e, --(CH.sub.2).sub.rOR.sub.b, --C.sub.3-6cycloalkyl
substituted with 0-3 R.sub.4a, aryl substituted with 0-3 R.sub.4a,
--(CH.sub.2).sub.r-4- to 6-membered saturated monocyclic
heterocyclyl substituted with 0-3 R.sub.4a, and
--(CH.sub.2).sub.r-5- to 6-membered heteroaryl substituted with 0-3
R.sub.4a;
[0133] R.sub.4a, at each occurrence, is independently selected from
C.sub.1-4alkyl substituted with 0-3 R.sub.e, --OR.sub.b, and
C(.dbd.O)NR.sub.aR.sub.a;
[0134] R.sub.a, at each occurrence, is independently selected from
H, CN, C.sub.1-4 alkyl substituted with 0-5 R.sub.e,
--(CH.sub.2).sub.r-heterocyclyl substituted with 0-3 R.sub.e; or
R.sub.a and R.sub.a together with the nitrogen atom to which they
are both attached form a heterocyclic ring, having 1 to 3
heteroatoms selected from N, O, S, and substituted with 0-3
R.sub.e;
[0135] R.sub.b, at each occurrence, is independently selected from
H, C.sub.1-4 alkyl substituted with 0-3 R.sub.e, and
heterocyclyl;
[0136] R.sub.c, at each occurrence, is independently C.sub.1-4
alkyl substituted with 0-3 R.sub.e;
[0137] R.sub.d, at each occurrence, is independently selected from
H and C.sub.1-4 alkyl substituted with 0-3 R.sub.e;
[0138] R.sub.e, at each occurrence, is independently selected from
C.sub.1-4 alkyl substituted with 0-4 R.sub.f, F, Cl, Br, .dbd.O,
--(CH.sub.2).sub.rOC.sub.1-5 alkyl, --(CH.sub.2).sub.rOH, and
--(CH.sub.2).sub.rNR.sub.fR.sub.f; and
[0139] R.sub.f, at each occurrence, is independently selected from
H and C.sub.1-3alkyl or R.sub.f and R.sub.f together with the
nitrogen atom to which they are both attached form a heterocyclic
ring;
[0140] r, at each occurrence, is independently selected from zero,
1, 2, and 3; and
[0141] m, at each occurrence, is independently selected from zero,
1, 2, and 3.
[0142] In still another embodiment, R.sub.2 is substituted with 1-5
R.sub.2a and is selected from phenyl and naphthyl.
[0143] In another embodiment, R.sub.2 is substituted with 0-5
R.sub.2a and is heteroaryl selected from thiazolyl, oxazolyl,
pyrazolyl, triazolyl, tetrazolyl, thiadiazolyl, isoxazolyl,
imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl,
indazolyl, isoindolyl, indolinyl, isoindolinyl, benzimidazolyl,
benzothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl,
tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
[0144] In another embodiment, R.sub.2 is selected from
##STR00009##
[0145] In another embodiment, R.sub.2a, at each occurrence, is
independently selected from F, Cl, Br, --OCF.sub.3, --OCHF.sub.2,
--CF.sub.3, CN, NO.sub.2, CH.sub.3, --OH, --OCH.sub.3, NH.sub.2,
--N(CH.sub.2CH.sub.3).sub.2, --NHC(.dbd.O)CH.sub.3,
--NHS(O).sub.2CH.sub.3, --NHC(.dbd.O)OCH.sub.3,
--NHC(.dbd.O)CH(CH.sub.3).sub.2, --NHC(.dbd.O)CH.sub.2CH.sub.3,
--C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3, C(.dbd.O)NH.sub.2,
--C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e. Non-limiting examples of the heterocyclyl include
pyrrolidine, imidazole, pyrazole, oxazole, oxadiazole, thiazole,
triazole, tetrazole, piperazine, piperidine, and morpholine.
[0146] In another embodiment, R.sub.2a is substituted with 0-2
R.sub.e and is selected from:
##STR00010##
[0147] In another embodiment, R.sub.3 is selected from H, F, Cl,
Br, CN, --OR.sub.b, --NR.sub.aR.sub.a, and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0148] In another embodiment, R.sub.3 is selected from H and
C.sub.1-6alkyl substituted with 0-5 R.sub.e.
[0149] In another embodiment, R.sub.3 is H.
[0150] In another embodiment, R.sub.4 is selected from H,
C.sub.1-6alkyl substituted with 0-5 R.sub.e,
--(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6cycloalkyl substituted with
0-3 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-3 R.sub.4a, and --(CR.sub.4bR.sub.4c).sub.r-aryl substituted
with 0-3 R.sub.4a;
[0151] In another embodiment, R.sub.4 is selected from
--(CH.sub.2)OR.sub.b, --(CH.sub.2CH.sub.2)OR.sub.b,
--(CH(CH.sub.3)CH.sub.2)OR.sub.b,
--(C(CH.sub.3).sub.2CH.sub.2)OR.sub.b,
--(CH.sub.2CH(CH.sub.3))OR.sub.b,
--(CH.sub.2C(CH.sub.3).sub.2)OR.sub.b, --(CH.sub.2)NR.sub.aR.sub.a,
--(CH.sub.2CH.sub.2)NR.sub.aR.sub.a,
--(CH(CH.sub.3)CH.sub.2)NR.sub.aR.sub.a,
--(C(CH.sub.3).sub.2CH.sub.2)NR.sub.aR.sub.a,
--(CH.sub.2CH(CH.sub.3))NR.sub.aR.sub.a, and
--(CH.sub.2C(CH.sub.3).sub.2)NR.sub.aR.sub.a, wherein R.sub.a, at
each occurrence, is independently selected from H and C.sub.1-6
alkyl substituted with 0-3 R.sub.e; or R.sub.a and R.sub.a together
with the nitrogen atom to which they are attached form a
heterocyclic ring selected from imidazolidinyl, imidazolinyl,
imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl,
isoquinolinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl,
pyrimidinyl, piperazinyl, pyrazinyl, pyrazolyl, pyridazinyl,
pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl,
quinazolinyl, quinolinyl, tetrazolyl, thiazolyl, triazinyl, and
triazolyl.
[0152] In another embodiment, R.sub.4 is substituted with 0-3
R.sub.4a and is selected from phenyl, naphthyl, biphenyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
cycloheptyl.
[0153] In another embodiment, R.sub.4 is
--(CH.sub.2).sub.0-2-heterocyclyl substituted with 0-3 R.sub.4a,
wherein said heterocyclyl is selected from azetidinyl, thiazolyl,
oxazolyl, pyrazolyl, triazolyl, tetrazolyl, thiadiazolyl,
isoxazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl,
pyridazinyl, indolyl, indazolyl, isoindolyl, indolinyl,
isoindolinyl, benzimidazolyl, benzothiazolyl, benzotriazolyl,
quinolinyl, isoquinolinyl, tetrahydroquinolinyl, and
tetrahydroisoquinolinyl.
[0154] In another embodiment, R.sub.4a, at each occurrence, is
independently selected from F, Cl, Br, C.sub.1-6alkyl substituted
with 0-5 R.sub.e, C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, OH,
CN, --SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl.
[0155] All aspects of the compounds, including individual variable
definitions, may be combined with other aspects to form additional
compounds. For example, in one embodiment of Formula (I), R.sub.1
is hydrogen and R.sub.3 is hydrogen or C.sub.1-4alkyl substituted
with 0-5 R.sub.e. In another embodiment, R.sub.1 can be hydrogen
and R.sub.3 can be OR.sub.b, --NR.sub.aR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.a, --NHS(O).sub.2R.sub.c,
--NHC(.dbd.O)R.sub.d, or --NHC(.dbd.O)OR.sub.b. In still another
embodiment, R.sub.1 is hydrogen, and R.sub.3, R.sub.5, and R.sub.6
are all hydrogen.
[0156] In certain embodiments, the present invention includes
compounds of Formula (I), or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
wherein:
[0157] R.sub.1 is H;
[0158] R.sub.2 is substituted with 0-5 R.sub.2a and is selected
from phenyl and naphthyl;
[0159] R.sub.2a, at each occurrence, is independently selected from
F, Cl, Br, --OCF.sub.3, --OCHF.sub.2, --CF.sub.3, CN, NO.sub.2,
CH.sub.3, --OH, --OCH.sub.3, NH.sub.2, --N(CH.sub.2CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.3, --NHS(O).sub.2CH.sub.3,
--NHC(.dbd.O)OCH.sub.3, --NHC(.dbd.O)CH(CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.2CH.sub.3, --C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3,
C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e. Non-limiting examples of the heterocyclyl include
pyrrolidine, imidazole, pyrazole, oxazole, oxadiazole, thiazole,
triazole, tetrazole, piperazine, piperidine, and morpholine;
[0160] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-5 R.sub.e, --(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6cycloalkyl substituted with
0-3 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-3 R.sub.4a, and --(CR.sub.4bR.sub.4c).sub.r-aryl substituted
with 0-3 R.sub.4a;
[0161] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, .dbd.O, CN,
--SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0162] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0163] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0164] In certain embodiments, the present invention includes
compounds of Formula (I), or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
wherein:
[0165] R.sub.1 is H;
[0166] R.sub.2 is substituted with 0-5 R.sub.2a and is heteroaryl
selected from thiazolyl, oxazolyl, pyrazolyl, triazolyl,
tetrazolyl, thiadiazolyl, isoxazolyl, imidazolyl, pyridyl,
pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, indazolyl,
isoindolyl, benzimidazolyl, benzothiazolyl, benzotriazolyl,
quinolinyl, and isoquinolinyl;
[0167] R.sub.2a, at each occurrence, is independently selected from
F, Cl, Br, --OCF.sub.3, --OCHF.sub.2, --CF.sub.3, CN, NO.sub.2,
CH.sub.3, --OH, --OCH.sub.3, NH.sub.2, --N(CH.sub.2CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.3, --NHS(O).sub.2CH.sub.3,
--NHC(.dbd.O)OCH.sub.3, --NHC(.dbd.O)CH(CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.2CH.sub.3, --C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e;
[0168] R.sub.3 is selected from H, F, Cl, Br, CN, --OR.sub.b,
--NR.sub.aR.sub.a, and C.sub.1-6alkyl substituted with 0-5
R.sub.e;
[0169] R.sub.4 is selected from H, C.sub.1-6alkyl substituted with
0-5 R.sub.e, --(CR.sub.4bR.sub.4c).sub.rOR.sub.b,
--(CR.sub.4bR.sub.4c).sub.rNR.sub.aR.sub.a,
--(CR.sub.4bR.sub.4c).sub.r--C.sub.3-6cycloalkyl substituted with
0-3 R.sub.4a, --(CR.sub.4bR.sub.4c).sub.r-heterocyclyl substituted
with 0-3 R.sub.4a, and --(CR.sub.4bR.sub.4c).sub.r-aryl substituted
with 0-3 R.sub.4a;
[0170] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, .dbd.O, CN,
--SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0171] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0172] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0173] In certain embodiments, the present invention includes
compounds of Formula (I), or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
wherein:
[0174] R.sub.1 is H;
[0175] R.sub.2 is selected from aryl substituted with 0-4 R.sub.2a
and heteroaryl substituted with 0-4 R.sub.2a;
[0176] R.sub.2a, at each occurrence and when valence allows, is
independently selected from F, Cl, Br, --CF.sub.3, CN, NO.sub.2,
CH.sub.3, --OH, --OCH.sub.3, NH.sub.2, --N(CH.sub.2CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.3, --NHS(O).sub.2CH.sub.3,
--NHC(.dbd.O)OCH.sub.3, --NHC(.dbd.O)CH(CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.2CH.sub.3, --C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e;
[0177] R.sub.4 is selected from --(CH.sub.2)OR.sub.b,
--(CH.sub.2CH.sub.2)OR.sub.b, --(CH(CH.sub.3)CH.sub.2)OR.sub.b,
--(C(CH.sub.3).sub.2CH.sub.2)OR.sub.b,
--(CH.sub.2CH(CH.sub.3))OR.sub.b,
--(CH.sub.2C(CH.sub.3).sub.2)OR.sub.b, --(CH.sub.2)NR.sub.aR.sub.a,
--(CH.sub.2CH.sub.2) NR.sub.aR.sub.a,
--(CH(CH.sub.3)CH.sub.2)NR.sub.aR.sub.a,
--(C(CH.sub.3).sub.2CH.sub.2)NR.sub.aR.sub.a,
--(CH.sub.2CH(CH.sub.3))NR.sub.aR.sub.a, and
--(CH.sub.2C(CH.sub.3).sub.2)NR.sub.aR.sub.a, wherein R.sub.a, at
each occurrence, is independently selected from H and C.sub.1-6
alkyl substituted with 0-3 R.sub.e; or R.sub.a and R.sub.a together
with the nitrogen atom to which they are attached form a
heterocyclic ring selected from imidazolidinyl, imidazolinyl,
imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl,
isoquinolinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl,
pyrimidinyl, piperazinyl, pyrazinyl, pyrazolyl, pyridazinyl,
pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl,
quinazolinyl, quinolinyl, tetrazolyl, thiazolyl, triazinyl, and
triazolyl;
[0178] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, OH, CN, --SO.sub.3H,
--S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0179] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0180] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0181] In certain embodiments, the present invention includes
compounds of Formula (I), or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
wherein:
[0182] R.sub.1 is H;
[0183] R.sub.2 is selected from aryl substituted with 0-4 R.sub.2a
and heteroaryl substituted with 0-4 R.sub.2a;
[0184] R.sub.2a, at each occurrence and when valence allows, is
independently selected from F, Cl, Br, --CF.sub.3, CN, NO.sub.2,
CH.sub.3, --OH, --OCH.sub.3, NH.sub.2, --N(CH.sub.2CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.3, --NHS(O).sub.2CH.sub.3,
--NHC(.dbd.O)OCH.sub.3, --NHC(.dbd.O)CH(CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.2CH.sub.3, --C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e;
[0185] R.sub.4 is substituted with 0-3 R.sub.4a and is selected
from phenyl, naphthyl, biphenyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, and cycloheptyl;
[0186] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, .dbd.O, CN,
--SO.sub.3H, --S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0187] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0188] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0189] In other embodiments, the present invention includes
compounds of Formula (I), or stereoisomers, tautomers,
pharmaceutically acceptable salts, solvates, or prodrugs thereof,
wherein:
[0190] R.sub.2 is selected from aryl substituted with 0-4 R.sub.2a
and heteroaryl substituted with 0-4 R.sub.2a;
[0191] R.sub.2a, at each occurrence and when valence allows, is
independently selected from F, Cl, Br, --CF.sub.3, CN, NO.sub.2,
CH.sub.3, --OH, --OCH.sub.3, NH.sub.2, --N(CH.sub.2CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.3, --NHS(O).sub.2CH.sub.3,
--NHC(.dbd.O)OCH.sub.3, --NHC(.dbd.O)CH(CH.sub.3).sub.2,
--NHC(.dbd.O)CH.sub.2CH.sub.3, --C(.dbd.O)OH, --C(.dbd.O)OCH.sub.3,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3, --S(O).sub.2CH.sub.3,
--S(O).sub.2NHCH.sub.3, --N(CH.sub.3)C(.dbd.O)CH.sub.3,
--NHS(O).sub.2NH.sub.2, --C(.dbd.O)-heterocyclyl substituted with
0-5 R.sub.e, --(CH.sub.2).sub.r-5- to 6-membered heterocyclyl
comprising carbon atoms and 1-4 heteroatoms selected from N, O, and
S(O).sub.p, wherein said heterocyclyl is substituted with 0-5
R.sub.e;
[0192] R.sub.4 is --(CH.sub.2).sub.0-2-heterocyclyl substituted
with 0-3 R.sub.4a, wherein said heterocyclyl is selected from
azetidinyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl,
thiadiazolyl, isoxazolyl, imidazolyl, pyridyl, pyrimidinyl,
pyrazinyl, pyridazinyl, indolyl, indazolyl, isoindolyl, indolinyl,
isoindolinyl, benzimidazolyl, benzothiazolyl, benzotriazolyl,
quinolinyl, isoquinolinyl, tetrahydroquinolinyl, and
tetrahydroisoquinolinyl;
[0193] R.sub.4a, at each occurrence, is independently selected from
F, Cl, Br, C.sub.1-6alkyl substituted with 0-5 R.sub.e,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, NO.sub.2, OH, CN, --SO.sub.3H,
--S(O).sub.pR.sub.c, --S(O).sub.2NR.sub.aR.sub.a,
--NR.sub.aS(O).sub.2R.sub.c, --OR.sub.b, --NR.sub.aR.sub.a,
--NR.sub.aC(.dbd.O)R.sub.d, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.a,
--C(.dbd.O)OR.sub.b, --C(.dbd.O)R.sub.d, --OC(.dbd.O)R.sub.d,
--C(.dbd.O)NR.sub.aR.sub.a, C.sub.3-6cycloalkyl, heterocyclyl, and
aryl;
[0194] R.sub.5 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e;
[0195] R.sub.6 is selected from hydrogen and C.sub.1-6alkyl
substituted with 0-5 R.sub.e.
[0196] Further embodiments of the invention relate to compounds of
Formulae (VIII), (IX), and (X), below, wherein the variables
R.sub.2 and R.sub.2a, where they appear, can be selected from any
of the embodiments as set forth above for compounds of Formula (I),
(II), (III), (IV), (V), (VI) and/or (VII) (including as recited in
any of the further embodiments).
##STR00011##
[0197] Compounds of the invention include, without limitation, the
following: [0198]
6-((3-cyano-4-methylphenyl)amino)-8-(2-pyridinylamino)imidazo[1,2-b]pyrid-
azine-3-carbonitrile. [0199]
N-(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2--
(trifluoromethoxy)phenyl)acetamide, [0200]
3-cyano-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amin-
o)benzenesulfonamide, [0201]
N-(3-cyano-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)a-
mino)phenyl)acetamide, [0202]
6-((5-cyano-2-methoxyphenyl)amino)-8-(cyclopropylamino)imidazo[1,2-b]pyri-
dazine-3-carbonitrile, [0203] methyl
(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2-me-
thylphenyl)carbamate, [0204]
3-((6-((3-acetamido-4-methylphenyl)amino)-3-cyanoimidazo[1,2-b]pyridazin--
8-yl)amino)-N-(2-(dimethylamino)ethyl)benzamide, [0205]
8-(cyclobutylamino)-6-((3-methoxy-5-(4H-1,2,4-triazol-4-yl)phenyl)amino)i-
midazo[1,2-b]pyridazine-3-carbonitrile, [0206]
6-((1-acetyl-2,3-dihydro-1H-indol-6-yl)amino)-8-(cyclopropylamino)imidazo-
[1,2-b]pyridazine-3-carbonitrile, [0207]
6-((3-cyano-5-((4-methyl-1-piperazinyl)sulfonyl)phenyl)amino)-8-(cyclopro-
pylamino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0208]
6-((2-chloro-5-cyano-4-methylphenyl)amino)-8-(2-pyridinylamino)imidazo[1,-
2-b]pyridazine-3-carbonitrile, [0209]
8-(cyclopropylamino)-6-((1,4-dimethyl-2-oxo-1,2-dihydro-7-quinolinyl)amin-
o)imidazo[1,2-b]pyridazine-3-carbonitrile, [0210]
3-cyano-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amin-
o)-N-ethylbenzenesulfonamide, [0211]
8-(cyclopropylamino)-6-((3-(4-(2-hydroxyethyl)-1-piperazinyl)-5-(4H-1,2,4-
-triazol-4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile,
[0212]
8-((5-methoxy-2-pyridinyl)amino)-6-((3-methoxy-5-(4H-1,2,4-triazol-4-yl)p-
henyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0213]
6-((2-chloro-5-cyanophenyl)amino)-8-(cyclopropylamino)imidazo[1,2-b]pyrid-
azine-3-carbonitrile, [0214] methyl
(3-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-5-(m-
ethylsulfonyl)phenyl)carbamate, [0215]
6-((5-cyano-2-methoxyphenyl)amino)-8-(cyclobutylamino)imidazo[1,2-b]pyrid-
azine-3-carbonitrile, [0216]
6-((5-cyano-2-methylphenyl)amino)-8-(cyclopropylamino)imidazo[1,2-b]pyrid-
azine-3-carbonitrile, [0217]
8-(cyclopropylamino)-6-((3-(2-(dimethylamino)ethoxy)-5-(4H-1,2,4-triazol--
4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0218]
6-((2-chloro-5-cyano-4-methylphenyl)amino)-8-(cyclopropylamino)imidazo[1,-
2-b]pyridazine-3-carbonitrile, [0219]
8-amino-6-((5-cyano-2-methoxyphenyl)amino)imidazo[1,2-b]pyridazine-3-carb-
onitrile, [0220]
8-amino-6-((3-cyano-4-methylphenyl)amino)imidazo[1,2-b]pyridazine-3-carbo-
nitrile, [0221]
N-(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2--
methylphenyl)acetamide, [0222]
6-((2-chloro-5-cyanophenyl)amino)-8-(cyclobutylamino)imidazo[1,2-b]pyrida-
zine-3-carbonitrile, [0223]
N-(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2,-
4-difluorophenyl)acetamide, [0224]
6-((4-fluoro-3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-8-((5-methoxy-2-pyrid-
inyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0225]
N-(5-((3-cyano-8-((5-(2-hydroxyethoxy)-2-pyridinyl)amino)imidazo[1,2-b]py-
ridazin-6-yl)amino)-2-methylphenyl)acetamide, [0226]
N-(5-((3-cyano-8-((5-methoxy-2-pyridinyl)amino)imidazo[1,2-b]pyridazin-6--
yl)amino)-2-methylphenyl)acetamide, [0227]
8-(cyclopropylamino)-6-((4-(2-(methylamino)ethoxy)-3-(4H-1,2,4-triazol-4--
yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0228]
N-(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2--
methoxyphenyl)acetamide, [0229]
6-((5-cyano-2-(2-(4-morpholinyl)ethoxy)phenyl)amino)-8-(cyclopropylamino)-
imidazo[1,2-b]pyridazine-3-carbonitrile, [0230]
8-((2-methoxyethyl)amino)-6-((3-methoxy-5-(4H-1,2,4-triazol-4-yl)phenyl)a-
mino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0231]
6-((3-cyano-4-(4-morpholinyl)phenyl)amino)-8-(cyclopropylamino)imidazo[1,-
2-b]pyridazine-3-carbonitrile, [0232] methyl
(5-((8-amino-3-cyanoimidazo[1,2-b]pyridazin-6-yl)amino)-2-methylphenyl)ca-
rbamate, [0233]
8-(cyclopropylamino)-6-((3-methoxy-5-(4H-1,2,4-triazol-4-yl)phenyl)amino)-
imidazo[1,2-b]pyridazine-3-carbonitrile, [0234] methyl
(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2,4--
difluorophenyl)carbamate, [0235] methyl
(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2-fl-
uorophenyl)carbamate, [0236]
6-((5-cyano-2-(trifluoromethoxy)phenyl)amino)-8-(cyclopropylamino)imidazo-
[1,2-b]pyridazine-3-carbonitrile, [0237]
N-(3-cyano-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)a-
mino)phenyl)methanesulfonamide, [0238]
N-(2-chloro-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)-
amino)phenyl)acetamide, [0239]
8-(cyclopropylamino)-6-((4-fluoro-3-(4H-1,2,4-triazol-4-yl)phenyl)amino)i-
midazo[1,2-b]pyridazine-3-carbonitrile, [0240]
8-(cyclopropylamino)-6-((4-(4-morpholinyl)-3-(4H-1,2,4-triazol-4-yl)pheny-
l)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0241]
8-(cyclopropylamino)-6-((3-methyl-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)i-
midazo[1,2-b]pyridazine-3-carbonitrile, [0242]
8-(cyclopropylamino)-6-((4-(3-(dimethylamino)propoxy)-3-(4H-1,2,4-triazol-
-4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile, [0243]
6-((4-cyano-2-pyridinyl)amino)-8-(cyclopropylamino)imidazo[1,2-b]pyridazi-
ne-3-carbonitrile, [0244]
3-cyano-5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amin-
o)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide, [0245]
8-(cyclopropylamino)-6-((2-fluoro-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)i-
midazo[1,2-b]pyridazine-3-carbonitrile, and [0246]
N-(3-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-4--
methylphenyl)acetamide.
[0247] The compounds of Formulae (I)-(X) may form salts with alkali
metals such as sodium, potassium and lithium, with alkaline earth
metals such as calcium and magnesium, with organic bases such as
dicyclohexylamine, tributylamine, pyridine and amino acids such as
arginine, lysine and the like. Such salts can be formed as known to
those skilled in the art.
[0248] The compounds for Formulae (I)-(X) may form salts with a
variety of organic and inorganic acids. Such salts include those
formed with hydrogen chloride, hydrogen bromide, methanesulfonic
acid, sulfuric acid, acetic acid, trifluoroacetic acid, oxalic
acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid and
various others (e.g., nitrates, phosphates, borates, tartrates,
citrates, succinates, benzoates, ascorbates, salicylates and the
like). Such salts can be formed as known to those skilled in the
art.
[0249] In addition, zwitterions ("inner salts") may be formed.
[0250] The present invention is also intended to include all
isotopes of atoms occurring in the present compounds. Isotopes
include those atoms having the same atomic number but different
mass numbers. By way of general example and without limitation,
isotopes of hydrogen include deuterium and tritium. Isotopes of
carbon include .sup.13C and .sup.14C. Isotopically-labeled
compounds of the invention can generally be prepared by
conventional techniques known to those skilled in the art or by
processes analogous to those described herein, using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
otherwise employed.
[0251] Compounds of the Formulae (I)-(X) may also have prodrug
forms. Since prodrugs are known to enhance numerous desirable
qualities of pharmaceuticals (e.g., solubility, bioavailability,
manufacturing, etc.) the compounds of the present invention may be
delivered in prodrug form. Thus, the present invention is intended
to cover prodrugs of the presently claimed compounds, methods of
delivering the same and compositions containing the same.
"Prodrugs" are intended to include any covalently bonded carriers
that release an active parent drug of the present invention in vivo
when such prodrug is administered to a mammalian subject. Prodrugs
of the present invention are prepared by modifying functional
groups present in the compound in such a way that the modifications
are cleaved, either in routine manipulation or in vivo, to the
parent compound. Prodrugs include compounds of the present
invention wherein a hydroxy, amino, or sulfhydryl group is bonded
to any group that, when the prodrug of the present invention is
administered to a mammalian subject, it cleaves to form a free
hydroxyl, free amino, or free sulfhydryl group, respectively.
Examples of prodrugs include, but are not limited to, acetate,
formate, and benzoate derivatives of alcohol and amine functional
groups in the compounds of the present invention.
[0252] Various forms of prodrugs are well known in the art. For
examples of such prodrug derivatives, see:
[0253] a) Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985),
and Methods in Enzymology, 112:309-396, K. Widder et al., eds.,
Academic Press (1985);
[0254] b) Bundgaard, H., Chapter 5, "Design and Application of
Prodrugs," A Textbook of Drug Design and Development, pp. 113-191,
P. Krosgaard-Larsen et al., eds., Harwood Academic Publishers
(1991); and
[0255] c) Bundgaard, H., Adv. Drug Deliv. Rev., 8:1-38 (1992).
[0256] It should further be understood that solvates (e.g.,
hydrates) of the compounds of Formulae (I)-(X) are also within the
scope of the invention. Methods of solvation are generally known in
the art. The inventive compounds may either be in the free or
hydrate form.
[0257] Compounds of this invention may have one or more asymmetric
centers. Unless otherwise indicated, all chiral (enantiomeric and
diastereomeric) and racemic forms of compounds of the present
invention are included in the present invention. Many geometric
isomers of olefins, C.dbd.N double bonds, and the like can also be
present in the compounds, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms. The present compounds can be isolated in optically active or
racemic forms. It is well known in the art how to prepare optically
active forms, such as by resolution of racemic forms or by
synthesis from optically active starting materials. All chiral,
(enantiomeric and diastereomeric) and racemic forms and all
geometric isomeric forms of a structure are intended, unless the
specific stereochemistry or isomer form is specifically indicated.
When no specific mention is made of the configuration (cis, trans
or R or S) of a compound (or of an asymmetric carbon), then any one
of the isomers or a mixture of more than one isomer is intended.
The processes for preparation can use racemates, enantiomers, or
diastereomers as starting materials. All processes used to prepare
compounds of the present invention and intermediates made therein
are considered to be part of the present invention. When
enantiomeric or diastereomeric products are prepared, they can be
separated by conventional methods, for example, by chromatography
or fractional crystallization. Compounds of the present invention,
and salts thereof, may exist in multiple tautomeric forms, in which
hydrogen atoms are transposed to other parts of the molecules and
the chemical bonds between the atoms of the molecules are
consequently rearranged. It should be understood that all
tautomeric forms, insofar as they may exist, are included within
the invention.
DEFINITIONS
[0258] The following are definitions of terms used in this
specification and appended claims. The initial definition provided
for a group or term herein applies to that group or term throughout
the specification and claims, individually or as part of another
group, unless otherwise indicated.
[0259] In accordance with a convention used in the art,
##STR00012##
is used in structural formulas herein to depict the bond that is
the point of attachment of the moiety or substituent to the core or
backbone structure.
[0260] A dash "-" that is not between two letters or symbols is
used to indicate a point of attachment for a substituent. For
example, --CONH.sub.2 is attached through the carbon atom.
[0261] As used herein, the term "alkyl" or "alkylene" is intended
to include both branched and straight-chain saturated aliphatic
hydrocarbon groups having the specified number of carbon atoms. For
example, "C.sub.1-10 alkyl" (or alkylene), is intended to include
C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.2,
C.sub.8, C.sub.9, and C.sub.10 alkyl groups. Additionally, for
example, "C.sub.1-C.sub.6 alkyl" denotes alkyl having 1 to 6 carbon
atoms. Alkyl groups can be unsubstituted or substituted so that one
or more of its hydrogens are replaced by another chemical group.
Example alkyl groups include, but are not limited to, methyl (Me),
ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g.,
n-butyl, isobutyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl,
neopentyl), and the like.
[0262] "Haloalkyl" is intended to include both branched and
straight-chain saturated aliphatic hydrocarbon groups having the
specified number of carbon atoms, substituted with 1 or more
halogen. Examples of haloalkyl include, but are not limited to,
fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl,
pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl,
heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl
also include "fluoroalkyl" which is intended to include both
branched and straight-chain saturated aliphatic hydrocarbon groups
having the specified number of carbon atoms, substituted with 1 or
more fluorine atoms.
[0263] The term "halogen" or "halo" refers to fluorine (F),
chlorine (Cl), bromine (Br) and iodine.
[0264] "Haloalkoxy" or "haloalkyloxy" represents a haloalkyl group
as defined above with the indicated number of carbon atoms attached
through an oxygen bridge. For example, "C.sub.1-6 haloalkoxy", is
intended to include C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5,
and C.sub.6 haloalkoxy groups. Examples of haloalkoxy include, but
are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy,
pentafluorothoxy, and the like. Similarly, "haloalkylthio" or
"thiohaloalkoxy" represents a haloalkyl group as defined above with
the indicated number of carbon atoms attached through a sulphur
bridge; for example trifluoromethyl-S--, pentafluoroethyl-S--, and
the like.
[0265] As used herein, "carbocycle," "carbocyclic residue," or
"carbocyclyl" is intended to mean any stable 3-, 4-, 5-, 6-, or
7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or
13-membered bicyclic or tricyclic ring, any of which may be
saturated, partially unsaturated, unsaturated or aromatic. Examples
of such carbocycles include, but are not limited to, cyclopropyl,
cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl,
cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane,
[4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane,
fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and
tetrahydronaphthyl (tetralin). As shown above, bridged rings are
also included in the definition of carbocycle (e.g.,
[2.2.2]bicyclooctane). Preferred carbocycles, unless otherwise
specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
phenyl, and indanyl. When the term "carbocycle," "carbocyclic
residue," or "carbocyclyl" is used, it is intended to include
"aryl". A bridged ring occurs when one or more carbon atoms link
two non-adjacent carbon atoms. Preferred bridges are one or two
carbon atoms. It is noted that a bridge always converts a
monocyclic ring into a tricyclic ring. When a ring is bridged, the
substituents recited for the ring may also be present on the
bridge.
[0266] The term "aryl" refers to monocyclic, bicyclic, tricyclic
aromatic hydrocarbon groups having 6 to 15 carbon atoms in the ring
portion, such as phenyl, naphthyl, biphenyl and diphenyl groups,
each of which may be substituted. Aryl groups which are bicyclic or
tricyclic must include at least one fully aromatic ring but the
other fused ring or rings may be aromatic or non-aromatic. When an
aryl is substituted with a further heterocyclic ring, said ring may
be attached to the aryl through a carbon atom or a heteroatom and
said ring in turn is optionally substituted with one to two
substituents as valence allows.
[0267] The terms "aryloxy", "arylamino", "arylalkylamino",
"arylthio", "arylalkanoylamino", "arylsulfonyl", "arylalkoxy",
"arylsulfinyl", "arylheteroaryl", "arylalkylthio", "arylcarbonyl",
"arylalkenyl", or "arylalkylsulfonyl" refer to an aryl or
substituted aryl bonded to an oxygen; an amino; an alkylamino; a
thio; an alkanoylamino; a sulfonyl; an alkoxy; a sulfinyl; a
heteroaryl or substituted heteroaryl; an alkylthio; a carbonyl; an
alkenyl; or an alkylsulfonyl, respectively.
[0268] The term "alkenyl" refers to straight or branched chain
hydrocarbon groups of 2 to 20 carbon atoms, preferably 2 to 15
carbon atoms, and most preferably 2 to 8 carbon atoms, having one
to four double bonds.
[0269] The term "alkynyl" refers to straight or branched chain
hydrocarbon groups of 2 to 20 carbon atoms, preferably 2 to 15
carbon atoms, and most preferably 2 to 8 carbon atoms, having one
to four triple bonds.
[0270] An "alkylidene" group refers to an alkylene group consisting
of at least two carbon atoms and at least one carbon-carbon double
bond. Substituents on this group include those in the definition of
"substituted alkyl".
[0271] The term "cycloalkyl" refers to an optionally substituted,
saturated cyclic hydrocarbon ring systems, preferably containing 1
to 3 rings and 3 to 7 carbons per ring. Exemplary groups include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, cyclodecyl, cyclododecyl, and adamantyl. Exemplary
substituents include one or more alkyl groups as described above,
or one or more groups described above as alkyl substituents.
[0272] As used herein, the term "heterocycle," "heterocyclyl,"
"heterocyclic ring" or "heterocyclic group" is intended to mean a
stable 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-,
9-, 10-, 11-, 12-, 13-, or 14-membered bicyclic heterocyclic ring
which is saturated, partially unsaturated or fully unsaturated or
aromatic, and which consists of carbon atoms and 1, 2, 3 or 4
heteroatoms independently selected from N, O and S; and including
any bicyclic group in which any of the above-defined heterocyclic
rings is fused to a benzene ring. The nitrogen and sulfur
heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and
S(O).sub.p). The nitrogen atom may be substituted or unsubstituted
(i.e., N or NR wherein R is H or another substituent, if defined).
The heterocyclic ring may be attached to its pendant group at any
heteroatom or carbon atom that results in a stable structure. The
heterocyclic rings described herein may be substituted on carbon or
on a nitrogen atom if the resulting compound is stable. A nitrogen
in the heterocycle may optionally be quaternized. It is preferred
that when the total number of S and O atoms in the heterocycle
exceeds 1, then these heteroatoms are not adjacent to one another.
It is preferred that the total number of S and O atoms in the
heterocycle is not more than 1. When the term "heterocycle,"
"heterocyclyl," "heterocyclic ring" or "heterocyclic group" is
used, it is intended to include heteroaryl.
[0273] Examples of heterocycles include, but are not limited to,
acridinyl, azocinyl, benzimidazolyl, benzofuranyl,
benzothiofuranyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl,
benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl,
benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl,
chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran,
furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl,
1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl,
3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl,
isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,
isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl,
methylenedioxyphenyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl,
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl,
4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl,
quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,
quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,
tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl,
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,
1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl,
thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl,
triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,
1,3,4-triazolyl, and xanthenyl. Also included are fused ring and
spiro compounds containing, for example, the above
heterocycles.
[0274] Preferred 5- to 10-membered heterocycles include, but are
not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl,
pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl,
indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl,
oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl,
thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl,
1H-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl,
benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl,
benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl,
isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl,
tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl,
isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl,
imidazolopyridinyl, and pyrazolopyridinyl.
[0275] Preferred 5- to 6-membered heterocycles include, but are not
limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl,
pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl,
indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl,
oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl,
thiadiazolyl, thiazolyl, triazinyl, and triazolyl. Also included
are fused ring and spiro compounds containing, for example, the
above heterocycles.
[0276] Bridged rings are also included in the definition of
heterocycle. A bridged ring occurs when one or more atoms (i.e., C,
O, N, or S) link two non-adjacent carbon or nitrogen atoms.
Preferred bridges include, but are not limited to, one carbon atom,
two carbon atoms, one nitrogen atom, two nitrogen atoms, and a
carbon-nitrogen group. It is noted that a bridge always converts a
monocyclic ring into a tricyclic ring. When a ring is bridged, the
substituents recited for the ring may also be present on the
bridge.
[0277] The term "heteroaryl" refers to substituted and
unsubstituted aromatic 5- or 6-membered monocyclic groups, 9- or
10-membered bicyclic groups, and 11- to 14-membered tricyclic
groups which have at least one heteroatom (O, S or N) in at least
one of the rings, said heteroatom-containing ring preferably having
1, 2, or 3 heteroatoms selected from O, S, and N. Each ring of the
heteroaryl group containing a heteroatom can contain one or two
oxygen or sulfur atoms and/or from one to four nitrogen atoms
provided that the total number of heteroatoms in each ring is four
or less and each ring has at least one carbon atom. Heteroaryl
groups can be substituted or unsubstituted. The nitrogen atom may
be substituted or unsubstituted (i.e., N or NR wherein R is H or
another substituent, if defined). The nitrogen and sulfur
heteroatoms may optionally be oxidized (i.e., N.fwdarw.O and
S(O).sub.p) and the nitrogen atoms may optionally be
quaternized.
[0278] Heteroaryl groups which are bicyclic or tricyclic must
include at least one fully aromatic ring but the other fused ring
or rings may be aromatic or non-aromatic. The heteroaryl group may
be attached at any available nitrogen or carbon atom of any ring.
The heteroaryl ring system may contain zero, one, two or three
substituents.
[0279] Exemplary monocyclic heteroaryl groups include pyrrolyl,
pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl,
thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl,
oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,
triazinyl and the like.
[0280] Exemplary bicyclic heteroaryl groups include indolyl,
benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl,
quinolinyl, dihydroisoquinolinyl, tetrahydroquinolinyl,
isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazinyl,
indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl,
cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridyl,
dihydroisoindolyl, and the like.
[0281] Exemplary tricyclic heteroaryl groups include carbazolyl,
benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl
and the like.
[0282] The term "heteroatoms" shall include oxygen, sulfur and
nitrogen.
[0283] As referred to herein, the term "substituted" means that one
or more hydrogen atoms is replaced with a non-hydrogen group,
provided that normal valencies are maintained and that the
substitution results in a stable compound. When a substituent is
keto (i.e., .dbd.O), then 2 hydrogens on the atom are replaced.
Keto substituents are not present on aromatic moieties. When a ring
system (e.g., carbocyclic or heterocyclic) is said to be
substituted with a carbonyl group or a double bond, it is intended
that the carbonyl group or double bond be part (i.e., within) of
the ring. Ring double bonds, as used herein, are double bonds that
are formed between two adjacent ring atoms (e.g., C.dbd.C, C.dbd.N,
or N.dbd.N).
[0284] When any variable occurs more than one time in any
constituent or formula for a compound, its definition at each
occurrence is independent of its definition at every other
occurrence. Thus, for example, if a group is shown to be
substituted with 0-3 R.sub.e, then said group may optionally be
substituted with up to three R.sub.e groups and R.sub.e at each
occurrence is selected independently from the definition of
R.sub.e. Also, combinations of substituents and/or variables are
permissible only if such combinations result in stable
compounds.
Utility
[0285] The compounds of the invention may be used to modulate
kinase activities. Types of kinases include, but are not limited
to, AAK1, ABL, ACK, ACTR2, ACTR2B, ADCK3, ADCK4, AKT1, AKT2, AKT3,
ALK, ALK1, ALK2, ALK4, AMPKA1, AMPKA2, ARG, AURA, AURB, AURC, AXL,
BCR-ABL, BIKE, BLK, BMPR1A, BMX, BRAF, BRSK2, BRK, BTK, CAMK1A,
CAMK2A, CAMK2B, CAMK1D, CAMK2D, CAMK1G, CAMK2G, CAMKK1, CAMKK2,
CDK1, CDK2, CDK5, CHK2, CK1A2, CK1D, CK1E, CK1G1, CK1G2, CK2A1,
CK2A2, CLK1, CLK2, CLK3, CLK4, CSK, DAPK2, DAPK3, DCAMKL3, DDR2,
DMPK1, DRAK1, DRAK2, DYRK1, DYRK2, EGFR, EPHA1, EPHA2, EPHA3,
EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4,
ERK1, ERK2, FAK, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1,
FLT3, FLT4, FMS, FRK, FYN, FUSED, GAK, GCN2, GPRK4, GPRK5, GPRK6,
GSK3A, GSK3B, HCK, HPK1, HER2/ERBB2, HER4/ERBB4, HH498, IGF1R,
IKK.alpha., IKK.beta., INSR, IRR, IRAK4, ITK, JAK1, JAK2, JAK3,
JNK1, JNK2, JNK3, KDR, KHS1, KHS2, KIT, LCK, LIMK1, LIMK2, LKB1,
LOK, LTK, LYN, MAP3K4, MAP3K5, MAPK1, MAPKAP-K2, MARK1, MARK2,
MARK4, MEK1, MER, MET, MKK4, MKK6, MLK3, MNK2, MPSK1, MRCKA, MSK1,
MSK2, MST1, MST2, MST3, MST4, MUSK, MYT1, NDR2, NEK2, NEK6, NEK7,
NEK9, NLK, P38A, P38B, P38G, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6,
PCTAIRE1, PDGFRA, PDGFRB, PDK1, PHKG1, PHKG2, PIM1, PIM2, PKA,
PKACA, PKACB, PKCA, PKCD, PKCH, PKCI, PKCT, PKCZ, PKD2, PKG1, PKG2,
PKN2, PLK1, PLK3, PLK4, PRKX, PYK2, QIK, RAF1, RET, RIPK2, ROCK-I,
ROCK-II, RON, ROS, RSK1, RSK2, RSK4, SAPK2a, SAPK2b, SAPK3, SAPK4,
SGK, SIK, SLK, SKMLCK, SRC, SRPK1, STK33, SYK, TESK1, TGFBR1, TIE2,
TLK1, TLK2, TNK1, TRKA, TRKB, TRKC, TTK, TXK, TYK2, TYRO3, ULK3,
WNK3, YANK2, YANK3, YES, YSK1, ZAP70, ZC1/HGK, ZC2/TNIK, and
mutants thereof.
[0286] Applicants have discovered that compounds of Formulae
(I)-(X) have particular utility in treating proliferative
conditions associated with the modulation of kinase activity, and
particularly the inhibition of serine/threonine kinase activities.
The compounds of the present invention can be used to treat
proliferative disorders associated with abnormal kinase activity.
As used herein, the terms "treating" and "treatment" encompass
either or both responsive and prophylaxis measures, e.g., measures
designed to inhibit or delay the onset of the disease or disorder,
achieve a full or partial reduction of the symptoms or disease
state, and/or to alleviate, ameliorate, lessen, or cure the disease
or disorder and/or its symptoms.
[0287] Accordingly, one aspect of the invention is the use of a
compound of the Formulae (I)-(X), or a pharmaceutically acceptable
salt thereof in the manufacture of a medicament for use in the
production of an antiproliferative effect in a warm-blooded animal
such as a human being.
[0288] According to a further feature of the invention there is
provided a method for producing an antiproliferative effect in a
warm-blooded animal, such as a human being, in need of such
treatment which comprises administering to said animal an effective
amount of a compound of Formulae (I)-(X) or a pharmaceutically
acceptable salt thereof as defined herein before.
[0289] The anti-proliferative treatment defined herein before may
be applied as a sole therapy or may involve, in addition to a
compound of the invention, one or more other substances and/or
treatments. Such treatment may be achieved by way of the
simultaneous, sequential or separate administration of the
individual components of the treatment. The compounds of this
invention may also be useful in combination with known anti-cancer
and cytotoxic agents and treatments, including radiation. Compounds
of Formulae (I)-(X) may be used sequentially with known anticancer
or cytotoxic agents and treatment, including radiation when a
combination formulation is inappropriate.
[0290] The term "anti-cancer" agent includes any known agent that
is useful for the treatment of cancer including the following:
17.alpha.-ethinylestradiol, diethylstilbestrol, testosterone,
prednisone, fluoxymesterone, dromostanolone propionate,
testolactone, megestrolacetate, methylprednisolone,
methyl-testosterone, prednisolone, triamcinolone, chlorotrianisene,
hydroxyprogesterone, aminoglutethimide, estramustine,
medroxyprogesteroneacetate, leuprolide, flutamide, toremifene,
ZOLADEX.RTM.; matrix metalloproteinase inhibitors; VEGF inhibitors,
such as anti-VEGF antibodies (AVASTIN.RTM.) and small molecules
such as ZD6474 and SU6668; Vatalanib, BAY-43-9006, SU11248,
CP-547632, and CEP-7055; HER 1 and HER 2 inhibitors including
anti-HER2 antibodies (HERCEPTIN.RTM.); EGFR inhibitors including
gefitinib, erlotinib, ABX-EGF, EMD72000, 11F8, and cetuximab; Eg5
inhibitors, such as SB-715992, SB-743921, and MKI-833; pan Her
inhibitors, such as canertinib, EKB-569, CI-1033, AEE-788, XL-647,
mAb 2C4, and GW-572016; Src inhibitors, e.g., GLEEVEC.RTM. and
dasatinib; CASODEX.RTM. (bicalutamide, Astra Zeneca), Tamoxifen;
MEK-1 kinase inhibitors, MAPK kinase inhibitors, PI3 kinase
inhibitors; PDGF inhibitors, such as imatinib; anti-angiogenic and
antivascular agents which, by interrupting blood flow to solid
tumors, render cancer cells quiescent by depriving them of
nutrition; castration, which renders androgen dependent carcinomas
non-proliferative; inhibitors of non-receptor and receptor tyrosine
kinases; inhibitors of integrin signaling; tubulin acting agents
such as vinblastine, vincristine, vinorelbine, vinflunine,
paclitaxel, docetaxel, 7-O-methylthiomethylpaclitaxel,
4-desacetyl-4-methylcarbonatepaclitaxel,
3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debe-
nzoyl-4-O-methoxycarbonyl-paclitaxel, C-4 methyl carbonate
paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D,
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7-11-dihydroxy-8,8,10,12,16-pen-
tamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17
oxabicyclo[14.1.0]heptadecane-5,9-dione (ixabepilone),
[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazol-
yl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4-17-dioxabic-
yclo[14.1.0]-heptadecane-5,9-dione, and derivatives thereof; other
CDK inhibitors, antiproliferative cell cycle inhibitors,
epidophyllotoxin, etoposide, VM-26; antineoplastic enzymes, e.g.,
topoisomerase I inhibitors, camptothecin, topotecan, SN-38;
procarbazine; mitoxantrone; platinum coordination complexes such as
cisplatin, carboplatin and oxaliplatin; biological response
modifiers; growth inhibitors; antihormonal therapeutic agents;
leucovorin; tegafur; antimetabolites such as purine antagonists
(e.g., 6-thioguanine and 6-mercaptopurine; glutamine antagonists,
e.g., DON (AT-125; d-oxo-norleucine); ribonucleotide reductase
inhibitors; mTOR inhibitors; and haematopoietic growth factors.
[0291] Additional cytotoxic agents include, cyclophosphamide,
doxorubicin, daunorubicin, mitoxanthrone, melphalan, hexamethyl
melamine, thiotepa, cytarabin, idatrexate, trimetrexate,
dacarbazine, L-asparaginase, bicalutamide, leuprolide,
pyridobenzoindole derivatives, interferons, and interleukins.
[0292] In the field of medical oncology it is normal practice to
use a combination of different forms of treatment to treat each
patient with cancer. In medical oncology the other component(s) of
such treatment in addition to the antiproliferative treatment
defined herein may be surgery, radiotherapy or chemotherapy. Such
chemotherapy may cover three main categories of therapeutic
agent:
[0293] (i) antiangiogenic agents that work by different mechanisms
from those defined herein before (for example, linomide, inhibitors
of integrin .alpha.v.beta.3 function, angiostatin, razoxane);
[0294] (ii) cytostatic agents such as antiestrogens (for example,
tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene),
progestogens (for example, megestrol acetate), aromatase inhibitors
(for example, anastrozole, letrozole, borazole, exemestane),
antihormones, antiprogestogens, antiandrogens (for example,
flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH
agonists and antagonists (for example, gosereline acetate,
leuprolide), inhibitors of testosterone 5.alpha.-dihydroreductase
(for example, finasteride), farnesyltransferase inhibitors,
anti-invasion agents (for example, metalloproteinase inhibitors
such as marimastat and inhibitors of urokinase plasminogen
activator receptor function) and inhibitors of growth factor
function, (such growth factors include for example, EGF, FGF,
platelet derived growth factor and hepatocyte growth factor, such
inhibitors include growth factor antibodies, growth factor receptor
antibodies such as AVASTIN.RTM. (bevacizumab) and ERBITUX.RTM.
(cetuximab); tyrosine kinase inhibitors and serine/threonine kinase
inhibitors); and
[0295] (iii) antiproliferative/antineoplastic drugs and
combinations thereof, as used in medical oncology, such as
antimetabolites (for example, antifolates such as methotrexate,
fluoropyrimidines such as 5-fluorouracil, purine and adenosine
analogues, cytosine arabinoside); intercalating antitumour
antibiotics (for example, anthracyclines such as doxorubicin,
daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin,
mithramycin); platinum derivatives (for example, cisplatin,
carboplatin); alkylating agents (for example, nitrogen mustard,
melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide,
nitrosoureas, thiotepa; antimitotic agents (for example, vinca
alkaloids like vincristine, vinorelbine, vinblastine and
vinflunine) and taxoids such as TAXOL.RTM. (paclitaxel), Taxotere
(docetaxel) and newer microbtubule agents such as epothilone
analogs (ixabepilone), discodermolide analogs, and eleutherobin
analogs; topoisomerase inhibitors (for example, epipodophyllotoxins
such as etoposide and teniposide, amsacrine, topotecan,
irinotecan); cell cycle inhibitors (for example, flavopyridols);
biological response modifiers and proteasome inhibitors such as
VELCADE.RTM. (bortezomib).
[0296] As stated above, the Formulae (I)-(X) compounds of the
invention are of interest for their antiproliferative effects. Such
compounds of the invention are expected to be useful in a wide
range of disease states including cancer, psoriasis, and rheumatoid
arthritis.
[0297] More specifically, the compounds of Formulae (I)-(X) are
useful in the treatment of a variety of cancers, including (but not
limited to) the following:
[0298] carcinoma, including that of the prostate, pancreatic ductal
adenocarcinoma, breast, colon, lung, ovary, pancreas, and
thyroid;
[0299] tumors of the central and peripheral nervous system,
including neuroblastoma, glioblastoma, and medulloblastoma; and
[0300] other tumors, including melanoma and multiple myeloma.
[0301] Due to the key role of kinases in the regulation of cellular
proliferation in general, inhibitors could act as reversible
cytostatic agents which may be useful in the treatment of any
disease process which features abnormal cellular proliferation,
e.g., benign prostate hyperplasia, familial adenomatosis polyposis,
neurofibromatosis, pulmonary fibrosis, arthritis, psoriasis,
glomerulonephritis, restenosis following angioplasty or vascular
surgery, hypertrophic scar formation and inflammatory bowel
disease.
[0302] The compounds of Formula (I)-(X) are especially useful in
treatment of tumors having a high incidence of serine/threonine
kinase activity, such as prostate, colon, brain, thyroid and
pancreatic tumors. Additionally, the compounds of the invention may
be useful in treatment of sarcomas and pediatric sarcomas. By the
administration of a composition (or a combination) of the compounds
of this invention, development of tumors in a mammalian host is
reduced.
[0303] Compounds of Formula (I)-(X) may also be useful in the
treatment of other cancerous diseases (such as acute myelogenous
leukemia) that may be associated with signal transduction pathways
operating through kinases such as DYRK1a, CDK, and GSK3.beta.. The
inventive compositions may contain other therapeutic agents as
described above and may be formulated, for example, by employing
conventional solid or liquid vehicles or diluents, as well as
pharmaceutical additives of a type appropriate to the mode of
desired administration (e.g., excipients, binders, preservatives,
stabilizers, flavors, etc.) according to techniques such as those
well known in the art of pharmaceutical formulation.
[0304] Accordingly, the present invention further includes
compositions comprising one or more compounds of Formula (I)-(X)
and a pharmaceutically acceptable carrier.
[0305] A "pharmaceutically acceptable carrier" refers to media
generally accepted in the art for the delivery of biologically
active agents to animals, in particular, mammals. Pharmaceutically
acceptable carriers are formulated according to a number of factors
well within the purview of those of ordinary skill in the art.
These include, without limitation: the type and nature of the
active agent being formulated; the subject to which the
agent-containing composition is to be administered; the intended
route of administration of the composition; and, the therapeutic
indication being targeted. Pharmaceutically acceptable carriers
include both aqueous and non-aqueous liquid media, as well as a
variety of solid and semi-solid dosage forms. Such carriers can
include a number of different ingredients and additives in addition
to the active agent, such additional ingredients being included in
the formulation for a variety of reasons, e.g., stabilization of
the active agent, binders, etc., well known to those of ordinary
skill in the art. Descriptions of suitable pharmaceutically
acceptable carriers, and factors involved in their selection, are
found in a variety of readily available sources such as, for
example, Remington's Pharmaceutical Sciences, 17th ed. (1985),
which is incorporated herein by reference in its entirety.
[0306] The pharmaceutical compositions of the invention containing
the active ingredient may be in a form suitable for oral use, for
example, as tablets, troches, lozenges, aqueous or oily
suspensions, dispersible powders or granules, emulsions, hard or
soft capsules, or syrups or elixirs. Compositions intended for oral
use may be prepared according to any method known to the art for
the manufacture of pharmaceutical compositions and such
compositions may contain one or more agents selected from the group
consisting of sweetening agents, flavoring agents, coloring agents
and preserving agents in order to provide pharmaceutically elegant
and palatable preparations.
[0307] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water soluble carrier such as
polyethyleneglycol or an oil medium, for example peanut oil, liquid
paraffin, or olive oil.
[0308] The pharmaceutical compositions may be in the form of
sterile injectable aqueous solutions. Among the acceptable vehicles
and solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. The sterile injectable
preparation may also be a sterile injectable oil-in-water
microemulsion where the active ingredient is dissolved in the oily
phase. For example, the active ingredient may be first dissolved in
a mixture of soybean oil and lecithin. The oil solution then
introduced into a water and glycerol mixture and processed to form
a microemulation.
[0309] The injectable solutions or microemulsions may be introduced
into a patient's blood-stream by local bolus injection.
Alternatively, it may be advantageous to administer the solution or
microemulsion in such a way as to maintain a constant circulating
concentration of the instant compound. In order to maintain such a
constant concentration, a continuous intravenous delivery device
may be utilized. An example of such a device is the Deltec
CADD-PLUS.RTM. Model 5400 intravenous pump.
[0310] The pharmaceutical compositions may be in the form of a
sterile injectable aqueous or oleagenous suspension for
intramuscular and subcutaneous administration. This suspension may
be formulated according to the known art using those suitable
dispersing or wetting agents and suspending agents which have been
mentioned above.
[0311] The compounds of Formulae (I)-(X) may be administered by any
means suitable for the condition to be treated, which may depend on
the need for site-specific treatment or quantity of drug to be
delivered. Topical administration is generally preferred for
skin-related diseases, and systematic treatment preferred for
cancerous or pre-cancerous conditions, although other modes of
delivery are contemplated. For example, the compounds may be
delivered orally, such as in the form of tablets, capsules,
granules, powders, or liquid formulations including syrups;
topically, such as in the form of solutions, suspensions, gels or
ointments; sublingually; bucally; parenterally, such as by
subcutaneous, intravenous, intramuscular or intrasternal injection
or infusion techniques (e.g., as sterile injectable aq. or non-aq.
solutions or suspensions); nasally such as by inhalation spray;
topically, such as in the form of a cream or ointment; rectally
such as in the form of suppositories; or liposomally. Dosage unit
formulations containing non-toxic, pharmaceutically acceptable
vehicles or diluents may be administered. The compounds may be
administered in a form suitable for immediate release or extended
release. Immediate release or extended release may be achieved with
suitable pharmaceutical compositions or, particularly in the case
of extended release, with devices such as subcutaneous implants or
osmotic pumps.
[0312] Exemplary compositions for topical administration include a
topical carrier such as Plastibase (mineral oil gelled with
polyethylene).
[0313] Exemplary compositions for oral administration include
suspensions which may contain, for example, microcrystalline
cellulose for imparting bulk, alginic acid or sodium alginate as a
suspending agent, methylcellulose as a viscosity enhancer, and
sweeteners or flavoring agents such as those known in the art; and
immediate release tablets which may contain, for example,
microcrystalline cellulose, dicalcium phosphate, starch, magnesium
stearate and/or lactose and/or other excipients, binders,
extenders, disintegrants, diluents and lubricants such as those
known in the art. The inventive compounds may also be orally
delivered by sublingual and/or buccal administration, e.g., with
molded, compressed, or freeze-dried tablets. Exemplary compositions
may include fast-dissolving diluents such as mannitol, lactose,
sucrose, and/or cyclodextrins. Also included in such formulations
may be high molecular weight excipients such as celluloses
(AVICEL.RTM.) or polyethylene glycols (PEG); an excipient to aid
mucosal adhesion such as hydroxypropyl cellulose (HPC),
hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl
cellulose (SCMC), and/or maleic anhydride copolymer (e.g.,
Gantrez); and agents to control release such as polyacrylic
copolymer (e.g., Carbopol 934). Lubricants, glidants, flavors,
coloring agents and stabilizers may also be added for ease of
fabrication and use.
[0314] Exemplary compositions for nasal aerosol or inhalation
administration include solutions which may contain, for example,
benzyl alcohol or other suitable preservatives, absorption
promoters to enhance absorption and/or bioavailability, and/or
other solubilizing or dispersing agents such as those known in the
art.
[0315] Exemplary compositions for parenteral administration include
injectable solutions or suspensions which may contain, for example,
suitable non-toxic, parenterally acceptable diluents or solvents,
such as mannitol, 1,3-butanediol, water, Ringer's solution, an
isotonic sodium chloride solution, or other suitable dispersing or
wetting and suspending agents, including synthetic mono- or
diglycerides, and fatty acids, including oleic acid.
[0316] Exemplary compositions for rectal administration include
suppositories which may contain, for example, suitable
non-irritating excipients, such as cocoa butter, synthetic
glyceride esters or polyethylene glycols, which are solid at
ordinary temperatures but liquefy and/or dissolve in the rectal
cavity to release the drug.
[0317] When a compound according to this invention is administered
into a human subject, the daily dosage will normally be determined
by the prescribing physician with the dosage generally varying
according to the age, weight, sex and response of the individual
patient, as well as the severity of the patient's symptoms.
Exemplary dosage amounts for a mammal may include from about 0.05
to 1000 mg/kg; 1-1000 mg/kg; 1-50 mg/kg; 5-250 mg/kg; 250-1000
mg/kg of body weight of active compound per day, which may be
administered in a single dose or in the form of individual divided
doses, such as from 1 to 4 times per day. It will be understood
that the specific dose level and frequency of dosage for any
particular subject may be varied and will depend upon a variety of
factors, including the activity of the specific compound employed,
the metabolic stability and length of action of that compound, the
species, age, body weight, general health, sex and diet of the
subject, the mode and time of administration, rate of excretion,
drug combination, and severity of the particular condition.
Preferred subjects for treatment include animals, most preferably
mammalian species such as humans, and domestic animals such as
dogs, cats, horses, and the like. Thus, when the term "patient" is
used herein, this term is intended to include all subjects, most
preferably mammalian species, that are affected by mediation of
protein kinase enzyme levels.
[0318] If formulated as a fixed dose, a combination product can,
for example, utilize a dosage of the compound of Formulae (I)-(X)
within the dosage range described above and the dosage of another
anti-cancer agent/treatment within the approved dosage range for
such known anti-cancer agent/treatment. If a combination product is
inappropriate, the compounds of Formulae (I)-(X) and the other
anti-cancer agent/treatment can, for example, be administered
simultaneously or sequentially. If administered sequentially, the
present invention is not limited to any particular sequence of
administration. For example, compounds of Formulas (I)-(X) can be
administered either prior to, or after, administration of the known
anti-cancer agent or treatment.
Biological Assays
A. CK2 Kinase Assay
[0319] The effectiveness of compounds of the present invention as
inhibitors of protein kinases can be readily tested by assays known
to those skilled in the art. For example, in vitro protein kinase
assays may be conducted with a relevant purified protein kinase and
an appropriate synthetic substrate to determine the inhibitory
activity of the compounds. Assays for inhibition of CK2 by the
instant compounds were performed in 384-well plates with reaction
mixtures containing 10 .mu.M of peptide substrate
(RRRADDSDDDDD-NH2), [.gamma.-.sup.33P]ATP (10 .mu.Ci) at 25 .mu.M
(CK2A1) or 5 .mu.M (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10
mM MgCl.sub.2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and
recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate
Biotechnology). Reaction mixtures were incubated at 30.degree. C.
for 1 hour, and reaction products were captured by binding to
phosphocellulose (P81) filter plates. Incorporation of radioactive
phosphate into the peptide substrate was determined by liquid
scintillation counting. The potency of compounds in inhibiting CK2
is expressed as IC.sub.50, defined as the concentrations of
compounds required to inhibit the enzymatic activity by 50%.
[0320] The inhibitory activity of the instant compounds may also be
measured by recombinant CK2 holoenzyme kinase assays. The assays
were performed in U-bottom 384-well plates. The final assay volume
was 30 .mu.l prepared from 15 .mu.l additions of enzyme and
substrates (fluoresceinated peptide FL-RRRADDSDDDDD-NH2 and ATP)
and test compounds in assay buffer (20 mM HEPES pH 7.4, 10 mM
MgCl.sub.2, 100 mM NaCl, 0.015% Brij35 and 0.25 mM DTT). The
reaction was initiated by the combination of bacterially expressed,
CK2 .alpha./.beta. or CK2 .alpha.'/.beta. holoenzyme with
substrates and test compounds. The reaction was incubated at room
temperature for 60 minutes and terminated by adding 30 .mu.l of 35
mM EDTA to each sample. The reaction mixture was analyzed on the
Caliper LABCHIP.RTM. 3000 (Caliper, Hopkinton, Mass.) by
electrophoretic separation of the fluorescent substrate and
phosphorylated product. Inhibition data were calculated by
comparison to no enzyme control reactions for 100% inhibition and
vehicle-only reactions for 0% inhibition. The final concentration
of reagents in the CK2 .alpha./.beta. assay was 25 .mu.M ATP, 1.5
.mu.M FL-RRRADDSDDDDD-NH2, 50 pM CK2 .alpha./.beta. holoenzyme, and
1.6% DMSO. The final concentration of reagents in the CK2
.alpha.'/.beta. assay was 10 .mu.M ATP, 1.5 .mu.M
FL-RRRADDSDDDDD-NH2, 100 pM CK2 .alpha.'/.beta. holoenzyme, and
1.6% DMSO. Dose response curves were generated to determine the
concentration required inhibiting 50% of kinase activity
(IC.sub.50). Compounds were dissolved at 10 mM in dimethylsulfoxide
(DMSO) and evaluated at eleven concentrations. IC.sub.50 values
were derived by non-linear regression analysis.
B. Cell Proliferation Inhibition Assay
[0321] Compounds were evaluated for their ability to inhibit cell
proliferation, using an assay that measures mitochondrial metabolic
activity, that is directly correlated with cell numbers. Cells were
plated at 2000 cells/well in 96-well plates and were cultured for
24 h in RPMI-1640 supplemented with 2% fetal bovine serum, before
test compounds were added. Compounds were diluted in culture medium
such that the final concentration of dimethyl sulfoxide never
exceeded 1%. Following the addition of compounds, the cells were
cultured for an additional 72 h before cell viability was
determined by measuring the conversion of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye using the CellTiter96 kit (Promega) or by measuring the
conversion of
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
)-2H-tetrazolium (MTS) dye using the CELLTITER 96.RTM. AQueous
(Promega).
[0322] The following compounds were found to have the IC.sub.50
described in Table 1 when measured in the assays described
above.
TABLE-US-00001 TABLE 1 CK2A1 (CK2.alpha./.beta.) CK2A2
(CK2.alpha.'/.beta.) HCT116 Example No. (IC.sub.50, .mu.M)
(IC.sub.50, .mu.M) (IC.sub.50, .mu.M) 1 0.0060 0.0075 0.030 31
0.1429 0.0257 0.460 37 0.0110 0.0045 0.163 44 1.3110 0.0351
>1.00 46 0.0043 0.0024 0.150 47 0.0074 0.0052 0.041 48 0.4167
0.1058 0.460 56 0.1548 0.0359 0.482 57 0.3097 0.0582 0.521 58
0.0122 0.0022 0.098 64 0.0120 0.0010 0.048 66 6.0640 0.7784
>2.50 71 0.2612 0.0156 0.945 73 4.6040 0.7379 2.243 80 4.6580
1.4930 >1.00 81 0.5125 0.1149 >1.00 82 0.4792 0.1258 0.127 89
6.6690 0.9400 >1.00 93 0.7120 0.0684 >1.00 95 0.0065 0.0030
0.022 111 0.1164 0.0240 0.034 160 0.0197 0.0046 0.045 167 0.1031
0.0125 >1.00 168 0.0119 0.0049 0.128 196 0.0122 0.0034 0.065 214
0.5957 0.1189 >10.00 224 0.7938 0.1261 >10.00 225 0.0082
0.0011 0.035 228 0.0090 0.0017 0.327 233 0.0071 0.0023 0.128 235
0.0250 0.0064 0.433 244 0.1023 0.0228 1.111
[0323] Compounds of the present invention exhibit enhanced CK2
inhibitory activity over the compounds disclosed in U.S.
Publication No. 2008/0045536. Comparing the data in Table 1 and
Table 2, compounds of the invention herein, e.g., compounds of
Formula (I) (including Formulae (II), (III), (IV), (V), (V), (VII),
(VIII), (IX), and (X)), are surprisingly advantageous for their CK2
enzyme inhibition activity and/or other drugability properties.
TABLE-US-00002 TABLE 2 Example No. CK2A1 CK2A2 in US 2008/0045536
Structure IC.sub.50 (.mu.M) IC.sub.50 (.mu.M) I(1) Page 27
##STR00013## >50 10.35 I(7) Page 29 ##STR00014## >50 >50
II (16) Page 46 ##STR00015## >50 31.77 XXV(1) Page 70
##STR00016## 2.69 8.09
Methods of Preparation
[0324] The compounds of the present invention may be prepared by
methods such as those illustrated in the following schemes.
Solvents, temperatures, pressures, and other reaction conditions
may readily be selected by one of ordinary skill in the art.
Starting materials are commercially available or readily prepared
by one of ordinary skill in the art. These schemes are illustrative
and are not meant to limit the possible techniques one skilled in
the art may use to manufacture compounds disclosed herein.
Different methods may be evident to those skilled in the art.
Additionally, the various steps in the synthesis may be performed
in an alternate sequence or order to give the desired compound(s).
All documents cited herein are incorporated herein by reference in
their entirety.
[0325] In general, the time taken to complete a reaction procedure
will be judged by the person performing the procedure, preferably
with the aid of information obtained by monitoring the reaction by
methods such as HPLC or TLC. A reaction does not have to go to
completion to be useful to this invention. The methods for the
preparation of various heterocycles used to this invention can be
found in standard organic reference books, for example, Katritzky,
A. R. et al., eds., Comprehensive Heterocyclic Chemistry, The
Structure, Reactions, Synthesis and Uses, of Heterocyclic
Compounds, First Edition, Pergamon Press, New York (1984), and
Katritzky, A. R. et al., eds., Comprehensive Heterocyclic Chemistry
II, A Review of the Literature 1982-1995: The Structure, Reactions,
Synthesis and Uses, of Heterocyclic Compounds, Pergamon Press, New
York (1996).
[0326] Unless otherwise specified, the various substituents of the
compounds are defined in the same manner as the Formula (I)
compound of the invention.
##STR00017##
Step 1
[0327] The first step in Scheme 1 is accomplished by treating an
appropriately substituted .alpha.-haloester (ii, A=C.sub.1-4 lower
alkyl, Hal.sub.1-Hal.sub.5=Cl, Br, I, F) with a formate ester (i)
such as ethyl formate in the presence of a base such as sodium
ethoxide in a suitable solvent such as ethanol to afford a compound
of Formula iii.
Step 2
[0328] Halogenation of a suitably substituted pyridazine-3-amine
(iv) such as 6-chloropyridazine-3-amine using a reagent such as
bromine in an appropriate solvent such as ethanol or methanol
provides compounds of Formula v.
Step 3
[0329] The reaction of compounds iii and v at elevated temperature,
for example above 80.degree. C., in an appropriate solvent such as
ethanol, results in formation of a mixture of esters vi and vii
(Hal.sub.4=Hal.sub.1 or Hal.sub.3) that may be used in subsequent
steps without separation.
Step 4
[0330] The acid catalyzed hydrolysis of vi/vii using, for example,
aqueous HCl in a solvent such as methanol at elevated temperature
affords compounds of Formula viii.
Step 5
[0331] Alternatively, compounds of Formula iv may be reacted with
an .alpha.-haloaldehyde at elevated temperature, for example above
80.degree. C., in an appropriate solvent such as ethanol to afford
compounds of Formula x.
Step 6
[0332] Treatment of compounds with general Formula x with a base
such as lithium diisopropylamide in an aprotic solvent, such as
tetrahydrofuran, followed by quenching with carbon dioxide may also
afford compounds of general Formula viii.
##STR00018##
Step 1
[0333] Further modifications may be made according to Scheme 2.
Activation of the carboxylic acid of compound viii through, for
example, formation of the acid chloride with thionyl chloride in a
suitable solvent such as dichloromethane affords compounds of
Formula xi.
Step 2
[0334] Reaction of xi with ammonia or a suitable equivalent in a
solvent such as 1,4-dioxane or THF affords amides of Formula xii.
Alternatively, steps 1-2 may be accomplished in a single step
through use of a coupling reagent such as BOP or DCC in the
presence of ammonia or a suitable equivalent in an appropriate
solvent such as DMF.
Step 3
[0335] Dehydration of compounds of Formula xii may be accomplished
through reaction with a suitable dehydrating reagent such as
POCl.sub.3 in an appropriate solvent such as chloroform to afford
compounds of Formula xiii.
Step 4
[0336] Treatment of compound xiii with an amine (R.sub.4R.sub.5NH)
such as N-(4-methoxybenzyl)cyclopropanamine or
N-(4-methoxybenzyl)pyridin-2-amine in the presence of a base such
as diisopropylethylamine or sodium tert-butoxide in an aprotic
solvent such as THF or DMF affords compounds of Formula ivx.
Step 5
[0337] Compounds of Formula xv may be formed through the direct
displacement of Hal.sub.2 with a suitable amine at elevated
temperature, for example above 100.degree. C., in an appropriate
solvent such as NMP. Alternatively, treatment of ivx with a
palladium catalyst, such as Pd.sub.2(dba).sub.3, in the presence of
a ligand, such as 4,5-bis(diphenyl-phosphino)-9,9-dimethylxanthene
(Xantphos) (Guari, Y. et al., Chem. Eur. J., 7:475-482 (2001)), and
a base, such as cesium carbonate, and an additive, such as copper
(I) iodide, may be used with an appropriately substituted amine
with a suitable solvent such as NMP to afford compounds of general
Formula xv. Alternatively, treatment of ivx with a palladium
catalyst, such as allyl palladium (II) chloride dimer, in the
presence of a ligand, such as
di-tert-butyl(1-methyl-2,2-diphenylcyclopropyl)phosphine (Suzuki,
K. et al., Adv. Synth. Catal., 350:652 (2008)), and a base, such as
sodium t-butoxide, may be used with an appropriately substituted
amine with a suitable solvent such as toluene to afford compounds
of general Formula xv.
Step 6
[0338] In cases where R.sub.5 is an amine protecting group, such as
p-methoxybenzyl, removal of the protecting group can be effected
through known methods. For example, treatment with trifluoroacetic
acid with or without an appropriate solvent, such as
dichloromethane in the presence of a cation trap such as
triethylsilane affords compounds of Formula xvi.
##STR00019##
Step 1
[0339] Alternatively, compounds of Formula xv may be prepared
according to Scheme 3. Treatment of compounds of Formula ivx with
an amine (R.sub.6NH.sub.2) at elevated temperatures, for example
above 100.degree. C., in an appropriate solvent such as DMF or DMA
may afford compounds of Formula xvii. Alternatively, treatment of
ivx with a palladium catalyst, such as Pd.sub.2(dba).sub.3, in the
presence of a ligand, such as
4,5-bis(diphenyl-phosphino)-9,9-dimethylxanthene (Xantphos) (Guari,
Y. et al., Chem. Eur. J., 7:475-482 (2001)), and a base, such as
cesium carbonate, and an additive, such as copper (I) iodide, may
be used with an appropriately substituted amine with a suitable
solvent such as NMP to afford compounds of general Formula xvii.
Alternatively, treatment of ivx with a palladium catalyst, such as
allyl palladium (II) chloride dimer, in the presence of a ligand,
such as di-tert-butyl(1-methyl-2,2-diphenylcyclopropyl)phosphine
(Suzuki, K. et al., Adv. Synth. Catal., 350:652 (2008)), and a
base, such as sodium t-butoxide, may be used with an appropriately
substituted amine with a suitable solvent such as toluene to afford
compounds of general Formula xvii.
Step 2
[0340] Compounds of Formula xvii may then be further modified
through reactions known to one skilled in art to afford compounds
of Formula xv. Such reactions may include treatment of xvii with an
aryl halide in the presence of a palladium catalyst, such as
Pd.sub.2(dba).sub.3 with an appropriate ligand, such as Xantphos,
and a base, such as cesium carbonate or sodium t-butoxide, and an
additive, such as copper (I) iodide.
##STR00020##
Step 1
[0341] An alternative route towards intermediates of general
Formula ivx is shown in Scheme 4. Compounds of Formula x may be
treated with an alcohol or phenol (A=C.sub.1-4 alkyl or Ph) in the
presence of a base, such as K.sub.2CO.sub.3 or NaH, in an
appropriate solvent, such as THF to afford compounds of Formula
xviii.
Step 2
[0342] Treatment of xviii with a suitable halogenating reagent such
as N-bromosuccinimide or N-chlorosuccinimide in an appropriate
solvent such as chloroform affords compounds of Formula ixx.
Step 3
[0343] A cyano group may be introduced either directly through
displacement of Hal.sub.1 with a reagent such as sodium cyanide in
an appropriate solvent such as DMSO or alternatively, through
palladium mediated coupling with a reagent such as Zn(CN).sub.2 in
the presence of Pd(PPh.sub.3).sub.4 in a solvent such as toluene or
DMF to afford compounds of Formula xx.
Step 4
[0344] Direct displacement of the alkoxy group (--OA) of compound
xx with an amine (R.sub.4R.sub.5NH) at elevated temperatures, for
example above 100.degree. C., with or without an appropriate
solvent such as DMF or DMA may afford compounds of Formula ivx.
Step 5
[0345] Alternatively, treatment of xx with an acid, such as aqueous
HCl affords compounds of Formula xxi.
Step 6
[0346] Compounds of Formula xxi may be converted to compounds of
Formula xiii by treatment with a halogenating reagent such as
POBr.sub.3 or POCl.sub.3, either neat or in an appropriate solvent
such as toluene.
[0347] It is anticipated that, where possible, the products of the
reaction schemes described above may be further elaborated by one
of ordinary skill in the art. For example, in instances where
R.sub.2 contains suitable functional groups, such as amino or
carboxy groups, further modifications may be made according to
methods well known to those skilled in the art (See e.g., March,
J., Advanced Organic Chemistry: Reactions, Mechanisms and
Structure, 4th Ed., John Wiley and Sons, New York (1992).)
EXAMPLES
[0348] The invention is further defined in the following Examples.
It should be understood that these Examples are given by way of
illustration only. From the above discussion and these Examples,
one skilled in the art can ascertain the essential characteristics
of this invention, and without departing from the spirit and scope
thereof, can make various changes and modifications to the
invention to adapt the invention to various uses and conditions. As
a result, the present invention is not limited by the illustrative
examples set forth herein below, but rather defined by the claims
appended hereto.
[0349] For ease of reference, the following abbreviations are used
herein:
BOC=tert-butoxycarbonyl bp=boiling point
BOP=(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate DMAP=4-dimethylaminopyridine DCC=Dicyclohexyl
carbodiimide
DCM=Dichloromethane
DIPEA or DIEA=N,N-diisopropylethylamine
[0350] DMA=dimethyl acetamide DME=1,2-dimethoxyethane DMF=dimethyl
formamide EDCI=N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride Et=ethyl Et.sub.2O=diethyl ether
HOBT=1-hydroxybenzotriazole EtOAc=ethyl acetate EtOH=ethanol
g=gram(s) h=hr(s)=hour(s) H=hydrogen l=liter mCPBA--meta chloro
perbenzoic acid Me=methyl MeCN=acetonitrile MeOH=methanol
min(s)=minute(s) NMP=1-methyl-2-pyrrolidinone
Pd.sub.2(dba).sub.3=Pd.sub.2
dba.sub.3=Tris(dibenzylineneacetone)dipalladium(0) Pd/C=palladium
on carbon Rt=retention time THF=tetrahydrofuran TEA=triethylamine
TFA=trifluoroacetic acid
Xantphos=4,5-bis(diphenyl-phosphino)-9,9-dimethylxanthene
mg=milligram(s) ml or mL=milliliter .mu.l=microliter mmol=millimole
.mu.mol=micromole mol=mole PSI=lbs/in.sup.2
SYNTHESIS OF INTERMEDIATES
Intermediate 1
3-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethyl)aniline
##STR00021##
[0352] 3-Bromo-5-(trifluoromethyl)aniline (3.5 g, 14.6 mmol),
copper(I) iodide (1.39 g, 7.3 mmol), potassium carbonate (6.0 g,
43.7 mmol) and 1H-1,2,4-triazole (3.0 g, 43.7 mmol) in NMP (10 mL)
were heated at 195.degree. C. for 2 hours. The reaction mixture was
filtered through a plug of silica gel, washed with ethyl acetate,
and concentrated. The crude residue was purified by silica gel
column chromatography (stepwise gradient, from hexanes to 75% ethyl
acetate/hexanes). The fractions were concentrated, dissolved in
diethyl ether (150 mL), washed with water (4.times.50 mL), dried
over Na.sub.2SO.sub.4, filtered and concentrated to afford
Intermediate 1 (1.95 g, 58.6% yield) as a tan solid. HPLC: Rt=1.193
min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90%
aqueous methanol containing 0.1% TFA, 2 min. gradient, flow rate=5
mL/min., detection at 254 nm). MS (ES): m/z=229.01 [M+H].sup.+.
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 8.27 (1H, s), 7.34
(1H, s), 6.47 (2H, d, J=2.29), 6.14 (1H, s). Intermediate 1 was
used in the synthesis of Examples 13, 104, 165, 169, and 175.
Intermediate 2
3-Methoxy-5-(1H-1,2,4-triazol-1-yl)aniline
##STR00022##
[0353] Intermediate 2A: Preparation of
1-(3-methoxy-5-nitrophenyl)-1H-1,2,4-triazole
##STR00023##
[0355] 1-Bromo-3-methoxy-5-nitrobenzene (500 mg, 2.16 mmol),
copper(I) iodide (205 mg, 1.08 mmol), potassium carbonate (893 mg,
6.5 mmol) and 1H-1,2,4-triazole (446 mg, 6.5 mmol) in NMP (2 mL)
were heated at 100.degree. C. for 12 hours. The reaction mixture
was diluted with DCM, filtered through a plug of silica gel and
washed with ethyl acetate. The filtrate was concentrated, and the
residue was purified by reverse phase HPLC to obtain Intermediate 2
(251 mg, 52.9% yield) as a yellow solid. HPLC: Rt=1.235 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90% aqueous
methanol containing 0.1% TFA, 2 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=221.0 [M+H].sup.+.
Preparation of 3-methoxy-5-(1H-1,2,4-triazol-1-yl)aniline
##STR00024##
[0357] A solution of Intermediate 2A (197 mg, 0.895 mmol) in ethyl
acetate (30 m) was passed through a 10% Pd/C cartridge of a H-Cube
hydrogenator (ThalesNano, 20 bar of hydrogen at 25.degree. C.).
After a second passage, the reaction mixture was concentrated to
give Intermediate 2 (131 mg, 77% yield) as a light yellow solid.
HPLC: Rt=0.298 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient,
flow rate=5 mL/min., detection at 254 nm). MS (ES): m/z=191.09
[M+H].sup.+. Intermediate 2 was used in the synthesis of Example
2.
[0358] The following intermediates in Table 3 were prepared using
the procedures described in the preparation of Intermediate 1 and
Intermediate 2.
TABLE-US-00003 TABLE 3 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name [M + H] (min.)* 3 ##STR00025## 103
3-(1H-Pyrazol-1-yl)- 5-(trifluoromethyl) aniline 228.17 1.38.sup.a
4 ##STR00026## 137 3-(1H-1,2,4-Triazol- 1-yl)-4- (trifluoromethoxy)
aniline 245.02 1.01.sup.a 5 ##STR00027## 145 5-(1H-1,2,4-Triazol-
1-yl)pyridin-3-amine 162.09 0.17.sup.a 6 ##STR00028## 155
3-Methyl-5-(1H- 1,2,4-triazol-1- yl)aniline 175.20 0.63.sup.a 7
##STR00029## 159 3-Amino-5-(1H-1,2,4- triazol-1-yl)phenyl) methanol
191.17 0.27.sup.a 8 ##STR00030## 192 3-Amino-5-(1H-1,2,4-
triazol-1-yl) benzamide 203.9 0.41.sup.a 9 ##STR00031## 170
2-Fluoro-5-(1H-1,2,4- triazol-1-yl)aniline 179.25 0.78.sup.a 10
##STR00032## 162 2-Methyl-5-(1H- 1,2,4-triazol-1- yl)aniline 175.14
1.01.sup.c 11 ##STR00033## 163 4-Fluoro-3-(1H-1,2,4-
triazol-1-yl)aniline 179.07 0.21.sup.a 12 ##STR00034## 167
5-(1H-1,2,4-Triazol- 1-yl)-2- (trifluoromethoxy) aniline 245.11
2.5.sup.c 13 ##STR00035## 160 2-Methoxy-5-(1H- 1,2,4-triazol-1-yl)
aniline 191.14 0.66.sup.b 14 ##STR00036## 194 3-Amino-N-methyl-5-
(1H-1,2,4-triazol-1-yl) benzamide 218.17 0.15.sup.a 15 ##STR00037##
156 3-Chloro-5-(1H-1,2,4- triazol-1-yl)aniline 195.12 1.03.sup.a
*HPLC conditions .sup.aPHENOMENEX .RTM. Luna 5 micron C18 4.6
.times. 30 mm, 0 to 100 B in 2 min. with 1 min. hold time, flow
rate = 5 mL/min., detection at 254 nm, Solvent A: 10% methanol/90%
water/0.1% TFA; Solvent B: 10% water/90% methanol/0.1% TFA
.sup.bCHROMOLITH .RTM. column 4.6 .times. 50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min,
monitoring at 220 nm. .sup.gWaters Sunfire C18 4.6 .times. 150 mm 5
micron. 1 mL/min., 0-100% Water-Methanol 0.2% H.sub.3PO.sub.4,
gradient over 4 min.
Intermediate 16
3-(2-(Dimethylamino)ethoxy)-5-(1H-1,2,4-triazol-1-yl)aniline
##STR00038##
[0359] Intermediate 16A: Preparation of
2-(3-bromo-5-nitrophenoxy)-N,N-dimethylethanamine
##STR00039##
[0361] 1-Bromo-3,5-dinitrobenzene (1 g, 4.1 mmol),
2-(dimethylamino)ethanol (0.54 g, 6.1 mmol), potassium hydroxide
(0.45 g, 8.1 mmol), and water (0.5 mL) in DMF (5 mL) were heated at
80.degree. C. After 20 hours, the reaction mixture was diluted with
cold water and extracted with dichloromethane (2.times.100 mL). The
organic phase was washed with brine, dried over sodium sulfate,
filtered and concentrated. The crude product was purified by silica
gel chromatography (stepwise gradient, 2% ethyl acetate in hexanes
to ethyl acetate) to give
2-(3-bromo-5-nitrophenoxy)-N,N-dimethylethanamine (669 mg, 57.2%
yield) as a brown oil. HPLC: Rt=1.04 min. (PHENOMENEX.RTM. Luna 5
micron C18 4.6.times.30 mm, 10-90% aqueous methanol containing 0.1%
TFA, 2 min. gradient, flow rate=5 mL/min., detection at 254 nm). MS
(ES): m/z=290.93 [M+H].sup.+.
Intermediate 16B: Preparation of
N,N-dimethyl-2-(3-nitro-5-(1H-1,2,4-triazol-1-yl)phenoxy)ethanamine
##STR00040##
[0363] Intermediate 16A (200 mg, 0.69 mmol), copper(I) iodide (65.9
mg, 0.35 mmol), potassium carbonate (287 mg, 2.1 mmol) and
1H-1,2,4-triazole (143 mg, 2.075 mmol) in NMP (2 mL) were heated at
120.degree. C. for 6 hours. The reaction mixture was diluted with
dichloromethane, and filtered through a plug of silica gel and
washed with ethyl acetate. The filtrate was concentrated, and the
residue was purified by reverse phase HPLC to obtain Intermediate
16B (109 mg, 56.8% yield) as a yellow solid. HPLC: Rt=0.74 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90% aqueous
methanol containing 0.1% TFA, 2 min. gradient, flow rate=5 mL/min,
detection at 254 nm). MS (ES): m/z=278.08 [M+H].sup.+.
Preparation of
3-(2-(dimethylamino)ethoxy)-5-(1H-1,2,4-triazol-1-yl)aniline
##STR00041##
[0365] Intermediate 16 B (97 mg, 0.35 mmol) and 10% Pd/C (22.3 mg,
0.21 mmol) in MeOH (10 mL) were stirred under a hydrogen atmosphere
(balloon) for 8 hours. The reaction mixture was filtered though a
pad of silica gel. The filtrate was concentrated to give
Intermediate 16 (81 mg, 94% yield) as a yellow solid. HPLC: Rt=0.26
min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90%
aqueous methanol containing 0.1% TFA, 2 min. gradient, flow rate=5
mL/min., detection at 254 nm). MS (ES): m/z=248.15 [M+H].sup.+.
Intermediate 16 was used in the synthesis of Examples 146 and
147.
[0366] The following intermediates in Table 4 were prepared using
the procedures described in the preparation of Intermediate 16.
TABLE-US-00004 TABLE 4 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name [M + H] (min)* 17 ##STR00042## 157
3-(1H-1,2,4-Triazol-1- yl)-5-(2,2,2- trifluoroethoxy)aniline 259.15
1.10.sup.a 18 ##STR00043## 174 tert-Butyl 2-(3-amino-5-
(1H-1,2,4-triazol-1-yl) phenoxy)ethyl(methyl) carbamate 334.15
1.35.sup.a *= HPLC conditions .sup.a = PHENOMENEX .RTM. Luna 5
micron C18 4.6 .times. 30 mm, 0 to 100 B in 2 min. with 1 min. hold
time, flow rate = 5 mL/min., detection at 254 nm, Solvent A: 10%
methanol/90% water/0.1% TFA; Solvent B: 10% water/90% methanol/0.1%
TFA.
Intermediate 19
N.sup.1-(2-Morpholinoethyl)-2-(1H-1,2,4-triazol-1-yl)benzene-1,4-diamine
##STR00044##
[0367] Intermediate 19A: Preparation of
2-bromo-N-(2-morpholinoethyl)-4-nitroaniline
##STR00045##
[0369] 2-Bromo-1-fluoro-4-nitrobenzene (1.0 g, 4.5 mmol),
2-morpholinoethanamine (0.77 g, 5.9 mmol) and potassium carbonate
(1.571 g, 11.4 mmol) in DMSO (5 mL) were stirred at room
temperature for 1.5 hours. The mixture was triturated with water,
and 2-bromo-N-(2-morpholinoethyl)-4-nitroaniline (1.1 g, 72.8%
yield) was collected via filtration. HPLC: Rt=0.61 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90% aqueous
methanol containing 0.1% TFA, 2 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=332.06 [M+H].sup.+.
Preparation of
N.sup.1-(2-morpholinoethyl)-2-(1H-1,2,4-triazol-1-yl)benzene-1,4-diamine
##STR00046##
[0371] Intermediate 19 was prepared from Intermediate 19A following
the procedure in Intermediate 2. HPLC: Rt=0.10 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90% aqueous
methanol containing 0.1% TFA, 2 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=289.12 [M+H].sup.+. Intermediate
19 was used in the synthesis of Example 148.
Intermediate 20
N.sup.1-(Tetrahydro-2H-pyran-4-yl)-2-(1H-1,2,4-triazol-1-yl)benzene-1,4-di-
amine
##STR00047##
[0373] Intermediate 20 was prepared from
2-bromo-1-fluoro-4-nitrobenzene following the procedure in
Intermediate 16. HPLC: Rt=0.63 min. (PHENOMENEX.RTM. Luna 5 micron
C18 4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 2
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=260.08 [M+H].sup.+. Intermediate 20 was used in the synthesis
of Example 158.
Intermediate 21
3-Fluoro-5-(1H-1,2,4-triazol-1-yl)aniline and
3,5-di(1H-1,2,4-triazol-1-yl)aniline
##STR00048##
[0375] 1,3-Difluoro-5-nitrobenzene (1 g, 6.29 mmol),
1H-1,2,4-triazole (0.43 g, 6.29 mmol), and potassium carbonate
(2.17 g, 15.7 mmol) in DMSO (5 mL) were stirred at room temperature
for 15 hours. The reaction mixture was triturated with water, and
the solid was collected via filtration. The solid was dissolved in
methanol (40 mL), and treated with 10% Pd/C (100 mg, 0.94 mmol) and
stirred under a hydrogen atmosphere at room temperature for 8
hours. The reaction mixture was filtered though a pad of silica
gel. The filtrate was concentrated to give Intermediate 21 as a
mixture of 3-fluoro-5-(1H-1,2,4-triazol-1-yl)aniline and
3,5-di(1H-1,2,4-triazol-1-yl)aniline (825 mg, 65% yield).
[0376] HPLC: Rt=0.78 min. (PHENOMENEX.RTM. Luna 5 micron C18
4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 2
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=179.07 [M+H].sup.+. HPLC: Rt=0.82 min. (PHENOMENEX.RTM. Luna 5
micron C18 4.6.times.30 mm, 10-90% aqueous methanol containing 0.1%
TFA, 2 min. gradient, flow rate=5 mL/min., detection at 254 nm). MS
(ES): m/z=228.10 [M+H].sup.+. Intermediate 21 was used in the
synthesis of the compounds of Examples 172, 173 and 207.
Intermediate 22
3-Amino-N-(tetrahydro-2H-pyran-4-yl)-5-(1H-1,2,4-triazol-1-yl)benzamide
##STR00049##
[0377] Intermediate 22A: Preparation of
3-nitro-5-(1H-1,2,4-triazol-1-yl)benzoic acid
##STR00050##
[0379] 3-Nitro-5-(1H-1,2,4-triazol-1-yl)benzoic acid was prepared
from 3-bromo-5-nitrobenzoic acid following the procedure in
Intermediate 2A. HPLC: Rt=1.12 min. (PHENOMENEX.RTM. Luna 5 micron
C18 4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 2
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=235.07 [M+H].sup.+.
Preparation of
3-amino-N-(tetrahydro-2H-pyran-4-yl)-5-(1H-1,2,4-triazol-1-yl)benzamide
##STR00051##
[0381] To a solution of Intermediate 22A (400 mg, 1.71 mmol),
tetrahydro-2H-pyran-4-amine (207 mg, 2.05 mmol) and TEA (0.36 mL,
2.56 mmol) in DMF (4 mL) was added BOP (1133 mg, 2.56 mmol), and
the reaction solution was stirred at room temperature for 2 hours.
The reaction mixture was filtered though a pad of silica gel. The
filtrate was concentrated and purified with reverse phase HPLC. The
fractions were concentrated, dissolved in methanol (30 mL), and
treated with 10% Pd/C (27.3 mg, 0.26 mmol) and stirred under a
hydrogen atmosphere at room temperature for 8 hours. The reaction
mixture was filtered though a pad of silica gel. The filtrate was
concentrated to give Intermediate 22 (276 mg, 56.2% yield) as a
yellow solid. HPLC: Rt=0.75 min. (PHENOMENEX.RTM. Luna 5 micron C18
4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 2
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=288.09 [M+H].sup.+. Intermediate 22 was used in the synthesis
of Example 171.
Intermediate 23
3-Amino-N-(2-(diethylamino)ethyl)-5-(1H-1,2,4-triazol-1-yl)benzamide
##STR00052##
[0383] Intermediate 23 was prepared from Intermediate 22A and
N.sup.1,N.sup.1-diethylethane-1,2-diamine following the procedure
in Intermediate 22. HPLC: Rt=0.65 min. (PHENOMENEX.RTM. S5
4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 4
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=303.15 [M+H].sup.+. Intermediate 23 was used in the synthesis
of Example 183.
Intermediate 24
3-Amino-4-(trifluoromethyl)benzonitrile
##STR00053##
[0384] Intermediate 24A: Preparation of
3-(4-methoxybenzylamino)-4-(trifluoromethyl)benzonitrile
##STR00054##
[0386] 3-Fluoro-4(trifluoromethyl)benzonitrile (1 g, 5.29 mmol),
(4-methoxyphenyl)methanamine (0.73 g, 5.29 mmol) and potassium
carbonate (1.46 g, 10.6 mmol) in DMSO (2 mL) were heated at
75.degree. C. for 6 hours. The reaction mixture was triturated with
water, and the solid was collected via filtration to isolate 24A
(1.14 g, 70.6% yield) as a yellow solid. HPLC: Rt=2.64 min.
(PHENOMENEX.RTM. S5 4.6.times.30 mm, 10-90% aqueous methanol
containing 0.1% TFA, 4 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=329.09 [M+H].sup.+.
Preparation of 3-amino-4-(trifluoromethyl)benzonitrile
##STR00055##
[0388] A solution of
3-(4-methoxybenzylamino)-4-(trifluoromethyl)benzonitrile (500 mg,
1.63 mmol) and triethylsilane (0.2 mL) in dichloroethane (2 mL) was
treated with TFA (1 mL) and stirred at room temperature for 30 min.
The reaction mixture was concentrated to obtain Intermediate 24
(284 mg, 93% yield) as an orange solid. HPLC: Rt=1.24 min.
(PHENOMENEX.RTM. S5 4.6.times.30 mm, 10-90% aqueous methanol
containing 0.1% TFA, 4 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=187.1 [M+H].sup.+. Intermediate
24 was used in the synthesis Examples 229, 230 and 241.
Intermediate 25
3-Amino-5-fluoro-4-methoxybenzonitrile
##STR00056##
[0389] Intermediate 25A: Preparation of
5-bromo-3-fluoro-2-methoxyaniline
##STR00057##
[0391] 5-Bromo-1-fluoro-2-methoxy-3-nitrobenzene (1.0 g, 4.0 mmol),
zinc (2.62 g, 40.0 mmol) and ammonium chloride (2.14 g, 40.0 mmol)
in EtOH (20 mL) and water (12 mL) were heated at 80.degree. C. for
10 minutes and then stirred at room temperature for 2 hours. The
reaction mixture was diluted with dichloromethane (100 mL) and
water (60 mL), and filtered through CELITE.RTM.. The organic phase
was dried over sodium sulfate and filtered and then concentrated to
afford Intermediate 25A (723 mg, 82% yield) as a gray solid. HPLC:
Rt=1.3 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm,
10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient, flow
rate=5 mL/min., detection at 254 nm). MS (ES): m/z=222.0
[M+H].sup.+.
Preparation of 3-amino-5-fluoro-4-methoxybenzonitrile
##STR00058##
[0393] A mixture of 5-bromo-3-fluoro-2-methoxyaniline (500 mg, 2.27
mmol), potassium ferrocyanide (II) hydrate (240 mg, 0.57 mmol),
sodium carbonate (241 mg, 2.27 mmol) and palladium(II) acetate
(25.5 mg, 0.11 mmol) in DMA (2 mL) was purged with nitrogen and
heated at 120.degree. C. for 6 hours. The reaction mixture was
diluted with ethyl acetate (20 mL) and filtered through
CELITE.RTM.. The filtrate was washed with water (20 mL), 5%
NH.sub.4OH (10 mL), dried over MgSO.sub.4, filtered and
concentrated to isolate Intermediate 25 (213 mg, 56.4% yield).
HPLC: Rt=0.73 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient,
flow rate=5 mL/min., detection at 254 nm). MS (ES): m/z=167.2
[M+H].sup.+. Intermediate 25 was used in the synthesis of Examples
234 and 239.
Intermediate 26
3-Amino-4-(trifluoromethoxy)benzonitrile
##STR00059##
[0395] 3-Amino-4-(trifluoromethoxy)benzonitrile was prepared from
4-bromo-2-nitro-1-(trifluoromethoxy)benzene following the procedure
in Intermediate 25. HPLC: Rt=1.29 min (PHENOMENEX.RTM. S5
4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 4
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=203.1 [M+H].sup.+. Intermediate 26 was used in the synthesis of
Example 237.
Intermediate 27
3-Amino-4-(2-morpholinoethoxy)benzonitrile
##STR00060##
[0396] Intermediate 27A: Preparation of
4-(2-morpholinoethoxy)-3-nitrobenzonitrile
##STR00061##
[0398] 4-Fluoro-3-nitrobenzonitrile (0.5 g, 3.0 mmol),
2-morpholinoethanol (0.37 mL, 3.0 mmol), and potassium carbonate
(0.42 g, 3.0 mmol) in DMSO (2 mL) were heated at 50.degree. C. for
16 hours. Water (10 mL) was added to the reaction mixture, and the
solid was collected via filtration. The solid was washed with water
(3.times.2 mL) to afford Intermediate 27A (422 mg, 50.6% yield) as
a tan solid. HPLC: Rt=0.78 min. (PHENOMENEX.RTM. S5 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 4 min. gradient,
flow rate=5 mL/min., detection at 254 nm). MS (ES): m/z=278.16
[M+H].sup.+.
Preparation of 3-amino-4-(2-morpholinoethoxy)benzonitrile
##STR00062##
[0400] To 4-(2-morpholinoethoxy)-3-nitrobenzonitrile (422 mg, 1.52
mmol) suspended in MeOH (20 mL) was added 10% Pd/C (100 mg), and
the reaction mixture stirred under hydrogen atmosphere (balloon).
After 30 min., the reaction mixture was filtered through
CELITE.RTM.. The filtrate was concentrated to give Intermediate 27
(322 mg, 86% yield) as a tan solid. HPLC: Rt=0.5 min.
(PHENOMENEX.RTM. S5 4.6.times.30 mm, 10-90% aqueous methanol
containing 0.1% TFA, 4 min. gradient, flow rate=5 mL/min.,
detection at 254 nm). MS (ES): m/z=248.18 [M+H].sup.+. Intermediate
27 was used in the synthesis of Example 238.
Intermediate 28
4-Fluoro-3-(4H-1,2,4-triazol-4-yl)aniline
##STR00063##
[0401] Intermediate 28A: Preparation of
4-(2-fluoro-5-nitrophenyl)-4H-1,2,4-triazole
##STR00064##
[0403] A solution of 2-fluoro-5-nitroaniline (415 mg, 2.7 mmol) in
pyridine (15 mL) was treated with N'-formylformohydrazide (703 mg,
7.98 mmol), and TMS-Cl (5.10 mL, 39.9 mmol) was then added
dropwise. After the addition, Et.sub.3N (2.60 mL, 18.6 mmol) was
added, and the reaction mixture was heated to 100.degree. C. for 4
hours. The reaction mixture was then cooled to room temperature and
concentrated to dryness. The resulting solid was suspended in
H.sub.2O (25 mL) and filtered. The filtrate was extracted with
EtOAc (4.times.20 mL), and the organics were dried
(Na.sub.2SO.sub.4), filtered and concentrated. The crude product
was dissolved in a small amount of DCM and purified by flash
chromatography (SiO.sub.2, hexanes to 100% EtOAc, 40 g column, 40
min. gradient) to afford Intermediate 28A (210 mg, 37.9%). HPLC:
Rt=1.497 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=209.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.05 (1H, s), 9.05 (1H, s), 8.72 (1H, dd,
J=6.55, 2.77 Hz), 8.39-8.45 (1H, m), 7.85 (1H, t, J=9.57 Hz).
Preparation of 4-fluoro-3-(4H-1,2,4-triazol-4-yl)aniline
##STR00065##
[0405] A solution of 4-(2-fluoro-5-nitrophenyl)-4H-1,2,4-triazole
(210 mg, 1.009 mmol) in MeOH (4 mL) was treated with 10% Pd/C (20
mg, 0.19 mmol) and stirred under a hydrogen atmosphere at room
temperature for 16 hours. The reaction mixture was filtered, and
the filtrate was concentrated to dryness to afford Intermediate 28
(155 mg, 86%). HPLC: Rt=0.343 min. (YMC S5 ODS 4.6.times.50 mm,
10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min.
gradient, monitored at 220 nm). MS (ES): m/z=179.1 [M+H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.85 (1H, s), 8.85
(1H, s), 7.15 (1H, dd, J=10.45, 8.94 Hz), 6.68 (1H, dd, J=6.55,
2.77 Hz), 6.61-6.66 (1H, m), 5.35 (2H, s). Intermediate 28 was used
in the synthesis of Examples 46 and 114.
[0406] The following intermediates in Table 5 were prepared using
the procedures described in the preparation of Intermediate 28.
TABLE-US-00005 TABLE 5 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name [M + H] (min.)* 29 ##STR00066## 106
4-Methyl-3-(4H-1,2,4- triazol-4-yl)aniline 175.1 0.28.sup.a 30
##STR00067## 17, 52, 111 3-(4H-1,2,4-Triazol-4-
yl)-4-(trifluoromethoxy) aniline 245.1 2.20.sup.a 31 ##STR00068##
169, 236 3-(4H-1,2,4-Triazol-4- yl)-5-(trifluoromethyl) aniline 229
1.28.sup.b *= HPLC conditions .sup.a = YMC S5 ODS 4.6 .times. 50
mm, 10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min.
gradient, monitored at 220 nm .sup.b = CHROMOLITH .RTM. column 4.6
.times. 50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min, monitoring at 220 nm.
Intermediate 32
1-(3-Amino-5-(4H-1,2,4-triazol-4-yl)phenyl)piperidin-4-ol
##STR00069##
[0408] A mixture of 4-(3-fluoro-5-nitrophenyl)-4H-1,2,4-triazole
(200 mg, 0.96 mmol) and piperidin-4-ol (486 mg, 4.80 mmol) in DMSO
(1 mL) was heated at 100.degree. C. overnight. The reaction mixture
was extracted with EtOAc five times. The combined extracts were
washed with brine, dried and concentrated to give an orange solid.
The solid was dissolved in MeOH (25 mL), and 10% Pd/C (55 mg) was
added. The mixture was degassed and stirred under a hydrogen
atmosphere for 1 hour. The catalyst was filtered off, and the
filtrate was concentrated to give Intermediate 32 (233 mg, 84%) as
a brown solid. HPLC: Rt=0.227 min. (CHROMOLITH.RTM. column
4.6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=260 [M+H].sup.+. Intermediate 32 was used in the synthesis of
Example 141.
Intermediate 33
tert-Butyl
(3R,4S)-1-(3-amino-5-(4H-1,2,4-triazol-4-yl)phenyl)-3-hydroxypi-
peridin-4-ylcarbamate
##STR00070##
[0409] Intermediate 33A. Preparation of
(3R,4S)-4-azido-1-(3-nitro-5-(4H-1,2,4-triazol-4-yl)phenyl)piperidin-3-ol
##STR00071##
[0411] A mixture of 4-(3-fluoro-5-nitrophenyl)-4H-1,2,4-triazole
(200 mg, 0.96 mmol), 4-azidopiperidin-3-ol (164 mg, 1.15 mmol) and
K.sub.2CO.sub.3 (199 mg, 1.44 mmol) in DMSO was heated at
100.degree. C. for 4 hours. The reaction mixture was poured into
water and extracted with EtOAc (two times). The combined extracts
were washed with water and brine, dried over MgSO.sub.4, filtered
and concentrated. The crude material was purified by flash
chromatography, (SiO.sub.2, 24 g column, 0-12% MeOH/DCM) to give
Intermediate 33A (135 mg, 43%) as a yellow solid. HPLC: Rt=1.722
min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm). MS (ES): m/z=331 [M+H].sup.+.
Preparation of tert-butyl
(3R,4S)-1-(3-amino-5-(4H-1,2,4-triazol-4-yl)phenyl)-3-hydroxypiperidin-4--
ylcarbamate
##STR00072##
[0413] To a solution of Intermediate 33A (135 mg, 0.41 mmol) in THF
(5 mL) was added trimethylphosphine (1.0 M solution in toluene, 3
mL, 3.00 mmol). The reaction mixture was stirred for 1 hour, and
MeOH (2 mL) and 1N NaOH (2 mL) were added and stirred for an
additional 30 min. The reaction mixture was extracted with EtOAc
(three times). The combined extracts were dried over MgSO.sub.4,
filtered and concentrated. The residue was dissolved in THF (30 mL)
with TEA (0.171 mL, 1.23 mmol) and Boc.sub.2O (0.190 mL, 0.82 mmol)
and stirred at room temperature for 2 hours. The reaction mixture
was diluted with water and extracted with EtOAc (three times). The
combined organic layers were washed with brine, dried over
MgSO.sub.4, filtered and concentrated. The crude was purified by
flash chromatography, (SiO.sub.2, 12 g column, MeOH/DCM=0-8%) to
give a yellow solid. The solid was dissolved in MeOH (20 mL), and
10% Pd/C (50 mg) was added. The mixture was stirred under hydrogen
atmosphere overnight. The reaction mixture was filtered and
concentrated to give Intermediate 33A (84 mg, 19%). HPLC: Rt=1.573
min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm). MS (ES): m/z=375 [M+H].sup.+. Intermediate
33 was used in the synthesis of Example 142.
Intermediate 34
4-Morpholino-3-(4H-1,2,4-triazol-4-yl)aniline
##STR00073##
[0415] To a solution containing
4-(2-fluoro-5-nitrophenyl)-4H-1,2,4-triazole (0.500 g, 2.402 mmol)
and morpholine (0.251 g, 2.88 mmol) in DMSO (6 mL) at room
temperature was added potassium carbonate (0.498 g, 3.60 mmol). The
dark brown mixture was stirred for 30 min. The solution was then
diluted with water, and a precipitate formed. Filtration of the
suspension afforded a brown solid. The solid was then suspended in
MeOH (15 mL), and 10% Pd/C (0.051 g, 0.480 mmol) was added. An
atmosphere of H.sub.2 (balloon) was introduced, and the black
suspension was stirred for 30 minutes at ambient temperature. The
catalyst was removed via filtration. The filtrate was concentrated
and dried overnight to afford Intermediate 34 (0.250 g, 42.4%
yield) as an orange solid. HPLC: Rt=0.327 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=246.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.79 (2H, s), 7.06 (1H, d, J=8.81 Hz), 6.64 (1H, dd, J=8.56,
2.52 Hz), 6.55 (1H, d, J=2.52 Hz), 5.25 (2H, br. s.), 3.43-3.54
(4H, m), 2.51-2.57 (4H, m). Intermediate 34 was used in the
synthesis of Examples 116, 118 and 119.
[0416] The following intermediates in Table 6 were prepared using
the procedures described in the preparation of Intermediate 34.
TABLE-US-00006 TABLE 6 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name M + H (min.)* 35 ##STR00074## 121
4-(4-Methylpiperazin- 1-yl)-3-(4H-1,2,4- triazol-4-yl)aniline 259.2
0.160.sup.a 36 ##STR00075## 4, 122, 166 N1-(2- (Dimethylamino)
ethyl)-2-(4H-1,2,4- triazol-4-yl)benzene- 1,4-diamine 247.2
0.152.sup.a 37 ##STR00076## 123 N1-(2-Methoxyethyl)-
2-(4H-1,2,4-triazol-4- yl)benzene-1,4- diamine 234.1 0.173.sup.a 38
##STR00077## 127 4-(2-Dimethylamino) ethoxy)-3-(4H-1,2,4-
triazol-4-yl)aniline 248.1 0.27.sup.b 39 ##STR00078## 129 N1-(3-
(Dimethylamino) propyl)-2-(4H-1,2,4- triazol-4-yl)benzene-
1,4-diamine 261.2 0.158.sup.a 40 ##STR00079## 132 N1-(2-
(Dimethylamino) ethyl)-N1-methyl-2- (4H-1,2,4-triazol-4-yl)
benzene-1,4-diamine 261.2 0.175.sup.a 41 ##STR00080## 135
N1-(2-Methoxyethyl)- N1-methyl-2-(4H- 1,2,4-triazol-4-yl)
benzene-1,4-diamine 248.2 0.663.sup.a 42 ##STR00081## 139
N1-(2-(Pyrrolidin-1- yl) ethyl)-2-(4H-1,2,4- triazol-4-yl)benzene-
1,4-diamine 273.1 0.158.sup.a 43 ##STR00082## 149
2-(4-(4-Amino-2-(4H- 1,2,4-triazol-4-yl) phenyl)piperazin-1-yl)
ethanol 289.1 0.157.sup.a 44 ##STR00083## 150 4-(2-Morpholino-
ethoxy)-3-(4H-1,2,4- triazol-4-yl)aniline 290.1 0.163.sup.a 45
##STR00084## 130, 152 3-(4-Methylpiperazin- 1-yl)-5-(4H-1,2,4-
triazol-4-yl)aniline 259 0.233.sup.b 46 ##STR00085## 133
2-(4-(3-Amino-5-(4H- 1,2,4-triazol-4-yl) phenyl)piperazin-1-yl)
ethanol 289 0.215.sup.b 47 ##STR00086## 151 tert-Butyl 3-((4-
amino-2-(4H-1,2,4- triazol-4- yl)phenylamino) methyl)morpholine-4-
carboxylate 375.2 3.260.sup.a 48 ##STR00087## 144 tert-Buyl
1-(4-amino- 2-(4H-1,2,4-triazol-4- yl)phenyl) piperidin-4-
ylcarbamate 259.1 2.527.sup.a *HPLC conditions .sup.aYMC S5 ODS 4.6
.times. 50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm
.sup.bCHROMOLITH .RTM. column 4.6 .times. 50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min,
monitoring at 220 nm.
Intermediate 49
4-(Trifluoromethoxy)benzene-1,3-diamine
##STR00088##
[0418] A mixture of 3-nitro-4-(trifluoromethoxy)aniline (500 mg,
2.25 mmol) and 10% Pd/C (240 mg, 0.225 mmol) in ethyl acetate (20
mL) was degassed with nitrogen. The mixture was stirred under a
hydrogen atmosphere overnight. The catalyst was filtered off, and
the filtrate was concentrated to give Intermediate 49 (433 mg,
100%) as a brown solid. HPLC: Rt=0.707 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=193.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 6.69 (1 H, dd, J=8.56, 1.26 Hz), 5.95 (1H, d, J=2.52 Hz), 5.75
(1H, dd, J=8.69, 2.64 Hz), 4.91 (2H, s), 4.89 (2H, s). Intermediate
49 was used in the synthesis of Examples 90 and 91.
Intermediate 50
4-(2-Methoxyethoxy)-3-(4H-1,2,4-triazol-4-yl)aniline
##STR00089##
[0420] To a solution containing 2-methoxyethanol (0.136 mL, 1.730
mmol) in anhydrous DMF (15 mL) at 0.degree. C. was added NaH (0.063
g, 1.585 mmol) as a 60% dispersion in mineral oil. A solution of
4-(2-fluoro-5-nitrophenyl)-4H-1,2,4-triazole (0.300 g, 1.441 mmol)
in DMF (2.0 mL) was added via syringe. After 30 minutes, the
reaction mixture was quenched with water. A brown precipitate was
collected by filtration and washed with water. The solid was
suspended in MeOH (10 mL) and treated with Pd/C (0.031 g, 0.29
mmol), and the reaction was stirred under a hydrogen atmosphere.
The dark suspension was stirred for 1 hour at ambient temperature.
The catalyst was removed via filtration, and the filtrate was
concentrated to dryness to give Intermediate 50 (0.073 g, 21.4%
yield) as a brown oil. HPLC: Rt=0.187 min. (YMC S5 ODS 4.6.times.50
mm, 10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min.
gradient, monitored at 220 nm). MS (ES): m/z=235.1 [M+H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.75 (2H, s), 7.01
(1H, d, J=9.57 Hz), 6.59-6.66 (2H, m), 5.04 (2H, s), 3.98-4.06 (2H,
m), 3.50-3.57 (2H, m), 3.22 (3H, s). Intermediate 50 was used in
the synthesis of Example 126.
Intermediate 51
4-(1-Methylpiperidin-4-yloxy)-3-(4H-1,2,4-triazol-4-yl)aniline
##STR00090##
[0422] To a solution of
4-(2-fluoro-5-nitrophenyl)-4H-1,2,4-triazole (0.150 g, 0.721 mmol)
in anhydrous DMF (0.721 mL) at room temperature was added cesium
carbonate (0.49 g, 1.5 mmol) and 1-methylpiperidin-4-ol (0.108 g,
0.94 mmol). The resulting solution was heated to 75.degree. C.
After 2 hours, the reaction was cooled and diluted with water. The
solution was extracted three times with 20 mL DCM, and the organics
were combined, washed with water and brine, and dried over
anhydrous sodium sulfate. The reaction mixture was filtered and
concentrated, and the solid was suspended in MeOH (10 mL) at
ambient temperature. To the mixture was added 10% Pd/C (0.015 g,
0.144 mmol), and the reaction was stirred under a hydrogen
atmosphere. The dark suspension was stirred for 1 hour. The
catalyst was removed via filtration, and the filtrate was
concentrated to give Intermediate 51 (0.064 g, 0.222 mmol, 30.9%
yield) as a beige solid. HPLC: Rt=0.160 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=274.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.70 (2H, s), 7.01 (1H, d, J=8.81 Hz), 6.57-6.66 (2H, m),
5.04-5.12 (2 H, m), 4.04 (1H, br. s.), 2.20-2.36 (2H, m), 2.07 (3H,
s), 1.66-1.78 (2H, m), 1.39-1.50 (2H, m). Intermediate 51 was used
in the synthesis of Example 128.
[0423] The following intermediates in Table 7 were prepared using
the procedures described in the preparation of Intermediate 50 and
Intermediate 51.
TABLE-US-00007 TABLE 7 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name M + H (min.)* 52 ##STR00091## 140
4-(3-(Dimethylamino) propoxy)-3-(4H-1,2,4- triazol-4-yl) aniline
262.1 0.173.sup.a 53 ##STR00092## 143 4-(2-(Pyrrolidin-1-
yl)ethoxy)-3-(4H- 1,2,4-triazol-4-yl) aniline 274.1 0.162.sup.a 54
##STR00093## 153 tert-Butyl 2-(4-amino- 2-(4H-1,2,4-triazol-4- yl)
phenoxy)ethyl (methyl)carbamate 334.1 2.158.sup.a *HPLC conditions
.sup.aYMC S5 ODS 4.6 .times. 50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm.
Intermediate 55
4-Chloro-3-(oxazol-5-yl)aniline
##STR00094##
[0425] To a solution of 2-chloro-5-nitrobenzaldehyde (2.5 g, 13.5
mmol) in DME (27 mL) at room temperature was added tosylmethyl
isocyanide (2.76 g, 14.15 mmol) and potassium carbonate (3.72 g,
26.9 mmol). The mixture was heated to reflux overnight. The mixture
was cooled and poured into EtOAc. The resulting suspension was
washed with H.sub.2O (2.times.100 mL) and brine (2.times.100 mL).
The organics were combined, dried over anhydrous magnesium sulfate,
filtered, and concentrated in vacuo. The crude intermediate was
dissolved in DCM and charged to a 80 g silica gel cartridge which
was eluted at 60 mL/min. with a 25 min. gradient from 100% hexanes
to 40% EtOAc/hexanes (monitoring at 254 nm). The appropriate
fractions were concentrated, and the resulting solid was dissolved
in THF (40 mL). Acetic acid (54.0 mL, 943 mmol) and iron powder
(1.88 g, 33.7 mmol) were then added, and the resulting mixture was
heated overnight at 50.degree. C. The reaction mixture was cooled
and poured into 500 mL of saturated aqueous sodium carbonate and
extracted with ethyl acetate (3.times.100 mL). The organics were
combined, washed with water and brine, and dried over anhydrous
magnesium sulfate, and concentrated. The crude product was
dissolved in a small amount of DCM and charged to a 80 g silica gel
cartridge which was eluted at 60 mL/min. with a 25 min. gradient
from 100% hexanes to 50% EtOAc/hexanes (monitoring at 254 nm). The
appropriate fractions were concentrated to afford Intermediate 55
(0.40 g, 15% yield) as a light yellow solid. HPLC: Rt=1.837 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=195.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.49 (1H, s), 7.67 (1H, s), 7.18 (1H, d, J=8.56 Hz),
7.01 (1H, d, J=2.77 Hz), 6.58 (1H, dd, J=8.56, 2.77 Hz), 5.49 (2H,
s). Intermediate 55 was used in the synthesis of Example 79.
Intermediate 56
4-Chloro-3-(oxazol-2-yl)aniline
##STR00095##
[0426] Intermediate 56A: Preparation of
2-(2-Chloro-5-nitrophenyl)oxazole
##STR00096##
[0428] To a cloudy suspension of 2-chloro-5-nitrobenzoic acid (1.0
g, 4.96 mmol) and DMF (0.019 mL, 0.25 mmol) in DCM (12.4 mL) at
0.degree. C. was added a 2M solution of oxalyl chloride in DCM
(2.98 mL, 5.95 mmol). The resulting suspension was stirred for 1
hour at room temperature. The reaction mixture was concentrated in
vacuo and azeotroped with toluene to remove HCl and oxalyl
chloride. The residue was dissolved in tetramethylenesulfone (12.4
mL), to which potassium carbonate (1.37 g, 9.92 mmol) and
1H-1,2,3-triazole (0.29 mL, 4.96 mmol) were added. The mixture was
heated to 150.degree. C. under nitrogen for 1 hour. The mixture was
cooled and diluted with EtOAc and water. The layers were separated,
and the aqueous phase extracted three times with EtOAc (50 mL). The
organics were combined, washed with water and brine, and then dried
over anhydrous magnesium sulfate. Filtration and concentration
afforded a dark brown oil which was dissolved in a small amount of
DCM and charged to a 80 g silica gel cartridge which was eluted at
65 mL/min. with a 25 min. gradient from 100% to 50% EtOAc/hexanes
(monitoring at 254 nm). Concentration of the appropriate fractions
afforded Intermediate 56A (0.431 g, 39% yield) as a light yellow
solid. HPLC: Rt=3.246 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=225.0 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.71 (1 H, d, J=2.77 Hz), 8.42
(1H, s), 8.33 (1H, dd, J=8.81, 2.77 Hz), 7.95 (1H, d, J=8.81 Hz),
7.56 (1H, s).
Preparation of 4-chloro-3-(oxazol-2-yl)aniline
##STR00097##
[0430] To a solution of Intermediate 56A (0.431 g, 1.92 mmol) and
acetic acid (7.69 mL, 134 mmol) in THF (19.2 mL) was added iron
powder (0.268 g, 4.80 mmol). The mixture was heated to 50.degree.
C. overnight. The reaction mixture was cooled and poured into 300
mL of saturated aqueous Na.sub.2CO.sub.3 and extracted with EtOAc
(3.times.75 mL), and washed with water and brine. The organic phase
was dried over anhydrous magnesium sulfate, filtered, and
concentrated. The dark brown oil was dissolved in a small amount of
DCM and charged to a 40 g silica gel cartridge which was eluted at
40 mL/min. with a 25 min. gradient from 100% hexanes to 70%
EtOAc/hexanes. Concentration of the appropriate fractions afforded
Intermediate 56 (0.301 g, 80% yield) as an orange oil. HPLC:
Rt=1.923 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=195.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.24 (1H, s), 7.38 (1H, s), 7.19 (1H, d,
J=8.56 Hz), 7.13 (1H, d, J=2.77 Hz), 6.67 (1H, dd, J=8.56, 2.77
Hz), 5.53 (2H, s). Intermediate 56 was used in the synthesis of
Example 81.
Intermediate 57
3-(Thiazol-2-yl)aniline
##STR00098##
[0431] Intermediate 57A: Preparation of
2-(3-Nitrophenyl)thiazole
##STR00099##
[0433] A yellow suspension of 3-nitrobenzothioamide (2.0 g, 10.98
mmol), 2-chloroacetaldehyde (45% in H.sub.2O) (2.01 g, 11.53 mmol),
and acetic acid (7.32 mL) was heated to reflux for 1 hour. The
mixture was cooled to room temperature, poured into ice water, and
rendered alkaline using 30 mL of 12 N NaOH solution. Ethyl acetate
was then added, and the resulting emulsion was filtered through
CELITE.RTM.. The aqueous layer was extracted twice with ethyl
acetate, and the combined organic layers were dried over magnesium
sulfate. Filtration and concentration under reduced pressure
afforded Intermediate 57A (2.107 g, 91% yield) as a brown solid.
HPLC: Rt=3.331 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous
methanol containing 0.2% H3PO4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=207.0 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.68 (1H, t, J=1.89 Hz), 8.34-8.41 (1H,
m), 8.28-8.34 (1H, m), 8.00-8.05 (1H, m), 7.94 (1H, d, J=3.27 Hz),
7.80 (1H, t, J=8.06 Hz).
Preparation of 3-(thiazol-2-yl)aniline
##STR00100##
[0435] To a suspension of Intermediate 57A (500 mg, 2.425 mmol) in
absolute ethanol (12 mL) at ambient temperature was added Raney
nickel (60 mg, 2.425 mmol). An atmosphere of hydrogen was then
introduced, and the mixture was stirred for 5 hours at ambient
temperature. The suspension was filtered through CELITE.RTM.,
concentrated under reduced pressure and dried in vacuo, furnishing
Intermediate 57 (0.32 g, 73.0% yield) as a yellow oil. HPLC:
Rt=1.433 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=177.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 7.85 (1H, d, J=3.02 Hz), 7.70 (1H, t,
J=3.40 Hz), 7.17 (1H, t, J=1.89 Hz), 7.02-7.15 (2H, m), 6.60-6.67
(1H, m), 5.34 (2H, s). Intermediate 57 was used in the synthesis of
Example 107.
Intermediate 58
Methyl 6-aminoindoline-1-carboxylate
##STR00101##
[0437] A suspension of methyl 6-nitroindoline-1-carboxylate (187
mg, 0.84 mmol) in MeOH (15 mL) was purged with nitrogen and treated
with 10% Pd/C (20 mg, 0.19 mmol). The reaction mixture was stirred
at room temperature under a hydrogen atmosphere for 5 hours. The
suspension was then purged with nitrogen, filtered and concentrated
to dryness to afford Intermediate 58 (93 mg, 57.5%). HPLC: Rt=1.54
min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=193.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 7.08 (1H, s), 6.80 (1H, d, J=7.81 Hz),
6.15 (1H, dd, J=7.93, 2.14 Hz), 4.97 (2H, s), 3.81-3.91 (2H, m),
3.70 (3H, s), 2.88 (2H, t, J=8.44 Hz). Intermediate 58 was used in
the synthesis of Example 43.
Intermediate 59
Methyl 5-amino-2-fluorophenylcarbamate
##STR00102##
[0438] Intermediate 59A: Preparation of methyl
2-fluoro-5-nitrophenylcarbamate
##STR00103##
[0440] A solution of 2-fluoro-5-nitroaniline (500 mg, 3.20 mmol) in
THF (20 mL) was treated with DIEA (0.84 mL, 4.8 mmol) followed by
methyl chloroformate (0.25 mL, 3.20 mmol). The reaction mixture was
stirred at room temperature overnight and concentrated to dryness.
The crude product was dissolved in a small amount of DCM and
purified by flash chromatography (SiO.sub.2, 20% ethyl
acetate/hexanes to 50% ethyl acetate/hexanes, 40 g column, 30 min.
gradient) to afford Intermediate 59A (450 mg, 65.6%). HPLC:
Rt=2.868 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.94 (1H, s),
8.72 (1H, dd, J=6.80, 2.77 Hz), 7.87-8.09 (1H, m), 7.52 (1H, t),
3.72 (3H, s).
Preparation of methyl 5-amino-2-fluorophenylcarbamate
##STR00104##
[0442] A solution of Intermediate 59A (450 mg, 2.10 mmol) in MeOH
(20 mL) was treated with 10% Pd/C (40 mg, 0.38 mmol) and stirred at
room temperature under a hydrogen atmosphere for 3 hours. The
reaction mixture was filtered and concentrated to a white solid to
afford Intermediate 59 (375 mg, 97%). HPLC: Rt=0.403 min. (YMC S5
ODS 4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=185.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.97 (1H, s), 6.76-6.86 (2H, m), 6.20-6.29 (1 H, m), 4.94 (2H,
s), 3.62 (3H, s). Intermediate 59 was used in the synthesis of
Examples 8, 68, and 39.
Intermediate 60
Methyl 6-amino-3,3-dimethylindoline-1-carboxylate
##STR00105##
[0443] Intermediate 60A: Preparation of methyl
2-bromo-5-nitrophenylcarbamate
##STR00106##
[0445] A solution of 2-bromo-5-nitroaniline (500 mg, 2.30 mmol) in
THF (40 mL) was treated with pyridine (0.19 mL, 2.3 mmol) and
methyl chloroformate (0.27 mL, 3.5 mmol) at room temperature. After
4 hours, additional methyl chloroformate (0.27 mL, 3.5 mmol) was
added, and the reaction mixture was stirred at room temperature for
an additional 3 hours. The reaction mixture was concentrated to
dryness and then taken up in EtOAc (30 mL) and washed with 1 N HCl
(3.times.25 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated. The crude product was dissolved in a small amount of
DCM and purified by flash chromatography (SiO.sub.2, 0% ethyl
acetate/hexanes to 30% ethyl acetate/hexanes, 40 g column, 30 min.
gradient) to afford Intermediate 60A (390 mg, 61.5%). HPLC:
Rt=3.215 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min gradient, monitored at 220
nm). MS (ES): m/z=274.9 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.39 (1H, s), 8.44 (1H, d, J=2.52 Hz),
7.92-7.96 (1H, m), 7.88-7.92 (1H, m), 3.71 (3H, s).
Intermediate 60B: Preparation of methyl
2-bromo-5-nitrophenyl(2-methylallyl)carbamate
##STR00107##
[0447] A solution of Intermediate 60B (250 mg, 0.91 mmol) in DMF
(25 mL) was treated with sodium hydride (43.6 mg, 1.1 mmol) at
0.degree. C. The mixture was warmed to room temperature for 10 min.
and then cooled back to 0.degree. C. The mixture was treated with
3-bromo-2-methylpropene (0.092 mL, 0.91 mmol), and the reaction was
warmed to room temperature for 4 hours. The mixture was poured into
EtOAc (50 mL) and washed with 10% aq. LiCl (3.times.25 mL). The
organics were dried (Na.sub.2SO.sub.4), filtered and concentrated
to dryness. The crude product was dissolved in a small amount of
DCM and purified by flash chromatography (SiO.sub.2, hexanes to 30%
ethyl acetate/hexanes, 40 g column, 30 min. gradient) to afford
Intermediate 60A (248 mg 83%). HPLC: Rt=3.835 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=331.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.14 (1H, d, J=2.52 Hz), 8.06-8.11 (1H, m), 8.00-8.05 (1H, m),
4.70-4.88 (1H, m), 4.41 (1H, d, J=15.36 Hz), 3.88 (1H, d, J=15.36
Hz), 3.57 (3H, s), 1.75 (3H, s).
Intermediate 60C: Preparation of methyl
3,3-dimethyl-6-nitroindoline-1-carboxylate
##STR00108##
[0449] A solution of Intermediate 60B (248 mg, 0.75 mmol) in
degassed DMF (3 mL) was treated with palladium(II) acetate (16.9
mg, 0.075 mmol), sodium formate (64.6 mg, 0.95 mmol), sodium
acetate (161 mg, 1.96 mmol), and tetraethylammonium chloride (0.146
mL, 0.95 mmol). The reaction mixture was purged with argon and
heated to 90.degree. C. for one hour, then cooled to room
temperature. The reaction mixture was filtered and diluted with
EtOAc (25 mL). The solution was washed with 10% aq. LiCl
(3.times.25 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated to dryness. The crude product was dissolved in a small
amount of DCM and purified by flash chromatography (SiO.sub.2, 0%
ethyl acetate/hexanes to 30% ethyl acetate/hexanes, 40 g column, 30
min. gradient) to afford 60C (196.1 mg, 99%). HPLC: Rt=3.831 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=251.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.43 (1H, s), 7.90 (1H, dd, J=8.31, 2.27 Hz), 7.52 (1H,
d, J=8.31 Hz), 3.82 (2H, s), 3.78 (3H, s), 1.32 (6H, s).
Preparation of methyl
6-amino-3,3-dimethylindoline-1-carboxylate
##STR00109##
[0451] A suspension of Intermediate 60C (196 mg, 0.783 mmol) in
MeOH (10 mL) was treated with 10% Pd/C (20 mg, 0.19 mmol) and
stirred at room temperature under a hydrogen atmosphere for three
hours, then filtered and concentrated to dryness. The crude product
was dissolved in a small amount of DCM and purified by flash
chromatography (SiO.sub.2, hexanes to 40% ethyl acetate/hexanes, 40
g column, 30 min. gradient) to afford Intermediate 60 (112 mg,
64.9%). HPLC: Rt=2.308 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=221.1 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 7.01 (1H, s), 6.81 (1H, d,
J=8.06 Hz), 6.17 (1H, dd, J=7.93, 2.14 Hz), 4.98 (2H, s), 3.70 (3H,
s), 3.61 (2H, s), 1.18 (6H, s). Intermediate 60 was used in the
synthesis of Example 45.
Intermediate 61
7-Amino-1,4-dimethylquinolin-2(1H)-one
##STR00110##
[0453] A solution of 7-amino-4-methylquinolin-2(1H)-one (530 mg,
3.04 mmol) in DMF (40 mL) was treated with sodium hydride (146 mg,
3.65 mmol), followed by methyl iodide (0.23 mL, 3.65 mmol). The
reaction was stirred at room temperature for 2 hours. The reaction
was quenched with water (60 mL), and extracted with EtOAc
(3.times.50 mL). The combined organics were washed with 10% aq LiCl
solution, dried (Na.sub.2SO.sub.4), filtered and concentrated to
dryness. The crude product was dissolved in a small amount of DCM
and purified by flash chromatography (SiO.sub.2, 0-10%
MeOH/CH.sub.2Cl.sub.2, 24 g column, 30 min. gradient) to afford
Intermediate 61 (124 mg, 21.7%). HPLC: Rt=1.93 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=189.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 7.42 (1H, d, J=9.03 Hz), 6.53 (1H, d, J=6.27 Hz), 6.52 (1H, s),
6.09 (1H, d, J=1.00 Hz), 5.87 (2H, s), 3.45 (3H, s), 2.30 (3H, d,
J=0.75 Hz). Intermediate 61 was used in the synthesis of Example
164.
Intermediate 62
N-(4-Aminopyridin-2-yl)acetamide
##STR00111##
[0454] Intermediate 62A: Preparation of methyl
2-acetamidoisonicotinate
##STR00112##
[0456] To a solution of methyl 2-aminoisonicotinate (0.5 g, 3.29
mmol) in AcOH (6.6 mL) at room temperature was added acetic
anhydride (0.37 mL, 3.94 mmol), and the mixture was refluxed for 1
hour. The mixture was cooled and transferred to a 100 mL
round-bottom, where the product was precipitated out of solution by
slowly adding water (.about.6 mL). The suspension was then filtered
and washed with water. The solid was dried in vacuo overnight,
furnishing Intermediate 62A (0.491 g, 76% yield) as a light yellow
solid. HPLC: Rt=1.927 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=195.1 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 10.76 (1H, s), 8.57 (1H, s),
8.48 (1H, d, J=5.04 Hz), 7.51 (1H, dd, J=5.04, 1.51 Hz), 3.88 (3H,
s), 2.11 (3H, s).
Intermediate 62B: Preparation of 2-acetamidoisonicotinoyl azide
##STR00113##
[0458] To a suspension of Intermediate 62A (0.250 g, 1.29 mmol) in
MeOH (2 mL) at room temperature was added anhydrous hydrazine
(0.048 mL, 1.55 mmol), and the mixture was heated to reflux for 1
hour. The suspension was cooled and filtered, washing the solid
with MeOH. The solid was dried in vacuo and used immediately. The
acyl hydrazide was suspended in 2N HCl (5 mL) and cooled to
0.degree. C., whereupon sodium nitrite (0.533 g, 7.72 mmol) was
added slowly in portions with vigorous stirring. The resulting
solution stirred for 1 hour at 0.degree. C. The reaction was then
quenched by carefully adding solid sodium bicarbonate to pH 6,
whereupon a precipitate formed. The solid was filtered, washed with
cold water, and dried in vacuo overnight to provide Intermediate
62B (0.182 g, 68% yield) as a white solid. HPLC: Rt=2.345 min. (YMC
S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 10.82 (1H, s), 8.58 (1H, s),
8.52 (1H, d, J=5.29 Hz), 7.51 (1H, dd, J=5.16, 1.64 Hz), 2.11 (3H,
s).
Preparation of N-(4-Aminopyridin-2-yl)acetamide
##STR00114##
[0460] A suspension of 2-acetamidoisonicotinoyl azide (0.180 g,
0.877 mmol) in AcOH (2 mL) and water (2 mL) was heated to
100.degree. C. for 30 min. The mixture was cooled and azeotroped
multiple times with toluene to remove water and AcOH. The resulting
white solid was dried in vacuo overnight, furnishing Intermediate
62 (0.178 g, 134% yield--residual toluene, acetic acid by NMR) as a
light tan solid. HPLC: Rt=0.183 min. (YMC S5 ODS 4.6.times.50 mm,
10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min.
gradient, monitored at 220 nm). MS (ES): m/z=152.1 [M+H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.94 (1H, s), 7.69
(1H, d, J=5.79 Hz), 7.28 (1H, s), 6.18 (1H, dd, J=5.67, 2.14 Hz),
6.03 (2H, s), 1.90 (3H, s). Intermediate 62 was used in the
synthesis of Example 69.
Intermediate 63
1-(3-Aminophenyl)pyrrolidin-2-one
##STR00115##
[0462] A 25 mL round-bottomed flask was charged with cesium
carbonate (1.38 g, 4.2 mmol), copper(I) bromide (0.029 g, 0.20
mmol), and ethyl 2-oxocyclohexanecarboxylate (0.064 mL, 0.40 mmol).
The mixture was pump/purged with argon three times, and then DMSO
(1.0 mL) was added. The mixture was stirred 30 min. at room
temperature under argon. A solution of 1-iodo-3-nitrobenzene (0.5
g, 2.0 mmol) and pyrrolidin-2-one (0.20 g, 2.4 mmol) in DMSO (1.0
mL) was then added, and the mixture was stirred for 2 days at room
temperature. The blue suspension was filtered through CELITE.RTM.,
and the filter cake was washed with EtOAc. The filtrate was washed
with brine, dried over Na.sub.2SO.sub.4, and then filtered and
concentrated. The solid was dissolved in a small amount of DCM and
charged to a 40 g silica gel cartridge which was eluted at 40
mL/min. with a 20 min. gradient from 100% to 30% EtOAc/DCM,
monitoring at 254 nm. The appropriate fractions were collected and
concentrated to provide 0.22 g of product as a light yellow solid.
The material was dissolved in EtOAc and charged with 10% Pd/C
(0.043 g, 0.402 mmol), and a hydrogen balloon was introduced at
room temperature. The dark suspension was stirred for 1 hour. The
catalyst was removed via filtration and the filtrate was
concentrated in vacuo, affording Intermediate 63 (0.190 g, 53%
yield) as a light yellow viscous oil. HPLC: Rt=0.543 min. (YMC S5
ODS 4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=177.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 6.89-7.00 (2 H, m), 6.70 (1H, dd, J=8.06, 1.26 Hz), 6.31 (1H,
dd, J=8.06, 1.26 Hz), 5.08 (2H, s), 3.72 (2H, t, J=6.92 Hz),
2.39-2.47 (2H, m), 1.95-2.07 (2H, m). Intermediate 63 was used in
the synthesis of Example 73.
Intermediate 64
1-(Methylsulfonyl)-1H-indol-6-amine
##STR00116##
[0463] Intermediate 64A: Preparation of
1-(methylsulfonyl)-6-nitro-1H-indole
##STR00117##
[0465] To a solution of 6-nitro-1H-indole (0.250 g, 1.54 mmol) in
dry THF (15.4 mL) at -78.degree. C. under nitrogen was added sodium
bis(trimethylsilyl)amide (1.850 mL, 1.850 mmol) dropwise via
syringe. The resulting solution was stirred for 20 minutes at
-78.degree. C., followed by addition of methanesulfonyl chloride
(0.14 mL, 1.85 mmol) dropwise via syringe. Following the addition,
the cooling bath was removed, and the mixture was allowed to warm
to room temperature. After 1 hour, the suspension was filtered, and
the resulting solid was taken up in 10 mL of aqueous MeOH and
heated to reflux. The hot mixture was filtered to afford a light
yellow solid which was dried in vacuo, furnishing Intermediate 64A
(0.208 g, 56% yield) as a light yellow solid. HPLC: Rt=3.160 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=241.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.70 (1H, d, J=2.01 Hz), 8.18 (1H, dd, J=8.81, 2.01
Hz), 7.98 (1H, d, J=3.78 Hz), 7.92 (1H, d, J=8.81 Hz), 7.05 (1H, d,
J=3.78 Hz), 3.55-3.66 (3H, m).
Preparation of 1-(Methylsulfonyl)-1H-indol-6-amine
##STR00118##
[0467] A suspension of Intermediate 64A (0.100 g, 0.42 mmol) and
platinum(IV) oxide (4.73 mg, 0.021 mmol) in MeOH (4.16 mL) was
hydrogenated at 40 PSI in a hydrogenation pressure vessel at room
temperature for 1 hour. The suspension was filtered, concentrated
in vacuo, and dried to give Intermediate 64 (0.095 g, 103% yield)
as a light yellow solid. HPLC: Rt=1.167 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=211.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 7.27 (1 H, d, J=8.31 Hz), 7.16 (1H, d, J=3.53 Hz), 7.03 (1H,
s), 6.54-6.63 (2H, m), 5.26 (2H, s), 3.24 (3H, s). Intermediate 64
was used in the synthesis of Example 64.
Intermediate 65
N-(5-Amino-2,4-difluorophenyl)acetamide
##STR00119##
[0469] Hydrogen was introduced via a balloon to a suspension of
N-(2,4-difluoro-5-nitrophenyl)acetamide (0.300 g, 1.39 mmol) and
10% Pd/C (0.052 g, 0.49 mmol) in ethyl acetate (5 mL) at room
temperature. The suspension was stirred for 1.5 hours. The catalyst
was removed via filtration, and the filtrate was concentrated in
vacuo to give Intermediate 65 (0.240 g, 93% yield) as an off-white
solid. HPLC: Rt=0.442 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=187.1 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.45 (1H, s), 7.23 (1H, dd,
J=9.44, 8.44 Hz), 7.04 (1H, t, J=10.83 Hz), 5.02 (2H, s), 1.96-2.07
(3H, m). Intermediate 65 was used in the synthesis of Example
76.
Intermediate 66
Methyl 3-amino-4-fluorophenylcarbamate
##STR00120##
[0471] To a solution of 4-fluoro-3-nitroaniline (0.500 g, 3.20
mmol) in THF (30 mL) was added DIEA (0.839 mL, 4.80 mmol) and
methyl chloroformate (0.248 mL, 3.20 mmol). The brown solution was
stirred overnight at room temperature. The solution was diluted
with water and EtOAc, and the layers were separated. The aqueous
phase was extracted twice with EtOAc, and the organics were
combined, washed with water and brine, and then dried over
anhydrous sodium sulfate. Filtration and concentration afforded a
light tan solid, which was taken up in EtOAc (30 mL) and treated
with 10% Pd/C (0.102 g, 0.961 mmol) and hydrogen (balloon) was
introduced. The resulting black suspension was stirred vigorously
for 2 hours at room temperature. The mixture was then filtered and
subjected to the same reaction conditions. After 1.5 hours, the
suspension was filtered, and the brown filtrate concentrated in
vacuo and azeotroped with toluene to remove residual MeOH. The
crude residue was dissolved in a small amount of DCM and charged to
a 24 g silica gel cartridge which was eluted at 30 mL/min. with a
20 min. gradient from 100% to 30% EtOAc/DCM (monitoring at 254 nm).
Appropriate fractions were concentrated, affording Intermediate 66
(0.44 g, 74% yield) as a light yellow solid. HPLC: Rt=185.1 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=0.837 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.02 (1H, s), 6.87 (1H, dd, J=10.58, 8.81 Hz),
6.47-6.53 (1H, m), 6.41-6.47 (1H, m), 3.67-3.81 (3H, m).
Intermediate 66 was used in the synthesis of Example 78.
Intermediate 67
Methyl
3-amino-5-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenylcarbamate
##STR00121##
[0473] To a solution of BOP (0.911 g, 2.06 mmol) and
3-amino-5-nitrobenzoic acid (0.25 g, 1.37 mmol) in DMF (6.5 mL) at
room temperature was added tetrahydro-2H-pyran-4-amine (0.17 g,
1.65 mmol). The solution was stirred overnight at ambient
temperature and then concentrated. The crude coupling product was
suspended in DCM (6.50 mL) and treated with pyridine (0.22 mL, 2.75
mmol), and methyl chloroformate (0.128 mL, 1.647 mmol). The solid
was isolated via filtration and dried overnight. To a suspension of
methyl 3-nitro-5-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenylcarbamate
(0.140 g, 0.433 mmol) in MeOH (5 mL) at room temperature was added
10% Pd/C (9 mg, 0.085 mmol). An atmosphere of hydrogen was
introduced. The reaction mixture was stirred for 30 minutes. The
catalyst was removed via filtration, and the filtrate was
concentrated under reduced pressure to give Intermediate 67 (0.134
g, 104% yield) as a light gray solid. HPLC: Rt=1.583 min. (YMC S5
ODS 4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=294.1 [M+H].sup.+. Intermediate 67 was used in the synthesis of
Example 177.
Intermediate 68
Methyl 3-amino-5-(methylsulfonyl)phenylcarbamate
##STR00122##
[0475] To a suspension of 3-(methylsulfonyl)-5-nitroaniline (0.026
g, 0.120 mmol) and pyridine (0.016 mL, 0.192 mmol) in DCM (3.00 mL)
at room temperature was added methyl chloroformate (0.010 mL, 0.129
mmol). The reaction mixture was stirred at room temperature for 30
min. The reaction mixture was quenched with water, and the layers
were separated. The aqueous phase was washed once with 5 mL DCM.
The organics were combined, washed with water and brine, then dried
over anhydrous sodium sulfate. Filtration and concentration
afforded a dark yellow solid. The crude solid was dissolved in MeOH
(3 mL) at ambient temperature, and 10% Pd/C (2.56 mg, 0.024 mmol)
was added. An atmosphere of hydrogen (balloon) was introduced, and
the suspension stirred for 1 hour. The catalyst was removed via
filtration, and the filtrate was concentrated under reduced
pressure and dried to afford Intermediate 68 (0.025 g, 85% yield)
as a light green solid. HPLC: Rt=1.370 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2% H3PO4, 4
min. gradient, monitored at 220 nm). MS (ES): m/z=245.0
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.73
(1H, s), 7.14 (1H, t, J=1.76 Hz), 6.98 (1H, t, J=1.88 Hz), 6.70
(1H, t, J=1.88 Hz), 5.70 (2H, s), 3.65 (3H, s), 3.06 (3H, s).
Intermediate 68 was used in the synthesis of Example 182.
Intermediate 69
(2,4-Diaminophenyl)(4-methylpiperazin-1-yl)methanone
##STR00123##
[0476] Intermediate 69A: Preparation of 2-Amino-4-nitrobenzoyl
chloride
##STR00124##
[0478] 2-Amino-4-nitrobenzoic acid (15 g, 82 mmol) was refluxed
with sulfurous dichloride (40 mL, 82 mmol) for 2.5 hours. The
reaction mixture was cooled to room temperature and concentrated to
give Intermediate 69A (19.7 g, 119%) as a brown oil. HPLC: Rt=2.323
(as methyl ester) min. (CHROMOLITH.RTM. column 4 6.times.50 mm
eluting with 10-90% aqueous methanol over 4 min. containing 0.1%
TFA, 4 mL/min., monitoring at 220 nm.). MS (ES): m/z=197 (as methyl
ester) [M+H].sup.+.
Intermediate 69B: Preparation of
(2-amino-4-nitrophenyl)(4-methylpiperazin-1-yl)methanone
##STR00125##
[0480] To a solution of 1-methylpiperazine (2.5 g, 24.96 mmol) in
DCM (30 mL) at 0.degree. C. was added a solution of Intermediate
69A (1.13 g, 5.63 mmol) in DCM (10 mL) slowly. The reaction was
stirred at room temperature for 1 hour. The reaction mixture was
washed with saturated aqueous NaHCO.sub.3, dried over MgSO.sub.4,
filtered and concentrated. The crude material was purified by flash
chromatography, (SiO.sub.2, 24 g, 0-10% MeOH/DCM) to give
Intermediate 69B (0.77 g, 52%) as a yellow oil. HPLC: Rt=0.360 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=265 [M+H].sup.+.
Intermediate 69C: Preparation of methyl
2-(4-methylpiperazine-1-carbonyl)-5-nitrophenylcarbamate
##STR00126##
[0482] To a solution of Intermediate 69B (540 mg, 2.04 mmol) in DCM
(20 mL) was added TEA (0.570 mL, 4.09 mmol), acetic anhydride
(0.289 mL, 3.06 mmol), and DMAP (2 mg, 0.016 mmol). The reaction
mixture was stirred overnight, then washed with saturated aqueous
NaHCO.sub.3, dried, and concentrated. The reaction mixture was
purified by flash chromatography, (SiO.sub.2, 24 g, 0-10% MeOH/DCM)
to give Intermediate 69C (600 mg, 96%) as a yellow solid. HPLC:
Rt=0.517 min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting with
10-90% aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm). MS (ES): m/z=307 [M+H].sup.+.
Preparation of
N-(5-amino-2-(4-methylpiperazine-1-carbonyl)phenyl)acetamide
##STR00127##
[0484] To a solution of Intermediate 69C (600 mg, 1.96 mmol) in
EtOAc (25 mL) and MeOH (5.0 mL) was added 10% Pd/C (208 mg, 0.196
mmol). The mixture was degassed and stirred under a hydrogen
atmosphere (balloon) overnight. The catalyst was filtered off, and
the filtrate was concentrated to give Intermediate 69 (505 mg, 93%)
as white solid. HPLC: Rt=0.243 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=277 [M+H].sup.+. Intermediate 69 was used in the synthesis of
Example 93 and Example 89.
Intermediate 70
1-(3-Aminophenyl)piperidin-4-ol
##STR00128##
[0486] A solution of 1-fluoro-3-nitrobenzene (200 mg, 1.42 mmol),
and piperidin-4-ol (430 mg, 4.25 mmol) in DMSO (1 mL) was heated at
80.degree. C. for two days. The reaction mixture was diluted with
water, extracted with EtOAc (two times), and the combined extracts
were washed with brine, dried and concentrated. The residue was
purified by flash chromatography (SiO.sub.2,12 g column, 0-100%
EtOAc/DCM) to give an oil. The residue was dissolved in MeOH, and
10% Pd/C was added. The mixture was stirred under a hydrogen
atmosphere (balloon) overnight. The catalyst was filtered off, and
the filtrate was concentrated to give Intermediate 70 (400 mg,
146%) as a yellow oil. HPLC: Rt=0.228 min. (CHROMOLITH.RTM. column
4 6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=193 [M+H].sup.+. Intermediate 70 was used in the synthesis of
Example 154.
Intermediate 71
3-Amino-5-cyano-N-methylbenzenesulfonamide
##STR00129##
[0487] Intermediate 71A: Preparation of
3-amino-5-nitrobenzonitrile
##STR00130##
[0489] To a suspension of 3,5-dinitrobenzonitrile (4.5 g, 23.30
mmol) in MeOH (100 mL) was added concentrated HCl (15 mL), followed
by iron powder (3.90 g, 69.9 mmol). The mixture was stirred at room
temperature for 30 min. and then concentrated. The residue was
treated with water and the resulting solid product was collected by
filtration to give Intermediate 71A (2.3 g, 61%). HPLC: Rt=1.245
min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
ppm 7.68 (1H, s), 7.64 (1H, s), 7.24 (1H, s), 6.33 (2H, s).
Intermediate 71B: Preparation of 3-cyano-5-nitrobenzene-1-sulfonyl
chloride
##STR00131##
[0491] To a solution of acetic acid (7.5 mL) and hydrochloric acid,
37% (1.5 mL) was added Intermediate 71A (1.49 g, 9.13 mmol). The
suspension was cooled to -5.degree. C. A solution of sodium nitrite
(0.882 g, 12.79 mmol) in water (2 mL) was added dropwise. The
resulting mixture was stirred at 0.degree. C. for 2 hours. A
mixture of copper (II) chloride (0.31 g, 2.28 mmol) in acetic acid
(15 mL) was saturated with sulfur dioxide by bubbling for 40 min.
The reaction mixture containing the diazonium salt was slowly
poured into the copper (II) chloride-SO.sub.2 mixture. The
resulting mixture was stirred at 0.degree. C. for 30 minutes,
diluted with ice-water, and extracted with DCM (three times). The
combined organic layers were dried over MgSO.sub.4, filtered and
concentrated to give Intermediate 71B (1.9 g, 84%) as yellow oil.
HPLC: Rt=1.622 min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting
with 10-90% aqueous methanol over 4 min. containing 0.1% TFA, 4
mL/min., monitoring at 220 nm).
Intermediate 71C: Preparation of
3-cyano-N-methyl-5-nitrobenzenesulfonamide
##STR00132##
[0493] To a solution of Intermediate 71B (150 mg, 0.61 mmol) in DCM
(4 mL) was added methylamine (2.0 M solution in THF, 1.5 mL, 3.0
mmol) and TEA (0.424 mL, 3.04 mmol). The reaction mixture was
stirred at room temperature for 1 hour, diluted with DCM, washed
with water, dried over MgSO.sub.4 and concentrated. The residue was
purified by silica gel chromatography (flash chromatography, 12 g,
EtOAC/hexane=0-100%) to give Intermediate 71C (45 mg, 31%) as a
white solid. HPLC: Rt=1.112 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. ppm 8.90 (1H, s), 8.71 (1H, s), 8.46
(1H, s), 4.76 (1H, br. s.), 2.81 (3H, d, J=4.95 Hz).
Preparation of 3-amino-5-cyano-N-methylbenzenesulfonamide
##STR00133##
[0495] Intermediate 71 was prepared from Intermediate 71C following
hydrogenation condition employed in the preparation of Intermediate
70. HPLC: Rt=0.84 min. (CHROMOLITH.RTM. column 4 6.times.50 mm
eluting with 10-90% aqueous methanol over 4 minutes containing 0.1%
TFA, 4 mL/min., monitoring at 220 nm). MS (ES): m/z=212
[M+H].sup.+. Intermediate 71 was used in the synthesis of Example
178.
Intermediate 72
3-Amino-5-cyano-N-(4-methoxybenzyl)benzenesulfonamide
##STR00134##
[0497] Intermediate 72 was prepared from Intermediate 71B and
(4-methoxyphenyl)methanamine following the procedure described in
the preparation of Intermediate 71. HPLC: Rt=1.932 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 8.13 (1H,
br. s.), 7.22 (1H, s), 7.08-7.16 (3H, m), 7.01 (1H, s), 6.83 (2H,
d, J=8.80 Hz), 6.12 (2H, s), 3.93 (2H, s), 3.72 (3H, s).
Intermediate 72 was used in the synthesis of Example 187.
Intermediate 73
3-Amino-5-cyano-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide
##STR00135##
[0499] Intermediate 73 was prepared from Intermediate 71B and
tetrahydro-2H-pyran-4-amine following a procedure employed for the
preparation of Intermediate 71. HPLC: Rt=1.180 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 7.86 (1H,
br. s.), 7.26 (1H, s), 7.22 (1H, s), 7.03 (1H, s), 6.15 (2H, s),
3.73 (2H, d, J=11.55 Hz), 3.06-3.28 (3H, m), 1.53 (2H, d, J=10.45
Hz), 1.25-1.42 (2H, m). Intermediate 73 was used in the synthesis
of Example 185.
[0500] The following intermediates in Table 8 were prepared using
the procedures described in the preparation of Intermediate 71.
TABLE-US-00008 TABLE 8 HPLC Inter- Retention mediate Used for Time
No. Structure Example Name M + H (min.)* 74 ##STR00136## 180
3-Amino-5-cyano-N- ethylbenzenesulfonamide 226 1.1.sup.a 75
##STR00137## 186 3-Amino-5-(4- methylpiperazin-1-
ylsulfonyl)benzonitrile 281 0.83.sup.a *HPLC conditions
.sup.aCHROMOLITH .RTM. column 4.6 .times. 50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min,
monitoring at 220 nm.
Intermediate 76
N-(3-Amino-5-cyanophenyl)-N-(methylsulfonyl)methanesulfonamide
##STR00138##
[0501] Intermediate 76A: Preparation of
N-(3-cyano-5-nitrophenyl)-N-(methylsulfonyl)methanesulfonamide
##STR00139##
[0503] To a suspension of 3-amino-5-nitrobenzonitrile (161 mg,
0.987 mmol) in DCM (8 mL) was added TEA (0.55 mL, 3.95 mmol),
followed by methanesulfonyl chloride (0.165 mL, 2.12 mmol). The
reaction mixture was stirred at room temperature for 60 min., then
diluted with DCM, washed with H.sub.2O, dried over
Na.sub.2SO.sub.4, and concentrated. The crude solid was triturated
with DCM and isolated by filtration to give Intermediate 76A (242
mg, 76%) as a white solid. HPLC: Rt=1.198 min. (CHROMOLITH.RTM.
column 4 6.times.50 mm eluting with 10-90% aqueous methanol over 4
min. containing 0.1% TFA, 4 mL/min, monitoring at 220 nm). .sup.1H
NMR (500 MHz, CDCl.sub.3) .delta. ppm 8.65 (1H, s), 8.45 (1H, s),
7.98 (1H, s), 3.48 (6H, s).
Intermediate 76: Preparation of
N-(3-Amino-5-cyanophenyl)-N-(methylsulfonyl)methanesulfonamide
##STR00140##
[0505] A suspension of Intermediate 76A (240 mg, 0.752 mmol) and
10% Pd/C (105 mg, 0.099 mmol) in MeOH (30 mL) and EtOAc (15 mL) was
degassed and then stirred under a hydrogen atmosphere (balloon) for
1.5 hours. The catalyst was filtered off, and the filtrate was
concentrated to give Intermediate 76 (215 mg, 99%). HPLC: Rt=0.847
min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 8.93 (1H, s), 8.82 (1H, d, J=1.76 Hz), 7.43 (1H, t, J=1.63 Hz),
7.23 (1H, s), 7.14 (1H, t, J=2.01 Hz), 3.55 (6H, s). Intermediate
76 was used in the synthesis of Example 179.
Intermediate 77
3-Amino-5-(methylsulfonyl)benzoic acid
##STR00141##
[0506] Intermediate 77A: Preparation of
3-(methylsulfonyl)-5-nitrobenzoic acid
##STR00142##
[0508] A mixture of 3-(methylsulfonyl)benzonitrile (1.2 g, 6.62
mmol) in 30% oleum (fuming H.sub.2SO.sub.4, 6 mL) was cooled to
0.degree. C., and fuming HNO.sub.3 acid (5 mL) was added dropwise.
The resulting mixture was heated at 70.degree. C. for 30 min. The
reaction mixture was poured over ice water. The solid was collected
by filtration, rinsed with water, and dried to give Intermediate
77A (832 mg, 51%) as a yellow solid. HPLC: Rt=1.088 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 14.24 (1H,
br. s.), 8.85 (1H, s), 8.82 (1H, s), 8.84 (1H, d, J=11.55 Hz), 8.73
(1H, s), 3.41 (3H, s).
Intermediate 77: Preparation of 3-amino-5-(methylsulfonyl)benzoic
acid
##STR00143##
[0510] Intermediate 77 was prepared from Intermediate 77A following
hydrogenation conditions employed in the preparation of
Intermediate 70. HPLC: Rt=0.465 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=216 [M+H].sup.+. Intermediate 77 was used in the synthesis of
Example 188.
Intermediate 78
N-(5-Amino-2-ethylphenyl)methanesulfonamide
##STR00144##
[0511] Intermediate 78A: Preparation of
N-(2-ethyl-5-nitrophenyl)methanesulfonamide
##STR00145##
[0513] To a solution of 2-ethyl-5-nitroaniline (200 mg, 1.20 mmol)
in DCM (5 mL) was added pyridine (0.195 mL, 2.41 mmol) and
methanesulfonyl chloride (0.11 mL, 1.44 mmol). The reaction mixture
was stirred at room temperature overnight. The mixture was diluted
with DCM, washed with water and brine and dried to give
Intermediate 78A (290 mg, 99%) as a yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 8.35 (1H, d, J=2.26 Hz), 8.04 (1H, dd,
J=8.53, 2.26 Hz), 7.44 (1H, d, J=8.53 Hz), 6.59 (1H, br. s.), 3.15
(3H, s), 2.76 (2H, q, J=7.53 Hz), 1.32 (3H, t, J=7.53 Hz).
Intermediate 78: Preparation of
N-(5-amino-2-ethylphenyl)methanesulfonamide
##STR00146##
[0515] Intermediate 78 was prepared from Intermediate 78A following
hydrogenation conditions employed in the preparation of
Intermediate 70. HPLC: Rt=0.230 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=215 [M+H].sup.+. Intermediate 78 was used in the synthesis of
Example 235.
Intermediate 79
N-(5-Amino-4-chloro-2-methylphenyl)methanesulfonamide
##STR00147##
[0516] Intermediate 79A: Preparation of
N-(4-chloro-2-methyl-5-nitrophenyl)methanesulfonamide
##STR00148##
[0518] Intermediate 79A was prepared from
4-chloro-2-methyl-5-nitroaniline following the procedure employed
in the preparation of Intermediate 78A. HPLC: Rt=1.618 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=265 [M+H].sup.+.
Intermediate 79: Preparation of
N-(5-amino-4-chloro-2-methylphenyl)methanesulfonamide
##STR00149##
[0520] A mixture of Intermediate 79A (175 mg, 0.66 mmol), zinc (432
mg, 6.61 mmol), ammonium chloride (354 mg, 6.61 mmol) in ethanol
(10 mL) and water (5.0 mL) was heated to reflux for 30 min. The
reaction mixture was concentrated, suspended in ethyl acetate and
filtered. The filtrate was washed with water, aqueous NaHCO.sub.3
and brine, dried over MgSO.sub.4 and concentrated to give
Intermediate 79 (149 mg, 96%) as a white solid. HPLC: Rt=0.453 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=235 [M+H].sup.+. Intermediate 79 was used in
the synthesis of Example 243.
Intermediate 80
2-(5-Amino-2-methylphenyl)acetic acid
##STR00150##
[0521] Intermediate 80A: Preparation of
2-(2-methyl-5-nitrophenyl)acetic acid
##STR00151##
[0523] A solution of 2-o-tolylacetic acid (3.54 g, 23.6 mmol) in
DCM (12 mL) was added to a pre-cooled mixture of concentrated
sulfuric acid (10 mL, 188 mmol) and 90% nitric acid (1 mL, 22.4
mmol) at -20.degree. C. The reaction mixture was stirred at
-20.degree. C. for 30 minutes, then slowly warmed to room
temperature and stirred overnight. The reaction mixture was poured
into ice-water. The white solid was collected by filtration, rinsed
with water, and concentrated. The solid was triturated with ether
and filtered to obtain Intermediate 80A (2.4 g, 42%) as a white
solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 12.62 (1H,
br. s.), 8.13 (1H, d, J=2.51 Hz), 8.04 (1H, dd, J=8.28, 2.51 Hz),
7.47 (1H, d, J=8.53 Hz), 3.80 (2H, s), 2.34 (3H, s).
Intermediate 80: Preparation of 2-(5-amino-2-methylphenyl)acetic
acid
##STR00152##
[0525] Intermediate 80 was prepared from Intermediate 80A following
the hydrogenation conditions employed in the preparation of
Intermediate 70. HPLC: Rt=0.705 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=166 [M+H].sup.+. Intermediate 80 was used in the synthesis of
Example 224.
Intermediate 81
4-(4-Methylpiperazin-1-yl)benzene-1,3-diamine
##STR00153##
[0526] Intermediate 81A:
1-(2,4-Dinitrophenyl)-4-methylpiperazine
##STR00154##
[0528] To 1-fluoro-2,4-dinitrobenzene (1 g, 5.37 mmol) was added
1-methylpiperazine (1.615 g, 16.12 mmol) slowly. Dilute aqueous
NaHCO.sub.3 was added, and the mixture was extracted with EtOAc.
The combined extracts were dried, concentrated and purified by ISCO
silica gel chromatography (24 g, stepwise gradient from DCM to 10%
MeOH/DCM) to give Intermediate 81 (1.4 g, 98%) as a yellow oil.
HPLC: Rt=1.032 min. (CHROMOLITH.RTM. column 4 6.times.50 mm eluting
with 10-90% aqueous methanol over 4 min. containing 0.1% TFA, 4
mL/min., monitoring at 220 nm). MS (ES): m/z=267 [M+H].sup.+.
Intermediate 81: 4-(4-Methylpiperazin-1-yl)benzene-1,3-diamine
##STR00155##
[0530] Compound 81 was prepared from 81A in a similar way as
Intermediate 70. HPLC: Rt=0.228 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=207 [M+H].sup.+. Intermediate 81 was used in the synthesis of
Examples 92 and 94.
Example 1
N-(5-((3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2-m-
ethylphenyl)acetamide
##STR00156##
[0531] 1A: Preparation of 4-bromo-6-chloropyridazin-3-amine
##STR00157##
[0533] To a 250 mL round-bottomed flask was added
6-chloropyridazin-3-amine (3.92 g, 30.3 mmol), sodium bicarbonate
(5.08 g, 60.5 mmol) and ethanol (20 mL). To the resulting solution,
bromine (1.559 mL, 30.3 mmol) was added dropwise. The resulting
mixture was stirred at room temperature for 16 hours. The solution
was filtered and then concentrated in vacuo. The residue was
dissolved in water, and the product extracted with ethyl acetate (3
times). The organic layers were combined, dried over anhydrous
sodium sulfate and concentrated in vacuo to give 1A (4.5 g, 71.3%
yield). HPLC: Rt=1.25 min (Waters Sunfire C18 column (4.6.times.50
mm) 10-90% aqueous methanol containing 0.1% TFA, 4 min gradient,
flow rate=4 mL/min, detection at 254 nm). MS (ES): m/z=207.88
[M+H].sup.+.
1B: Preparation of ethyl 2-chloro-3-oxopropanoate
##STR00158##
[0535] To a flask was added sodium (4.45 g, 194 mmol) and ethanol
(56.5 mL, 968 mmol) and the mixture was stirred at room temperature
for 4 hours until all of the metal had dissolved. Diethyl ether
(100 mL) was added, followed by the slow addition of ethyl formate
(17.2 mL, 213 mmol) and ethyl chloroacetate (22.79 mL, 213 mmol) as
a solution in diethyl ether (100 mL). The reaction solution was
stirred at room temperature for 16 hours. The resulting precipitate
that formed was filtered and washed with ether, and dissolved in
water. The aqueous layer was acidified with HCl (1N) to pH 4, and
the product was extracted with diethyl ether (3 times). The organic
layers were combined, dried over anhydrous sodium sulfate and
concentrated to give 1B (4.5 g, 15.4% yield).
1C: Preparation of ethyl
8-bromo-6-chloroimidazo[1,2-b]pyridazine-3-carboxylate and ethyl
6,8-dichloroimidazo[1,2-b]pyridazine-3-carboxylate
##STR00159##
[0537] To a 250 mL round-bottomed flask was added 1B (4.33 g, 28.8
mmol) and 1A (5 g, 24.0 mmol). The solution was heated to
90.degree. C. for 16 hours. The solution was quenched with ethyl
acetate and washed with water. The organic layer was dried over
anhydrous sodium sulfate and concentrated in vacuo. The crude was
purified by flash chromatography (SiO.sub.2,10% ethyl acetate/DCM;
80 g column) to give a mixture of 1C-1 and 1C-2 (2.1 g, 29%
yield).
[0538] 1C-1: HPLC: Rt=2.54 min (Waters Sunfire C18 column
(4.6.times.50 mm) 10-90% aqueous methanol containing 0.1% TFA, 4
min gradient, flow rate=4 mL/min, detection at 254 nm). MS (ES):
m/z=256.96 [M+H].sup.+.
[0539] 1C-2: HPLC: Rt=2.63 min (Waters Sunfire C18 column
(4.6.times.50 mm) 10-90% aqueous methanol containing 0.1% TFA, 4
min gradient, flow rate=4 mL/min, detection at 254 nm). MS (ES):
m/z=303.92 [M+H].sup.+.
1D: Preparation of
8-bromo-6-chloroimidazo[1,2-b]pyridazine-3-carboxylic acid and
6,8-dichloroimidazo[1,2-b]pyridazine-3-carboxylic acid
##STR00160##
[0541] To a vial was added the mixture of 1C (300 mg, 0.98 mmol) in
methanol (10 mL). To this mixture was added 6 N HCl (1.64 mL, 9.85
mmol). The solution was heated at 90.degree. C. for 16 hours. The
solution was diluted with ethyl acetate, and the product extracted
with saturated aqueous sodium bicarbonate solution. The combined
aqueous layer was acidified with HCl (1N) to pH 4 and extracted
with ethyl acetate (3 times). The ethyl acetate extracts were
combined, dried over anhydrous sodium sulfate and concentrated in
vacuo to give a mixture of 1D-1 and 1D-2 (150 mg, 55%).
[0542] 1D-1: HPLC: Rt=1.67 min (Waters Sunfire C18 column
(4.6.times.50 mm) 10-90% aqueous methanol containing 0.1% TFA, 4
min gradient, flow rate=4 mL/min, detection at 254 nm). MS (ES):
m/z=231.87 [M+H].sup.+.
[0543] 1D-2: HPLC: Rt=1.81 min (Waters Sunfire C18 column
(4.6.times.50 mm) 10-90% aqueous methanol containing 0.1% TFA, 4
min gradient, flow rate=4 mL/min, detection at 254 nm). MS (ES):
m/z=275.79 [M+H].sup.+.
1E: Preparation of
8-bromo-6-chloroimidazo[1,2-b]pyridazine-3-carboxamide and
6,8-dichloroimidazo[1,2-b]pyridazine-3-carboxamide
##STR00161##
[0545] A 1 L flask was charged with a mixture of 1D-1 and 1D-2 (10
g, 36.2 mmol) and DCM (100 mL). DMF (0.280 mL, 3.62 mmol) was
added, followed by the dropwise addition of oxalyl chloride (72.3
mL, 145 mmol). The resulting reaction was heated to 45.degree. C.
for 2 hours and then concentrated to dryness. The crude acid
chloride was taken up in 1,4-dioxane (100 mL) and treated with
ammonia (0.5 N ammonia in THF) in THF (72.3 mL, 36.2 mmol). The
reaction mixture was stirred at room temperature for 1 hour, and
more ammonia in THF (72.3 mL, 36.2 mmol) was added. The resulting
suspension was stirred for 1 hour and then concentrated to dryness.
The crude material was suspended in water (100 mL) and stirred for
2 hours. The solid was collected by filtration, and dried under
reduced pressure to afford a mixture of 1E-1 and 1E-2 (8.7 g,
87%).
[0546] 1E-1: HPLC: Rt=2.08 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min gradient,
monitored at 220 nm); MS (ES): m/z=231 [M+H].sup.+.
[0547] 1E-2: HPLC: Rt=2.20 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min gradient,
monitored at 220 nm); MS (ES): m/z=275 [M+H].sup.+.
1F: Preparation of
8-bromo-6-chloroimidazo[1,2-b]pyridazine-3-carbonitrile and
6,8-dichloroimidazo[1,2-b]pyridazine-3-carbonitrile
##STR00162##
[0549] A suspension of 1D-1 and 1D-2 (8.7 g, 31.6 mmol) in
CHCl.sub.3 (500 mL) was treated with POCl.sub.3 (35.3 mL, 380 mmol)
and heated to reflux for 3 days. The resulting solution was cooled
to room temperature and poured into cold saturated aqueous
NaHCO.sub.3 (1 L). Solid Na.sub.2CO.sub.3 was added until neutral
pH was achieved. The resulting layers were separated and the
aqueous layer was extracted with CHCl.sub.3 (1 L). The combined
organics were dried with Na.sub.2SO.sub.4, filtered and
concentrated to dryness to afford a mixture of 1F-1 and 1F-2 as a
yellow powder (5.6 g, 68.9%).
[0550] 1F-1: HPLC: Rt=2.53 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min gradient,
monitored at 220 nm); MS (ES): m/z=213 [M+H].sup.+.
[0551] 1F-2: HPLC: Rt=2.67 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min gradient,
monitored at 220 nm); MS (ES): m/z=258.9 [M+H].sup.+.
1G: Preparation of
6-chloro-8-(cyclopropyl(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazine-3--
carbonitrile
##STR00163##
[0553] To a solution of 1F-1 and 1F-2 and
N-(4-methoxybenzyl)cyclopropanamine (1, 4.13 g, 23.30 mmol) in THF
(155 mL) at room temperature was added DIEA (4.1 mL, 23.3 mmol).
The resulting solution was heated to reflux for 5 hours, and then
cooled to room temperature and concentrated. The crude solid was
dried under reduced pressure overnight. The crude solid was stirred
in MeOH for 1 hour at room temperature, filtered, and washed with
MeOH. The solid was dried under reduced pressure to afford 1G (5.17
g, 14.03 mmol, 90% yield) as an off-white solid. HPLC: Rt=4.26 min
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS
(ES): m/z=354.0 [M+H].sup.+.
Example 1
Preparation of
N-(5-((3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2--
methylphenyl)acetamide
##STR00164##
[0555] DMA (1.5 mL) was placed in a 1-dram vial with a teflon-lined
septum cap, and the solvent was degassed by bubbling argon through
it for 10 minutes. 1G (0.15 g, 0.42 mmol),
N-(5-amino-2-methylphenyl)acetamide (0.104 g, 0.636 mmol),
copper(I) iodide (0.040 g, 0.212 mmol), xantphos (0.049 g, 0.085
mmol), and Pd.sub.2(dba).sub.3 (0.039 g, 0.042 mmol) were added in
one portion, and the suspension was pump/purged three times with
argon. The vessel was then heated to 125.degree. C. for 45 min. and
then cooled to room temperature. The solids were removed via
filtration through CELITE.RTM., washing with THF. The filtrate was
then diluted with water and EtOAc. The layers were separated, and
the aqueous phase extracted EtOAc (3.times.10 mL). The organics
were combined, washed with water and brine, and dried over
anhydrous sodium sulfate. Filtration and concentration afforded a
tan solid, which was triturated in DCM and cooled to 0.degree. C.
The resulting precipitate was filtered and washed with cold DCM.
The filtrate was dissolved in a small amount of DCM and purified by
flash chromatography (SiO.sub.2, 0% EtOAc/DCM to 60% EtOAc/DCM, 24
g column, 30 mL/min, 20 min gradient, monitoring at 254 nm). The
appropriate fractions were pooled and concentrated under reduced
pressure. The material isolated from chromatography, and the solid
were combined, suspended in DCM (3 mL) and treated with
triethylsilane (0.68 mL, 4.24 mmol) and TFA (0.3 mL). After 30
minutes, the suspension was cooled in an ice bath and filtered. The
solid was suspended in EtOAc (20 mL) and stirred with saturated
aqueous sodium bicarbonate (15 mL). After 30 minutes, the solid was
isolated via filtration, washed with water and EtOAc, and dried
overnight in vacuo to afford Example 1 (0.154 g, 0.422 mmol, 100%)
as a white solid. HPLC: Rt=3.496 min (YMC S5 ODS 4.6.times.50 mm,
10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min
gradient, monitored at 220 nm). MS (ES): m/z=362.0 [M+H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.24 (1H, s), 9.21
(1H, s), 8.10 (1H, s), 7.81 (1H, s), 7.64 (2H, s), 7.11 (1H, d,
J=8.03 Hz), 6.25 (1H, s), 2.52-2.55 (1H, m), 2.15 (3H, s), 2.06
(3H, s), 0.75-0.82 (2H, m), 0.61-0.68 (2H, m).
Example 2
N-(6-(3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-ylamino)pyridi-
n-2-yl)acetamide
##STR00165##
[0556] 2A: Preparation of
6-(6-aminopyridin-2-ylamino)-8-(cyclopropyl(4-methoxybenzyl)amino)imidazo-
[1,2-b]pyridazine-3-carbonitrile
##STR00166##
[0558] A sealed tube was charged with DME (1.5 mL) and purged with
argon. The vessel was then charged with 1G (0.050 g, 0.14 mmol),
pyridine-2,6-diamine (0.039 g, 0.35 mmol), cesium carbonate (0.184
g, 0.57 mmol), copper(I) iodide (0.013 g, 0.071 mmol), Xantphos
(0.016 g, 0.028 mmol), and Pd.sub.2(dba).sub.3 (0.013 g, 0.014
mmol), in one portion. The resulting suspension was pump/purged
with argon three times. The cap was placed on the vessel, and the
suspension heated to 125.degree. C. overnight. The solids were
filtered off, and the filtrate was concentrated in vacuo. The crude
product was dissolved in a small amount of DCM and charged to a 24
g silica gel cartridge which was eluted at 30 mL/min with a 20 min
gradient from 100% DCM to 60% EtOAc/DCM, monitoring at 254 nm,
affording 2A (0.014 g, 23% yield) as a tan solid. HPLC: Rt=3.62 min
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS
(ES): m/z=427.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.19-8.28 (1H, m), 7.41 (1H, s), 7.03-7.12 (3H, m),
6.96-7.03 (1H, m), 6.79-6.86 (2H, m), 6.13 (1H, s), 5.49 (2H, s),
3.68 (3H, s), 3.49-3.65 (3H, m), 2.45 (1H, d, J=3.78 Hz), 0.91-0.98
(2H, m), 0.74 (2H, m).
Example 2
Preparation of
N-(6-(3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-ylamino)pyrid-
in-2-yl)acetamide
##STR00167##
[0560] 2A (0.014 g, 0.033 mmol) was suspended in acetic acid (3 mL)
at room temperature, and acetic anhydride (3.72 .mu.L, 0.039 mmol)
was added. The resulting clear yellow solution was refluxed for 30
min. The solution was cooled to room temperature, and water was
added slowly until a precipitate formed. The resulting solid was
filtered and washed with water, then dissolved in THF and
azeotroped three times with toluene to remove residual
AcOH/H.sub.2O. The resulting intermediate was dried in vacuo for 1
hour, and then dissolved in TFA (0.4 mL) and triethylsilane (0.021
mL, 0.13 mmol) was added immediately. The mixture was stirred for
30 min. at room temperature. The volatiles were removed via a
stream of nitrogen, and the solid was dissolved in DMF and purified
via preparatory HPLC using a YMC ODS C-18 column (30.times.250 mm),
0%-100% B. Solvent B: (90% MeOH, 10% H.sub.2O, 0.1% TFA). Solvent
A: (10% MeOH, 90% H.sub.2O, 0.1% TFA). Gradient, start % B=0, final
% B=100, gradient time 30 min (total run time: 37 min), flow rate
25 mL/min, monitoring at 254 nm Rt=27.582 min. Fractions were
concentrated and lyophilized overnight, affording Example 2 (0.005
g, 32% yield) as a white solid. HPLC: Rt=3.14 min (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS (ES):
m/z=349.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.00 (1H, s), 9.65 (1H, s), 8.16 (1H, s), 7.96 (1 H, d, J=1.51
Hz), 7.68 (1H, d, J=7.81 Hz), 7.58 (2H, d, J=8.06 Hz), 6.93 (1H,
s), 2.55-2.64 (1H, m), 2.10 (3H, s), 0.74-0.82 (2H, m), 0.60-0.70
(2H, m).
Example 3
N-(3-(3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-ylamino)phenyl-
)methanesulfonamide
##STR00168##
[0561] 3A: Preparation of
6-(3-aminophenylamino)-8-(cyclopropyl(4-methoxybenzyl)amino)imidazo[1,2-b-
]pyridazine-3-carbonitrile
##STR00169##
[0563] A 1-dram vial was charged with
1-methoxy-2-(2-methoxyethoxy)ethane (1.5 mL) and purged for 10 min
with argon. The vessel was then charged with 1G (0.100 g, 0.28
mmol), benzene-1,3-diamine (0.037 g, 0.34 mmol), cesium carbonate
(0.368 g, 1.13 mmol), copper(I) iodide (0.027 g, 0.14 mmol),
Xantphos (0.033 g, 0.057 mmol), and Pd.sub.2(dba).sub.3 (0.026 g,
0.028 mmol) in one portion. The resulting suspension was heated to
125.degree. C. overnight. The suspension was filtered through a
medium-porosity frit, and the solid was washed with THF. The
filtrate was diluted with EtOAc and water, and the layers were
separated. The aqueous phase was extracted three times with EtOAc.
The organics were then combined, dried over anhydrous sodium
sulfate, filtered and concentrated in vacuo. The crude residue was
dissolved in DMF and purified via preparatory HPLC using a YMC ODS
C-18 column (30.times.250 mm), 0%-100% B. Solvent B: (90% MeOH, 10%
H.sub.2O, 0.1% TFA). Solvent A: (10% MeOH, 90% H.sub.2O, 0.1% TFA).
Gradient, start % B=0, final % B=100, gradient time 60 min, flow
rate 25 mL/min, monitoring at 220 nm. Rt=53.697 min. The
appropriate fractions were concentrated and lyophilized to dryness,
affording 3A (11 mg, 9% yield). HPLC: Rt=3.68 min (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS (ES):
m/z=426.0 [M+H].sup.+.
Example 3
Preparation of
N-(3-(3-cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-ylamino)pheny-
l)methanesulfonamide
##STR00170##
[0565] To a solution of 3A (0.011 g, 0.026 mmol) in THF (0.5 mL) at
0.degree. C. was added pyridine (6.27 .mu.L, 0.078 mmol) and
methanesulfonyl chloride (2.2 .mu.L, 0.028 mmol). The reaction was
stirred overnight at room temperature. The reaction mixture was
diluted with water and EtOAc, and the aqueous layer was extracted
twice with EtOAc. The organic extracts were combined, dried over
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The
crude material was dissolved in TFA (0.5 mL) and triethylsilane
(0.041 mL, 0.26 mmol) was added. The reaction was stirred for 30
min. at room temperature. The volatiles were removed under a stream
of nitrogen, and the crude material was dissolved in DCM/EtOAc
(1:1) and charged to a 12 g silica gel cartridge which was eluted
at 30 mL/min with a 15 min gradient from 100% DCM to 40% EtOAc/DCM.
Example 3 was isolated as a light yellow solid (5 mg, 52% yield).
HPLC: Rt=3.52 min (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous
methanol containing 0.2% H.sub.3PO.sub.4, 4 min gradient, monitored
at 220 nm). MS (ES): m/z=383.9 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.71 (1H, s), 9.35 (1H, s), 8.12 (1H, s),
7.86 (1H, d, J=1.76 Hz), 7.69 (1H, dd, J=8.18, 1.38 Hz), 7.33 (1 H,
t, J=2.01 Hz), 7.24 (1H, t, J=8.06 Hz), 6.77 (1H, dd, J=7.55, 1.76
Hz), 6.26 (1H, s), 3.00 (3H, s), 2.51-2.56 (1H, m), 0.75-0.83 (2H,
m), 0.62-0.68 (2H, m).
Example 4
8-(Cyclobutylamino)-6-((4-((2-(dimethylamino)ethyl)amino)-3-(4H-1,2,4-tria-
zol-4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00171##
[0566] 4A: Preparation of N-(4-methoxybenzyl)cyclobutanamine
##STR00172##
[0568] 4-Methoxybenzaldehyde (5.63 mL, 46.4 mmol) and
cyclobutanamine (3.3 g, 46.4 mmol) in dichloromethane (40 mL) were
stirred at room temperature. After 45 min., magnesium perchlorate
(0.231 g, 2.320 mmol) was added, and the reaction mixture was
stirred at room temperature. After 16 hours, the reaction mixture
was treated with Na.sub.2SO.sub.4 (2 g) and stirred at room
temperature for 2 hours, filtered and concentrated to dryness. The
reaction mixture was dissolved in methanol (40 mL), cooled to
0.degree. C., and NaBH.sub.4 (1.6 g, 69.6 mmol) was added. After 15
min., the reaction mixture was warmed to room temperature. After 2
hours, the reaction mixture was diluted with 1N NaOH (100 mL) and
extracted with ethyl acetate (3.times.100 mL). The combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
to isolate 4A (8.5 g, 82% yield) as a clear oil. HPLC: Rt=0.82 min
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 10-90% aqueous
methanol containing 0.1% TFA, 2 min gradient, flow rate=5 mL/min,
detection at 254 nm). MS (ES): m/z=192.6 [M+H].sup.+.
4B: Preparation of
6-chloro-8-(cyclobutyl(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazine-3-c-
arbonitrile
##STR00173##
[0570] A mixture of 1F (500 mg, 1.94 mmol), 4A (464 mg, 2.43 mmol),
and DIEA (0.509 mL, 2.91 mmol) in DMF (0.5 mL) was heated to
80.degree. C. After 1 hour, the reaction mixture was concentrated
to dryness, and triturated with methanol to isolate 4B (582 mg, 77%
yield) as a yellow solid. HPLC: Rt=2.02 min (PHENOMENEX.RTM. Luna 5
micron C18 4.6.times.30 mm, 10-90% aqueous methanol containing 0.1%
TFA, 2 min gradient, flow rate=5 mL/min, detection at 254 nm). MS
(ES): m/z=367.98 [M+H].sup.+.
Example 4
Preparation of
8-(cyclobutylamino)-6-((4-((2-(dimethylamino)ethyl)amino)-3-(4H-1,2,4-tri-
azol-4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00174##
[0572] A suspension of 4B (79 mg, 0.22 mmol), Intermediate 36 (50
mg, 0.20 mmol) and
di-tert-butyl(1-methyl-2,2-diphenylcyclopropyl)phosphine (14.3 mg,
0.041 mmol) in toluene (1 mL) were purged with nitrogen, and
allylpalladium (II) chloride dimer (7.4 mg, 0.020 mmol) and sodium
tert-butoxide (23.4 mg, 0.244 mmol) were added. The reaction
mixture was heated at 100.degree. C. for 45 min. The reaction
mixture was concentrated, and then taken up in water (50 mL) and
extracted with DCM (3.times.25 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated. The reaction mixture was dissolved in
dichloroethane (4 mL) and treated with triethylsilane (0.5 ml) and
TFA (1 mL). After 15 min., the reaction mixture was concentrated,
and then purified using reverse phase HPLC and lyophilized from 1N
HCl to isolate Example 4 (8 mg, 7.1% yield) as a yellow solid.
HPLC: Rt=1.38 min (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 2 min gradient,
flow rate=5 mL/min, detection at 254 nm). MS (ES): m/z=458.17
[M+H].sup.+. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 9.77
(2H, s), 8.26 (1H, d, J=2.75 Hz), 8.10 (1H, s), 7.56 (1H, dd,
J=8.94, 2.52 Hz), 7.10 (1H, d, J=8.71 Hz), 5.91 (1H, s), 4.11 (1H,
t, J=7.79 Hz), 3.58 (2H, t, J=5.96 Hz), 3.41 (2H, t, J=5.96 Hz),
2.87-3.01 (6H, m), 2.39-2.65 (2H, m), 2.02-2.21 (2H, m), 1.84-2.00
(2H, m).
Example 5
N-(5-(3-Cyano-8-(5-methoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-ylam-
ino)-2-methylphenyl)acetamide
##STR00175##
[0573] 5A: Preparation of
5-methoxy-N-(4-methoxybenzyl)pyridine-2-amine
##STR00176##
[0575] 5A was prepared from 4-methoxybenzaldehyde and
5-methoxypyridin-2-amine following the procedure employed for the
preparation of 4A. HPLC: Rt=1.30 min (PHENOMENEX.RTM. Luna C18
4.6.times.30 mm 3u, A10-90% aqueous methanol containing 0.1% TFA in
2 min; 4 mL/min flow). MS (ES): m/z=244.9 [M+H].sup.+.
5B: Preparation of
6-chloro-8-((5-methoxypyridin-2-yl)(4-methoxybenzyl)amino)imidazo[1,2-b]p-
yridazine-3-carbonitrile
##STR00177##
[0577] To a mixture of 1F (100 mg, 0.47 mmol) and 5A (138 mg, 0.56
mmol) in DMF (3 mL) was added KHMDS (1.13 mL, 0.5 molar solution)
dropwise at 0.degree. C. After 10 minutes, the reaction was
quenched with saturated aqueous ammonia chloride, extracted with
ethyl acetate (3.times.15 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated. The resulting residue was dissolved in
DCM and purified by silica chromatography (gradient=0% to 100%,
hexanes to ethyl acetate in 12 min.) to give 5B (156 mg, 63.2%
yield). HPLC: Rt=1.13 min (PHENOMENEX.RTM. Luna C18 4.6.times.30 mm
3u, 10-90% aqueous methanol containing 0.1% TFA in 2 min; 4 mL/min
flow). MS (ES): m/z=421.0 [M+H].sup.+.
5C: Preparation of
N-(5-(3-cyano-8-((5-methoxypyridin-2-yl)(4-methoxybenzyl)amino)imidazo[1,-
2-b]pyridazin-6-ylamino)-2-methylphenyl)acetamide
##STR00178##
[0579] A mixture of 5B (60 mg, 0.14 mmol),
N-(5-amino-2-methylphenyl)acetamide (46.8 mg, 0.29 mmol),
Pd.sub.2(dba).sub.3 (13.1 mg, 0.014 mmol), Xantphos (18.2 mg, 0.031
mmol), copper(I) iodide (13.6 mg, 0.071 mmol) and Cs.sub.2CO.sub.3
(186 mg, 0.57 mmol) in DMA (1 mL) was purged with nitrogen and
heated at 125.degree. C. After 1.5 hours, the reaction mixture was
diluted with ethyl acetate, washed with 15% NH.sub.4OH, dried over
Na.sub.2SO.sub.4, and concentrated to dryness under reduced
pressure. The resulting oil was purified by silica column
chromatography (gradient=0%-100% hexanes to ethyl acetate in 12
min.) to isolate 5C (47.5 mg, 60.7% yield). HPLC: Rt=3.805 min (YMC
S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS (ES):
m/z=549.2 [M+H].sup.+.
Example 5
Preparation of
N-(5-(3-cyano-8-(5-methoxypyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yla-
mino)-2-methylphenyl)acetamide
##STR00179##
[0581] A solution of 5C (60 mg, 0.11 mmol) in DCM (0.5 mL) was
treated with triethylsilane (0.03 mL, 0.19 mmol) followed by TFA
(0.06 mL, 0.78 mmol). The reaction mixture was stirred at
45.degree. C. for 1.5 hours, concentrated, purified with reverse
phase HPLC, and lyophilized with 1.0 N HCl to yield Example 5 (21.9
mg, 37.1% yield). MS (ES): m/z=429.1 [M+H].sup.+. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 9.88 (1H, s), 9.42 (1H, s), 9.22
(1H, s), 8.19 (1H, s), 8.04 (1H, s), 8.02 (1H, dd, J=2.38, 1.13
Hz), 7.60-7.69 (2H, m), 7.44-7.47 (2H, m), 7.10 (1H, d, J=8.28 Hz),
3.80 (3H, s), 2.12 (3H, s), 2.03 (3H, s).
Example 6
N-(5-((8-(3-Azetidinylamino)-3-cyanoimidazo[1,2-b]pyridazin-6-yl)amino)-2--
methylphenyl)acetamide
##STR00180##
[0582] 6A: Preparation of tert-butyl
3-(4-methoxybenzylamino)azetidine-1-carboxylate
##STR00181##
[0584] 6A was prepared from 4-methoxybenzaldehyde and tert-butyl
3-aminoazetidine-1-carboxylate following the procedure employed for
the preparation of 4A. HPLC: Rt=3.0 min (PHENOMENEX.RTM. Luna C18
4.6.times.30 mm 3u, 10-90% aqueous methanol containing 0.1% TFA in
2 min; 4 mL/min flow). MS (ES): m/z=293.9 [M+H].sup.+.
6B: Preparation of tert-butyl
3-((6-chloro-3-cyanoimidazo[1,2-b]pyridazin-8-yl)(4-methoxybenzyl)amino)a-
zetidine-1-carboxylate
##STR00182##
[0586] A solution of 1F (100 mg, 0.47 mmol) in THF (5 mL) was
treated with 6A (274 mg, 0.94 mmol) and DIEA (0.246 mL, 1.41 mmol)
and heated at 70.degree. C. After 18 hours, the reaction mixture
was diluted with water, extracted with ethyl acetate (3.times.15
mL), dried over Na.sub.2SO.sub.4, filtered and concentrated. The
residue was purified by flash chromatography, silica column (12 g,
gradient=12 min, 100% hexanes to 70% ethyl acetate/hexanes) to
provide 6B (142.8 mg, 0.305 mmol, 64.9.0% yield) as a tan solid.
HPLC: Rt=4.55 min (PHENOMENEX.RTM. Luna C18 4.6.times.30 mm 3u,
10-90% aqueous methanol containing 0.1% TFA in 5 min; 4 mL/min
flow). MS (ES): m/z=469.0 [M+H].sup.+.
Example 6
Preparation of
N-(5-(8-(azetidin-3-ylamino-3-cyanoimidazo[1,2-b]pyridazin-6-ylamino)-2-m-
ethylphenyl)acetamide
##STR00183##
[0588] A mixture of 6B (50 mg, 0.11 mmol),
N-(5-amino-2-methylphenyl)acetamide (35.0 mg, 0.213 mmol),
Pd.sub.2(dba).sub.3 (9.76 mg, 10.7 .mu.mol), xantphos (13.6 mg,
0.023 mmol), copper (I) iodide (10.2 mg, 0.053 mmol) and
Cs.sub.2CO.sub.3 (139 mg, 0.43 mmol) in DMA (1 mL) was purged with
nitrogen and heated at 125.degree. C. After 2 hours, the reaction
mixture was diluted with ethyl acetate, washed with 15% NH.sub.4OH,
dried over Na.sub.2SO.sub.4, filtered and concentrated. The
resulting oil was dissolved in DCM (1 mL), treated with Et.sub.3SiH
(0.1 mL) and TFA (0.1 mL), and heated at 60.degree. C. After 10
min., the reaction mixture was concentrated, purified by reverse
phase HPLC, lyophilized with 1.0 N HCl to isolate Example 6 (18.0
mg, 37.6%). HPLC: Rt=9.610 min (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 15 min gradient,
monitored at 220 nm). MS (ES): m/z=377.1 [M+H].sup.+. .sup.1HNMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 9.25 (1H, s), 9.24 (1H, s),
9.10 (1H, br. s.), 8.89 (1H, br. s.), 8.17 (1H, s), 7.57-7.63 (2H,
m), 7.11 (1H, d), 5.91 (1H, s), 4.56 (1H, br. s.), 4.19-4.27 (2H,
m), 4.09-4.18 (2H, m), 2.14 (3 H, s), 2.05 (3H, s).
Example 7
N-(3-(3-Cyano-8-(phenylamino)imidazo[1,2-b]pyridazin-6-ylamino)phenyl)acet-
amide
##STR00184##
[0589] 7A: Preparation of
6-chloro-8-((4-methoxybenzyl)(phenyl)amino)imidazo[1,2-b]pyridazine-3-car-
bonitrile
##STR00185##
[0591] A solution of 1F (0.200 g, 0.94 mmol) and
N-(4-methoxybenzyl)aniline (0.210 g, 0.99 mmol) in THF (9.4 mL) was
cooled to 0.degree. C. Potassium tert-butoxide (1.0 M solution,
1.03 mL, 1.03 mmol) was then added dropwise via syringe. The
resulting solution was stirred for 10 min. at 0.degree. C., and
then warmed to room temperature. The reaction was quenched with
water and diluted with EtOAc. The aqueous phase was extracted twice
with EtOAc, and the organics were combined, dried over sodium
sulfate, filtered, and concentrated. The crude product was
dissolved in a small amount of DCM and charged to a 24 g silica gel
flash chromatography (SiO.sub.2) which was eluted at 30 mL/min.
with a 20 min. gradient from 100% hexanes to 15% EtOAc/hexanes
(monitoring at 254 nm). Concentration of the appropriate fractions
afforded 7A (0.13 g, 33% yield) as a light brown solid. HPLC:
Rt=4.5 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=390.0 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.41 (1H, s), 7.45 (2H, t, J=7.68 Hz),
7.36 (1H, t, J=7.43 Hz), 7.22-7.30 (2H, m), 7.17 (2H, d, J=8.81
Hz), 6.77-6.84 (2 H, m), 5.91 (1H, s), 5.78 (2H, s), 3.68 (3H,
s).
Example 7
Preparation of
N-(3-(3-cyano-8-(phenylamino)imidazo[1,2-b]pyridazin-6-ylamino)phenyl)ace-
tamide
##STR00186##
[0593] A sealed tube was charged with DME (1.5 mL) and purged with
argon for 10 min. 7A (0.046 g, 0.31 mmol), cesium carbonate (0.209
g, 0.641 mmol), copper(I) iodide (0.012 g, 0.064 mmol), Xantphos
(0.015 g, 0.026 mmol), and Pd.sub.2(dba).sub.3 (0.012 g, 0.013
mmol) were all added in one portion, and the vessel was pump/purged
three times with argon. The vessel was then sealed and heated to
125.degree. C. overnight. The solids were filtered off, and the
filtrate was concentrated in vacuo. The crude product was dissolved
in a small amount of DCM and charged to a 12 g silica gel cartridge
which was eluted at 30 mL/min. with a 15 min. gradient from 100%
DCM to 50% EtOAc/DCM (monitoring at 254 nm). The fractions were
concentrated, dissolved in TFA (0.4 mL), and triethylsilane (0.082
mL, 0.513 mmol) was immediately added. The mixture was stirred for
20 min. at room temperature. A gray precipitate formed after 20
minutes, and the reaction was filtered, affording Example 7 (0.047
g, 73% yield) as a gray solid. HPLC: Rt=3.928 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=384.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 9.88 (1H, s), 9.49 (1H, s), 9.28 (1H, s), 8.23 (1H, s), 7.81
(1H, d, J=6.29 Hz), 7.73 (1H, s), 7.40-7.47 (4H, m), 7.15-7.25 (2H,
m), 6.97 (1H, s), 6.57 (1H, s), 2.04 (3H, s).
Example 8
Methyl
(5-((3-cyano-8-(2-pyridinylamino)imidazo[1,2-b]pyridazin-6-yl)amino-
)-2-fluorophenyl)carbamate
##STR00187##
[0594] 8A: Preparation of
6-chloro-8-((4-methoxybenzyl)(2-pyridinyl)amino)imidazo[1,2-b]pyridazine--
3-carbonitrile
##STR00188##
[0596] 8A was prepared from a mixture of 1F and
N-(4-methoxybenzyl)pyridin-2-amine following the procedure employed
for the preparation of 5B. HPLC: Rt=3.881 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min gradient, monitored at 220 nm). MS (ES):
m/z=391.0 [M+H].sup.+.
8B: Preparation of
6-(3-amino-4-fluorophenylamino)-8-((4-methoxybenzyl)(pyridin-2-yl)amino)i-
midazo[1,2-b]pyridazine-3-carbonitrile
##STR00189##
[0598] A solution of Intermediate 59 (70.7 mg, 0.384 mmol) in
degassed DME (5 mL) was treated with 8A (75 mg, 0.192 mmol),
Xantphos (24.4 mg, 0.042 mmol), bis(dibenzylideneacetone)palladium
(11.03 mg, 0.019 mmol), cesium carbonate (250 mg, 0.768 mmol), and
copper (I) iodide (18.3 mg, 0.096 mmol). The reaction mixture was
purged with argon and heated in a sealed tube to 125.degree. C. for
8 hours. The reaction was cooled to room temperature and filtered.
The filtrate was concentrated to dryness. The crude product was
dissolved in a small amount of DCM and purified by flash
chromatography (SiO.sub.2, DCM to 50% ethyl acetate/DCM, 40 g
column, 40 min. gradient) to afford 8B (82 mg, 89% yield).
[0599] HPLC: Rt=3.71 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm); MS (ES): m/z=481.1 [M+H].sup.+.
8C: Preparation of methyl
5-(3-cyano-8-((4-methoxybenzyl)(pyridin-2-yl)amino)imidazo[1,2-b]pyridazi-
n-6-ylamino)-2-fluorophenylcarbamate
##STR00190##
[0601] A solution of 8B (82 mg, 0.17 mmol) in THF (3 mL) was
treated with DIEA (0.039 mL, 0.22 mmol), followed by methyl
chloroformate (0.048 mL, 0.62 mmol). The resulting solution was
stirred at room temperature for 12 hours and then concentrated to
dryness. The crude product was dissolved in a small amount of DCM
and purified by flash chromatography (SiO.sub.2, DCM to 20% ethyl
acetate/DCM, 24 g column, 40 min. gradient) to afford 8C (15 mg,
16.3%). HPLC: Rt=3.98 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=539.2 [M+H].sup.+.
Example 8
Preparation of methyl
5-(3-cyano-8-(pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-ylamino)-2-fluo-
rophenylcarbamate
##STR00191##
[0603] A solution of 8C (15 mg, 0.028 mmol) in triethylsilane
(0.044 mL, 0.279 mmol) and TFA (0.5 mL, 0.028 mmol) was heated at
45.degree. C. for 2 hours. The reaction mixture was concentrated to
dryness. The crude reaction product was dissolved in a small amount
of MeOH and purified by reversed phase HPLC (YMC ODS-A 5 um
30.times.250 mm, 10-90% aqueous methanol containing 0.1% TFA, 25
mL/min., 40 min. gradient, monitored at 254 nm) to afford Example 8
(3.2 mg, 20.3%). HPLC: Rt=4.04 min. (YMC S5 ODS 4.6.times.50 mm,
10-90% aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min.
gradient, monitored at 220 nm); MS (ES): m/z=419.1 [M+H].sup.+.
Example 9
6-((5-Cyano-2-methoxyphenyl)amino)-8-((2,2,2-trifluoroethyl)amino)imidazo[-
1,2-b]pyridazine-3-carbonitrile
##STR00192##
[0604] 9A: Preparation of
6-chloro-8-((2,2,2-trifluoroethyl)amino)imidazo[1,2-b]pyridazine-3-carbon-
itrile
##STR00193##
[0606] 9A was prepared from a mixture of 1F and
2,2,2-trifluoroethanamine following the procedure employed for the
preparation of 4A. HPLC: Rt=0.88 min. (BEH C18 2.1.times.50 mm,
1.7u, 0 to 100 B in 1 min. with 0.5 min. hold time, flow rate=1
mL/min., detection at 254 nm, Solvent A: 100% water/0.1% TFA;
Solvent B: 100% ACN1/0.1% TFA). MS (ES): m/z=276.1 [M+H].sup.+.
Example 9
Preparation of
6-((5-cyano-2-methoxyphenyl)amino)-8-((2,2,2-trifluoroethyl)amino)imidazo-
[1,2-b]pyridazine-3-carbonitrile
##STR00194##
[0608] A mixture of 9A (100 mg, 0.36 mmol),
3-amino-4-methoxybenzonitrile (108 mg, 0.73 mmol) and
di-tert-butyl(1-methyl-2,2-diphenylcyclopropyl)phosphine (25.6 mg,
0.073 mmol) in toluene (1 mL) was purged with nitrogen.
Allylpalladium (II) chloride dimer (13.3 mg, 0.036 mmol) and sodium
tert-butoxide (41.8 mg, 0.435 mmol) were added, and the reaction
mixture was purged with nitrogen and heated at 100.degree. C. After
20 minutes, the reaction mixture was cooled to room temperature,
diluted with DCM, and filtered through CELITE.RTM.. The filtrate
was concentrated under reduced pressure, dissolved in
DMSO/methanol, and purified by reverse phase HPLC (PHENOMENEX.RTM.
Luna Axia 5 micron 30.times.250 mm) 20% B (Solvent B=90% MeOH-10%
H.sub.2O-0.1% TFA) to 100% B in (Solvent A=10% MeOH-90%
H.sub.2O-0.1% TFA) in 15 min.) to obtain Example 9, (9.9 mg, 0.020
mmol, 5.4% yield) as a light yellow solid. HPLC: Rt=0.95 min. (BEH
C18 2.1.times.50 mm, 1.7u, 0 to 100 B in 1 min. with 0.5 min. hold
time, flow rate=1 mL/min., detection at 254 nm, Solvent A: 100%
water/0.1% TFA; Solvent B: 100% ACN1/0.1% TFA). MS (ES): m/z=388.3
[M+H].sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 8.76
(1H, d, J=1.94 Hz), 8.67 (1H, s), 8.23 (1H, s), 8.03-8.12 (1H, m),
7.41-7.55 (1H, m), 7.24 (1H, d, J=8.32 Hz), 6.75 (1H, s), 4.06-4.17
(2H, m), 4.00 (3H, s).
Example 10
6-(3-Cyano-5-(trifluoromethyl)phenylamino)-8-(isopropylamino)imidazo[1,2-b-
]pyridazine-3-carbonitrile
##STR00195##
[0609] 10A: Preparation of
6-chloro-8-(isopropyl(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazine-3-ca-
rbonitrile
##STR00196##
[0611] 10A was prepared from a mixture of 1F and
N-(4-methoxybenzyl)propan-2-amine following the procedure employed
for the preparation of 1G. HPLC: Rt=4.27 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=356.1 [M+H].sup.+.
Example 10
Preparation of
6-(3-cyano-5-(trifluoromethyl)phenylamino)-8-(isopropylamino)imidazo[1,2--
b]pyridazine-3-carbonitrile
##STR00197##
[0613] A solution of 3-amino-5-(trifluoromethyl)benzonitrile (0.078
g, 0.42 mmol) in DMA (1 mL) was placed in a 1-dram vial with a
teflon-lined septum cap, and the solvent was purged with argon. 10A
(0.100 g, 0.281 mmol), cesium carbonate (0.366 g, 1.124 mmol),
copper(I) iodide (0.027 g, 0.141 mmol), Xantphos (0.033 g, 0.056
mmol), and Pd.sub.2(dba).sub.3 (0.026 g, 0.028 mmol) were added in
one portion, and the suspension was pump/purged three times with
argon. The vessel was then heated to 125.degree. C. for 45 min. The
solids were removed via filtration through CELITE.RTM. and washed
with THF. The dark brown filtrate was concentrated under reduced
pressure and then diluted with water and ethyl acetate. The layers
were separated, and the aqueous phase extracted with ethyl acetate
(2.times.10 mL). The organics were combined, washed with water and
brine, dried over sodium sulfate, filtered, concentrated, and the
residue was purified by flash chromatography (SiO.sub.2, hexanes to
40% EtOAc/hexanes, 12 g column, 30 mL/min., 20 min. gradient,
monitoring at 254 nm). The fractions were concentrated, dissolved
in DCM (1 mL), and treated with triethylsilane (0.45 mL, 2.8 mmol),
and TFA (0.3 mL) at room temperature. After 20 min., the volatiles
were removed via a stream of nitrogen. The residue was triturated
with MeOH, forming a white precipitate. The solid was isolated via
filtration, washed with MeOH, and suspended in 1:1 1N HCl/MeCN and
lyophilized, affording Example 10, (0.081 g, 68.3% yield) as a
white solid. HPLC: Rt=4.35 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=386.0 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 9.98 (1H, s), 8.52 (1H, s),
8.24 (1H, s), 8.19 (1H, s), 7.82 (1H, s), 7.48 (1H, d, J=8.03 Hz),
5.94 (1H, s), 2.52-2.55 (1H, m), 1.28 (6H, d, J=6.27 Hz).
Example 11
N-(5-(3-Cyano-8-(2-hydroxyethylamino)imidazo[1,2-b]pyridazin-6-ylamino)-2--
methylphenyl)acetamide
##STR00198##
[0614] 11A: Preparation of
6-chloro-8-((2-hydroxyethyl)(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazi-
ne-3-carbonitrile
##STR00199##
[0616] 11A was prepared from 2-((4-methoxybenzyl)amino)ethanol and
a mixture of 1F following the procedure employed in the preparation
of 4A. HPLC: Rt=3.64 min. (YMC S5 ODS 4.6.times.50 mm, 10-90%
aqueous methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=358.0 [M+H].sup.+.
Example 11
Preparation of
N-(5-(3-cyano-8-(2-hydroxyethylamino)imidazo[1,2-b]pyridazin-6-ylamino)-2-
-methylphenyl)acetamide
##STR00200##
[0618] A mixture of 11A (50 mg, 0.14 mmol),
N-(5-amino-2-methylphenyl)acetamide (45.9 mg, 0.28 mmol),
Pd.sub.2(dba).sub.3 (12.80 mg, 0.014 mmol), Xantphos (17.79 mg,
0.031 mmol), copper (I) iodide (13.31 mg, 0.070 mmol) and cesium
carbonate (182 mg, 0.56 mmol) in DMA (1.0 mL) was purged with
nitrogen, cooled to room temperature and then reaction mixture was
stirred at 125.degree. C. in a sealed vial for 2 hours, and then
diluted with ethyl acetate. The reaction mixture was washed with
20% NH.sub.4OH, dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The resulting solid was
triturated with ether and isolated by filtration. The solid
obtained was suspended in DCM (2 mL), and treated with
triethylsilane (0.1 mL, 0.63 mmol) and TFA (0.1 mL, 1.3 mmol), and
stirred for 20 min. at room temperature. The reaction mixture was
concentrated and purified by reverse phase HPLC, lyophilized with
1.0 N HCl to yield Example 11 (15.0 mg, 26.7% yield). HPLC:
Rt=11.424 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 15 min. Gradient, monitored at 220
nm). MS (ES): m/z=366.0 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.24 (1H, s), 9.15 (1H, s), 8.13 (1H, s),
7.62 (2H, s), 7.26-7.37 (1H, m), 7.12 (1H, d, J=8.03 Hz), 5.99 (1H,
s), 4.92 (1H, t, J=5.40 Hz), 3.65 (2H, q, J=5.77 Hz), 3.22-3.42
(2H, m), 2.15 (3H, s), 2.01-2.13 (3H, m).
Example 12
8-((1-(2-Hydroxyethyl)-1H-pyrazol-3-yl)amino)-6-((3-methoxy-5-(5-methyl-1H-
-tetrazol-1-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00201##
[0619] 12A: Preparation of
8-((1-(2-((tert-butyl(dimethyl)silyl)oxy)ethyl)-1H-pyrazol-3-yl)amino)-6--
chloroimidazo[1,2-b]pyridazine-3-carbonitrile
##STR00202##
[0621] 12A was prepared from a mixture of 1F and
1-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-pyrazol-3-amine
following the procedure employed in the preparation of 4A. HPLC:
Rt=4.26 min. (Waters Sunfire C18 column (4.6.times.50 mm). 10-90%
aqueous methanol containing 0.1% TFA, 4 min. gradient, flow rate=4
mL/min., detection at 254 nm). MS (ES): m/z=418.2 [M+H].sup.+.
Example 12
Preparation of
8-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)amino)-6-((3-methoxy-5-(5-methyl-1-
H-tetrazol-1-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00203##
[0623] A suspension of 12A (39 mg, 0.093 mmol),
3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)aniline (28.7 mg, 0.14
mmol), and di-tert-butyl(1-methyl-2,2-diphenylcyclopropyl)
phosphine (6.58 mg, 0.019 mmol) in toluene (0.75 mL) was purged
with nitrogen. Allylpalladium (II) chloride dimer (3.41 mg, 9.3
.mu.mol) and sodium tert-butoxide (10.76 mg, 0.11 mmol) were added,
and the reaction mixture was purged with nitrogen and heated at
100.degree. C. After 15 minutes, the reaction mixture was
concentrated, suspended in water (50 mL), extracted with 10%
isopropanol/dichloromethane (3.times.25 mL), dried over
Na.sub.2SO.sub.4, and concentrated. The crude was purified with
silica gel chromatography (stepwise gradient, 20 to 50% ethyl
acetate/hexanes to neat ethyl acetate). The fractions were
concentrated, dissolved in dichloromethane (2 mL) and treated with
TFA (2 mL). After 3 hours, the reaction mixture was concentrated,
purified using reverse phase HPLC, and lyophilized with 1.0 N HCl
to isolate Example 12, (2.1 mg, 3.84% yield) as a tan solid. HPLC:
Rt=1.65 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm,
10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient, flow
rate=5 mL/min., detection at 254 nm). MS (ES): m/z=473.06
[M+H].sup.+. .sup.1H NMR (500 MHz, methanol-d.sub.3) .delta. ppm
8.03 (1H, s), 7.86 (1H, s), 7.61 (1H, d, J=1.83 Hz), 7.51 (1H, s),
7.47 (1H, s), 6.68-6.89 (1H, m), 6.13 (1H, d, J=2.29 Hz), 4.23 (2H,
t, J=5.27 Hz), 3.97 (2H, t, J=5.27 Hz), 3.94 (3H, s), 2.69 (3H,
s).
Example 13
8-(Ethylamino)-6-((3-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl)ami-
no)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00204##
[0624] 13A: Preparation of
6-chloro-8-(ethyl(4-methoxybenzyl)amino)imidazo[1,2-b]pyridazine-3-carbon-
itrile
##STR00205##
[0626] 13A was prepared from N-(4-methoxybenzyl)ethanamine and a
mixture of 1F following the procedure employed in the preparation
of 4A. HPLC: Rt=1.88 min. (PHENOMENEX.RTM. Luna 5 micron C18
4.6.times.30 mm, 10-90% aqueous methanol containing 0.1% TFA, 2
min. gradient, flow rate=5 mL/min., detection at 254 nm). MS (ES):
m/z=341.9 [M+H].sup.+.
Example 13
Preparation of
8-(ethylamino)-6-((3-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl)am-
ino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00206##
[0628] A mixture of 13A (100 mg, 0.29 mmol), Intermediate 1 (100
mg, 0.44 mmol), Pd.sub.2(dba).sub.3 (26.8 mg, 0.029 mmol), cesium
carbonate (381 mg, 1.17 mmol), copper (I) iodide (27.9 mg, 0.15
mmol), and Xantphos (33.9 mg, 0.059 mmol) in DMA (2 mL) was purged
with nitrogen and heated at 125.degree. C. for 1 hour. The reaction
mixture was filtered through a pad of silica gel and washed with
30% methanol/chloroform. The filtrate was concentrated and
dissolved in dichloroethane (4 mL), and treated with triethylsilane
(0.3 mL) and TFA (1 mL). After 30 min., the reaction mixture was
concentrated to dryness, dissolved in DMSO (1 mL) and methanol (1
mL), purified using reverse phase HPLC, and lyophilized with 1.0 N
HCl to isolate Example 13, as a tan solid (20 mg, 15.2% yield).
HPLC: Rt=1.9 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient,
flow rate=5 mL/min., detection at 254 nm). MS (ES): m/z=414.98
[M+H].sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 9.26
(1H, s), 8.71 (1H, s), 7.41-7.87 (4H, m), 7.14 (1H, s), 5.27 (1H,
s), 2.87-3.50 (2H, m), 2.57-2.79 (1H, m), 0.58 (3H, t, J=7.10
Hz).
Example 14
8-Amino-6-((3-chloro-5-cyanophenyl)amino)imidazo[1,2-b]pyridazine-3-carbon-
itrile
##STR00207##
[0629] 14A: Preparation of
8-(bis(4-methoxybenzyl)amino)-6-chloroimidazo[1,2-b]pyridazine-3-carbonit-
rile
##STR00208##
[0631] 14A was prepared from a mixture of 1F and
N-(4-methoxybenzyl)-1-(4-methoxyphenyl)methanamine following the
procedure employed in the preparation of 4A. HPLC: Rt=1.13 min.
(BEH C18 2.1.times.50 mm, 1.7u, 0 to 100 B in 1 min. with 0.5 min.
hold time, flow rate=1 mL/min., detection at 254 nm, Solvent A:
100% water/0.1% TFA; Solvent B: 100% ACN1/0.1% TFA). MS (ES):
m/z=434.2 [M+H].sup.+.
Example 14
Preparation of
8-amino-6-((3-chloro-5-cyanophenyl)amino)imidazo[1,2-b]pyridazine-3-carbo-
nitrile
##STR00209##
[0633] A mixture of 14A (100 mg, 0.23 mmol), cesium carbonate (225
mg, 0.69 mmol), copper(I) iodide (21.95 mg, 0.12 mmol),
3-amino-5-chlorobenzonitrile (38.7 mg, 0.25 mmol),
Pd.sub.2(dba).sub.3 (21.10 mg, 0.023 mmol) and Xantphos (29.3 mg,
0.051 mmol) in DMA (2 mL) was purged with nitrogen and heated at
125.degree. C. After 13 hours, the reaction mixture was diluted
with DCM, filtered through a silica gel plug (20 g) and washed with
10% MeOH in DCM. The filtrate was concentrated, triturated with
water, and the solid was collected via filtration. The solid was
dried under reduced pressure, dissolved in DCM (2 mL), and treated
with triethylsilane (0.64 mL) and TFA (1.3 mL). After 1 hour, the
reaction mixture was concentrated, re-dissolved in MeOH/DMSO and
purified by HPLC (PHENOMENEX.RTM. Luna Axia 5 micron 30.times.100
mm) 30% B (Solvent B=90% MeOH-10% H.sub.2O-0.1% TFA) to 100% B in A
(Solvent A=10% MeOH-90% H.sub.2O-0.1% TFA) in 15 min.) to isolate
Example 14 (9 mg, 0.029 mmol, 12.61% yield) as a light brown solid.
HPLC: Rt=0.88 min. (PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30
mm, 10-90% aqueous methanol containing 0.1% TFA, 2 min. gradient,
flow rate=5 mL/min., detection at 254 nm). MS (ES): m/z=310.0
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.71
(1H, s), 8.19 (1H, s), 8.14 (1H, t, J=2.01 Hz), 7.97-8.07 (1H, m),
7.46-7.57 (1H, m), 7.28 (2H, br. s.), 6.04 (1H, s).
Example 15
6-((3-Cyano-5-(trifluoromethyl)phenyl)amino)-8-((2-methoxyethyl)amino)imid-
azo[1,2-b]pyridazine-3-carbonitrile
##STR00210##
[0634] 15A: Preparation of
6-chloro-8-((4-methoxybenzyl)(2-methoxyethyl)amino)imidazo[1,2-b]pyridazi-
ne-3-carbonitrile
##STR00211##
[0636] 15A was prepared from
2-methoxy-N-(4-methoxybenzyl)ethanamine and 1F following the
procedure employed in the preparation of 1G. HPLC: Rt=3.20 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=372.1 [M+H].sup.+.
Example 15
Preparation of
6-((3-cyano-5-(trifluoromethyl)phenyl)amino)-8-((2-methoxyethyl)amino)imi-
dazo[1,2-b]pyridazine-3-carbonitrile
##STR00212##
[0638] A solution of 3-amino-5-(trifluoromethyl)benzonitrile (0.075
g, 0.40 mmol) in DMA (1 mL) was placed in a 1-dram vial with a
teflon-lined septum cap, and the solvent was purged with argon. 15A
(0.100 g, 0.269 mmol), cesium carbonate (0.351 g, 1.076 mmol),
copper (I) iodide (0.026 g, 0.134 mmol), Xantphos (0.031 g, 0.054
mmol), and Pd.sub.2(dba).sub.3 (0.025 g, 0.027 mmol) were added in
one portion, and the suspension was pump/purged three times with
argon. The vessel was heated to 125.degree. C. for 45 min. and then
cooled to room temperature. The solids were removed via filtration
through CELITE.RTM. and washed with THF. The filtrate was
concentrated under reduced pressure and diluted with water and
EtOAc. The layers were separated, and the aqueous phase extracted
with EtOAc (3.times.10 mL). The organics were combined, washed with
water and brine, dried over anhydrous sodium sulfate, filtered and
concentrated. The crude product was dissolved in DCM and purified
by flash chromatography (SiO.sub.2, hexanes to 40% EtOAc/hexanes,
12 g column, 30 mL/min., 20 min. gradient, monitoring at 254 nm).
The fractions were concentrated, dissolved in DCM (1 mL) and
treated with triethylsilane (0.430 mL, 2.7 mmol) and TFA (0.3 mL)
at room temperature. After 20 minutes, the volatiles were removed
via a stream of nitrogen, and the residue was triturated with MeOH.
The solid was isolated via filtration, suspended in 1:1 1N
HCl/MeCN, and lyophilized overnight, furnishing Example 15, (0.080
g, 0.181 mmol, 67.3% yield) as a gray solid. HPLC: Rt=4.160 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=402.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 9.98 (1H, s), 8.52 (1H, s), 8.25 (1H, s), 8.20 (1H, s),
7.82 (1H, s), 7.68 (1H, s), 5.99 (1H, s), 3.54-3.62 (2 H, m),
3.40-3.52 (2H, m), 3.30 (3H, s).
Example 16
6-((3-Cyano-5-(trifluoromethyl)phenyl)amino)-8-(methylamino)imidazo[1,2-b]-
pyridazine-3-carbonitrile
##STR00213##
[0639] 16A: Preparation of
6-chloro-8-((4-methoxybenzyl)(methyl)amino)imidazo[1,2-b]pyridazine-3-car-
bonitrile
##STR00214##
[0641] 16A was prepared from 1F and
1-(4-methoxyphenyl)-N-methylmethanamine following the procedure
employed in the preparation of 1G. HPLC: Rt=3.12 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=328.1 [M+H].sup.+.
Example 16
Preparation of
6-((3-cyano-5-(trifluoromethyl)phenyl)amino)-8-(methylamino)imidazo[1,2-b-
]pyridazine-3-carbonitrile
##STR00215##
[0643] A mixture of 16A (80 mg, 0.24 mmol),
3-amino-5-(trifluoromethyl)benzonitrile (68.1 mg, 0.37 mmol),
Pd.sub.2(dba).sub.3 (22.35 mg, 0.024 mmol), xantphos (28.2 mg,
0.049 mmol), copper (I) iodide (23.2 mg, 0.12 mmol) and cesium
carbonate (318 mg, 0.976 mmol) in DMA (0.8 mL) was purged with
N.sub.2 and then heated at 120.degree. C. for 6 hours. The reaction
mixture was cooled to room temperature and diluted with DCM (5 mL).
The mixture was loaded onto a short silica gel pad and eluted with
10% MeOH/DCM. The filtrate was concentrated and purified by reverse
phase preparative HPLC (XTERRA.RTM. C-8 20.times.100 mm, 40-90%
aqueous acetonitrile containing 0.1% TFA, 15 min. gradient,
monitored at 254 nm). The desired fraction was concentrated. The
residue was dissolved in DCM (2 mL) and treated with Et.sub.3SiH
(200 .mu.L) and TFA (2 mL). The reaction mixture was stirred at
room temperature for 30 min. and then concentrated. The residue was
triturated with DMF and methanol, filtered and washed with a mixed
solvent of DCM and 2N ammonia in MeOH. The solid was dissolved in
ethyl acetate and filtered through silica gel. The filtrate was
concentrated to afford Example 16 (47 mg, 53%). HPLC: Rt=3.268 min.
(CHROMOLITH.RTM. column 4 6.times.50 mm eluting with 10-90% aqueous
methanol over 4 min. containing 0.1% TFA, 4 mL/min., monitoring at
220 nm). MS (ES): m/z=358 [M+H].sup.+.
Example 17
8-((2-(4-Morpholinyl)ethyl)amino)-6-((3-(4H-1,2,4-triazol-4-yl)-4-(trifluo-
romethoxy)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00216##
[0644] 17A: Preparation of
6-chloro-8-((4-methoxybenzyl)(2-(4-morpholinyl)ethyl)amino)imidazo[1,2-b]-
pyridazine-3-carbonitrile
##STR00217##
[0646] 17A was prepared from 1F and
N-(4-methoxybenzyl)-2-(4-morpholinyl)ethanamine following the
procedure employed in the preparation of 1G. HPLC: Rt=2.95 min.
(YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol containing
0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS
(ES): m/z=427.1 [M+H].sup.+.
17B: Preparation of
6-(3-(4H-1,2,4-triazol-4-yl)-4-(trifluoromethoxy)phenylamino)-8-((4-metho-
xybenzyl)(2-morpholinoethyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00218##
[0648] A solution of 17A (56 mg, 0.131 mmol) in DMA (2 mL) was
treated with Intermediate 30 (64.1 mg, 0.26 mmol),
Pd.sub.2(dba).sub.3 (12.0 mg, 0.013 mmol), copper (I) iodide (12.49
mg, 0.066 mmol), xantphos (15.2 mg, 0.026 mmol), and cesium
carbonate (214 mg, 0.66 mmol). The reaction mixture was purged with
argon and heated to 125.degree. C. for 2 hours, and then cooled to
room temperature. The reaction mixture was filtered and
concentrated. The residue was taken up in EtOAc (10 mL) and washed
with 10% LiCl solution (2.times.10 mL). The organic layer was dried
(Na.sub.2SO.sub.4), filtered and concentrated to dryness. The crude
product was dissolved in a small amount of CH.sub.2Cl.sub.2 and
purified by flash chromatography (SiO.sub.2, DCM to 10% MeOH/DCM,
24 g column, 30 min. gradient) to afford 17B (73 mg, 88% yield).
HPLC: Rt=3.441 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous
methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm). MS (ES): m/z=635.2 [M+H].sup.+.
Example 17
Preparation of
842-(4-morpholinyl)ethyl)amino)-6-((3-(4H-1,2,4-triazol-4-yl)-4-(trifluor-
omethoxy)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00219##
[0650] A suspension of 17B (73 mg, 0.12 mmol) in DCM (3 mL) was
treated with triethylsilane (0.092 mL, 0.58 mmol), followed by TFA
(0.1 mL, 1.298 mmol). The resulting solution was stirred at room
temperature for 2 hours and concentrated. The crude reaction
product was dissolved in a small amount of MeOH and DMF, purified
by reversed phase HPLC (YMC ODS-A 5 um 30.times.250 mm, 10-90%
aqueous methanol containing 0.1% TFA, 25 mL/min., 30 min. gradient,
monitored at 254 nm), and lyophilized with 1:1 1N HCl:ACN to afford
Example 17 (8 mg, 11.3%). HPLC: Rt=2.995 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=515.2 [M+H].sup.+.
[0651] The compounds listed below were prepared by the similar
synthetic procedure used for Examples 1 through 17.
TABLE-US-00009 TABLE 9 HPLC Retention Example Time No. Structure
Name [M + H].sup.+ (min.)* 18 ##STR00220## 6-((3-Amino-5-
(trifluoromethyl)phenyl) amino)-8- (cyclopropylamino)imidazo
[1,2-b]pyridazine-3- carbonitrile 374.1 1.57.sup.c 19 ##STR00221##
6-((3-Amino-5- cyanophenyl)amino)-8- (cyclopropylamino)imidazo
[1,2-b]puridazine-3- carbonitrile 331.1 1.48.sup.c 20 ##STR00222##
N-(3-Cyano-5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) phenyl)acetamide 373.1 1.64.sup.c 21
##STR00223## N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-5-(trifluoromethyl) phenyl)acetamide
416.1 1.8.sup.c 22 ##STR00224## N-(3-Chloro-5-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)amino)
phenyl)acetamide 382.1 1.72.sup.c 23 ##STR00225## Methyl
(3-chloro-5-((3- cyano-8-(cyclopropylamino)
imidazo[1,2-b]pyridazin-6- yl)amino)phenyl)carbamate 398.1
1.79.sup.c 24 ##STR00226## 6-((3-Cyanophenyl)amino)-
8-(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 316.1
1.74.sup.c 25 ##STR00227## 6-((3-Cyano-4-fluorophenyl) amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 334.1
1.81.sup.c 26 ##STR00228## 6-((3-Cyano-4- methylphenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 330.2
1.83.sup.c 27 ##STR00229## 8-(Cyclopropylamino)-6-((3-
(trifluoromethyl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 359.1 1.93.sup.c 28 ##STR00230##
8-(Cyclopropylamino)-6-((3- (difluoromethoxy)phenyl)
amino)imidazo[1,2-b] pyridazine-3-carbonitrile 357.1 1.83.sup.c 29
##STR00231## 6-((5-Cyano-2- methylphenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 330.2
1.69.sup.c 30 ##STR00232## (3-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-5-methoxyphenyl) cyanamide 361.2 1.7.sup.c 31 ##STR00233##
6-((4-Cyano-3- (trifluoromethyl) phenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 384.2
1.86.sup.c 32 ##STR00234## 6-((3-Cyano-2-fluorophenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 334.1
1.76.sup.c 33 ##STR00235## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6- yl)amino)-5-
(trifluoromethyl) phenyl)carbamate 432.1 1.76.sup.c 34 ##STR00236##
6-((3-Cyano-4- (trifluoromethoxy)phenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 400.1
1.97.sup.c 35 ##STR00237## 6-((3-Cyano-5- methoxyphenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 346.2
1.93.sup.c 36 ##STR00238## 6-((3-Cyano-5-fluorophenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 334.1
1.86.sup.c 37 ##STR00239## 8-(Cyclopropylamino)-6-((3-
methoxy-5-(5-methyl-1H- tetrazol-1-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 403.2 1.5.sup.c 38
##STR00240## N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) phenyl)acetamide 348.0 3.62.sup.a 39
##STR00241## Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-fluorophenyl) carbamate 382.1
3.856.sup.a 40 ##STR00242## 8-(Cyclopropylamino)-6-((3-
(1H-imidazol-4-yl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 357.1 3.313.sup.a 41 ##STR00243##
8-(Cyclopropylamino)-6-((3- (2-methyl-1H-imidazol-1-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 371.1
3.116.sup.a 42 ##STR00244## 8-(Cyclopropylamino)-6-((3-
(1H-imidazol-1-yl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 357.1 3.186.sup.a 43 ##STR00245## Methyl
6-((3-cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-1- indolinecarboxylate 390.1 4.185.sup.a 44 ##STR00246##
3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) benzoic acid 335.2 3.816.sup.a 45
##STR00247## Methyl 6-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-3,3-dimethyl-1- indolinecarboxylate
418.1 4.41.sup.a 46 ##STR00248## 8-(cyclopropylamino)-6-((4-
fluoro-3-(4H-1,2,4-triazol-4- yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 376.1 3.715.sup.a 47 ##STR00249##
6-((2-Chloro-5-cyanophenyl) amino)-8- (cyclopropylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 350.1 3.996.sup.a 48
##STR00250## 8-(Cyclopropylamino)-6-((3- (4-methyl-4H-1,2,4-
3-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile 372.1
3.341.sup.a 49 ##STR00251## 8-(Cyclopropylamino)-6-((3-
(1H-pyrazol-5-yl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 357.2 3.286.sup.a 50 ##STR00252##
6-((3-Amino-4- (trifluoromethoxy)phenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 390.1
3.973.sup.a 51 ##STR00253## 6-((3-Amino-4- methylphenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 320.2
2.988.sup.a 52 ##STR00254## 8-(Cyclopropylamino)-6-((3-
(4H-1,2,4-triazol-4-yl)-4- (trifluoromethoxy)phenyl)
amino)imidazo[1,2-b] pyridazine-3-carbonitrile 442.1 3.915.sup.a 53
##STR00255## N-(5-((3-Cyano-8-((2- methoxyethyl)amino)
imidazo[1,2-b]pyridazin-6- yl)amino)-2-methylphenyl) acetamide 380
12.43.sup.b 54 ##STR00256## N-(5-((3-Cyano-8-((2-(4-
morpholinyl)ethyl)amino) imidazo[1,2-b]pyridazin-6-
yl)amino)-2-methylphenyl) acetamide 435.1 9.673.sup.d 55
##STR00257## N-(5-((3-Cyano-8-((2- hydroxy-2-methylpropyl)
amino)imidazo[1,2-b] pyridazin-6-yl)amino)-2-
methylphenyl)acetamide 394.1 3.263.sup.a 56 ##STR00258##
8-(Cyclopropylamino)-6- ((3,4-dimethoxyphenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 351.2 1.69.sup.c 57 ##STR00259##
6-((5-Cyano-1,3-thiazol-2- yl)amino)-8- (cyclopropylamino)
imidazo[1,2-a]pyridazine-3- carbonitrile 323.1 1.67.sup.c 58
##STR00260## 8-(Cyclopropylamino)-6-((4-
methyl-2-oxo-1,2-dihydro-7- quinolinyl)amino)imidazo[1,
2-b]pyridazine-3-carbonitrile 372.0 3.961.sup.a 59 ##STR00261##
N-(5-((3-Cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin-6-
yl)amino)-2-fluorophenyl acetamide 366.0 3.595.sup.a 60
##STR00262## 6-((3-Aminophenyl)amino)- 8-(cyclopropylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 306.1 2.82.sup.a 61
##STR00263## N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridiazin-6-yl) amino)-4-fluorophenyl) acetamide 366.0
3.483.sup.a 62 ##STR00264## 8-(Cyclopropylamino)-6-((2-
methyl-1H-benzimidazol-5- yl)amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 345.0 3.131.sup.a 63 ##STR00265## Methyl
(3-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) phenyl)carbamate 364.1 3.788.sup.a 64
##STR00266## 6-((1-Acetyl-2,3-dihydro- 1H-indol-6-yl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 374.1
3.931.sup.a 65 ##STR00267## N-(3-((3-Cyano-8-(2-
pyridinylamino)imidazo[1,2- b]pyridazin-6-yl)amino)
phenyl)acetamide 385.0 3.761.sup.a 66 ##STR00268##
N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) phenyl)-2- methylpropanamaide 376.1
3.863.sup.a 67 ##STR00269## N-(3-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)amino)
phenyl)propanamide 362.1 3.769.sup.a 68 ##STR00270## Methyl
(5-((3-cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin-6-
yl)amino)-2-fluorophenyl) carbamate 382.0 3.841.sup.a 69
##STR00271## N-(4-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-pyridinyl) acetamide 349.1
2.965.sup.a 70 ##STR00272## N-(5-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-fluorophenyl) methanesulfonamide 402.0 3.56.sup.a 71
##STR00273## 3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) benzamide 334.1 3.496.sup.a 72
##STR00274## 8-(Cyclopropylamino)-6-((4-
methyl-2-oxo-1,2-dihydro-6- quinolinyl)amino)imidazo[1,
2-b]pyridazine-3-carbonitrile 372.1 4.093.sup.a 73 ##STR00275##
8-(Cyclopropylamino)-6-((3- (2-oxo-1-pyrrolidinyl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 374.1
3.978.sup.a 74 ##STR00276## N-(3-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)amino)
phenyl)-N-methylacetamide 362.1 3.858.sup.a 75 ##STR00277##
8-(Cyclopropylamino)-6-((1- (methylsulfanyl)-1H-indol-
6-yl)amino)imidazo[1,2-b] pyridazine-3-carbonitrile 408.1
3.956.sup.a 76 ##STR00278## N-(5-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2,4-difluorophenyl) acetamide 384.1 3.481.sup.a 77
##STR00279## Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2,4-difluorophenyl) carbamate 462
2.395.sup.a 78 ##STR00280## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-4-fluorophenyl carbamate 382.1 3.673.sup.a 79 ##STR00281##
6-((4-Chloro-3-(1,3-oxazol- 5-yl)phenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 392.1
4.368.sup.a 80 ##STR00282## 8-(Cyclopropylamino)-6-((3-
(2-methyl-1,3-thiazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 388.1 4.271.sup.a 81 ##STR00283##
6-((4-Chloro-3-(1,3-oxazol- 2-yl)phenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 392.1
4.201.sup.a 82 ##STR00284## 8-(Cyclopropylamino)-6-((3-
(1,3,4-oxadiazol-2-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 359.2 3.4.sup.a 83 ##STR00285##
8-(Cyclopropylamino)-6-((3- (1-methyl-1H-tetrazol-5-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 373.2
3.688.sup.a 84 ##STR00286## N-(5-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-methoxyphenyl) acetamide 378 2.492.sup.b 85 ##STR00287##
N-(2-Chloro-5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) phenyl)acetamide 382 2.643.sup.b 86
##STR00288## 8-(Cyclopropylamino)-6-((3- (methylsulfonyl)phenyl)
amino)imidazo[1,2-b] pridazine-3-carbonitrile 401 2.675.sup.b 87
##STR00289## 3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-N- methylbenzenesulfonamide 384
2.405.sup.b
88 ##STR00290## N-(5-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-(trifluoromethoxy) phenyl)acetamide
432 3.098.sup.b 89 ##STR00291## 6-((3-Amino-4-((4-methyl-1-
piperazinyl)carbonyl)phenyl) amino)-8- (cyclopropylamino)imidazo
[1,2-b]pyridazine-3- carbonitrile 432.1 2.008.sup.b 90 ##STR00292##
Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-(trifluoromethoxy) phenyl)carbamate
448 3.298.sup.b 91 ##STR00293## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-4-(trifluoromethoxy) phenyl)carbamate 448 3.136.sup.b 92
##STR00294## Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-(4-methyl-1- piperazinyl)phenyl)
carbamate 462 2.395.sup.b 93 ##STR00295## Methyl (5-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-((4-methyl-1- piperazinyl)carbonyl)phenyl) carbamate 490
2.272.sup.b 94 ##STR00296## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-4-(4-methyl-1- piperazinyl)phenyl) carbamate 462 2.283.sup.b
95 ##STR00297## Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-methylphenyl) carbamate 378
2.916.sup.b 96 ##STR00298## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-4-methylphenyl) carbamate 378 2.891.sup.b 97 ##STR00299##
N-(5-((3-Cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-methylphenyl) methanesulfonamide 398 2.838.sup.b 98
##STR00300## N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-4-methylphenyl) acetamide 362.20
2.66.sup.c 99 ##STR00301## N-(5-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-(trifluoromethyl) phenyl)acetamide 416.10 2.94.sup.c 100
##STR00302## Methyl (5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-(trifluoromethyl) phenyl)carbamate
432.10 3.22.sup.c 101 ##STR00303## N-(5-((3-Cyano-8-((2-
methoxyethyl)amino) imidazo[1,2-b]pyridazin-6-
yl)amino)-2-methylphenyl) acetamide 380.00 12.434.sup.d 102
##STR00304## 8-(Cyclopropylamino)-6-((3- methoxy-5-(5-methyl-1H-
tetrazol-1-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3-
carbonitrile 403.17 1.5.sup.c 103 ##STR00305##
8-(Cyclopropylamino)-6-((3- (1H-pyrazol-1-yl)-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 425.12 2.045.sup.c 104 ##STR00306##
8-(Cyclopropylamino)-6-((3- (1H-1,2,4-triazol-1-yl)-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 426.11 1.958.sup.c 105 ##STR00307##
8-(Cyclopropylamino)-6-((3- (3-ethyl-1H-1,2,4-triazol-5-
yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 386.10
3.370.sup.a 106 ##STR00308## 8-(Cyclopropylamino)-6-((4-
methyl-3-(4H-1,2,4-triazol- 4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 372.10 3.606.sup.a 107
##STR00309## 8-(Cyclopropylamino)-6-((3- (1,3-thiazol-2-yl)phenyl)
amino)imidazo[1,2-b] pyridazine-3-carbonitrile 374.10 4.216.sup.a
108 ##STR00310## 8-(Cyclopropylamino)-6-((3-
(1,3-oxazol-4-yl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 358.10 4.115.sup.a 109 ##STR00311##
8-((2-Methoxyethyl)amino)- 6-((3-methoxy-5-(5-methyl-
1H-tetrazol-1-yl)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 421.20 1.675.sup.c 110 ##STR00312##
N-(5-((5-Cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin--yl)
amino)-2-methylphenyl)-2- methylpropanamide 390.30 3.753.sup.a 111
##STR00313## 8-((5-Methoxy-2-pyridinyl) amino)-6-((3-(4H-1,2,4-
triazol-4-yl)-4- (trifluoromethoxy)phenyl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 509.10 4.160.sup.a 112 ##STR00314##
6-((3-Methoxy-5-(5-methyl- 1H-tetrazol-1-yl)phenyl)
amino)-8-((5-methoxy-2- pyridinyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 470.06 1.918.sup.c 113
##STR00315## N-(5-((3-Cyano-8- (isopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-methylphenyl) acetamide 364.20
3.556.sup.a 114 ##STR00316## 6-((4-Fluoro-3-(4H-1,2,4-
triazol-4-yl)phenyl)amino)- 8-((5-methoxy-2-pyridinyl)
amino)imidazo[1,2-b] pyridazine-3-carbonitrile 443.04 1.755.sup.c
115 ##STR00317## 8-(Cyclopropylamino)-6-((3-
methoxy-5-(4H-1,2,4-triazol- 4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 388.10 3.815.sup.a 116
##STR00318## 8-(Cyclopropylamino)-6-((4- (4-morpholinyl)-3-(4H-
1,2,4-triazol-4- yl)phenyl)amino) imidazo[1,2-b]pyridazine-3-
carbonitrile 443.00 3.638.sup.a 117 ##STR00319##
8-((5-Methoxy-2-pyridinyl) amino)-6-((3-methoxy-5-
(4H-1,2,4-triazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 455.10 4.118.sup.a 118 ##STR00320##
8-((5-Methoxy-2-pyridinyl) amino)-6-((4-(4-
morpholinyl)-3-(4H-1,2,4- triazol-4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 510.20 3.951.sup.a 119
##STR00321## 8-((2-Methoxyethyl)amino)- 6-((4-(4-morpholinyl)-3-
(4H-1,2,4-triazol-4- yl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 461.20 3.445.sup.a 120 ##STR00322##
8-((2-Methoxyethyl)amino)- 6-((3-methoxy-5-(4H-1,2,4-
triazol-4-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile
406.10 3.628.sup.a 121 ##STR00323## 8-(Cyclopropylamino)-6-((4-
(4-methyl-1-piperazinyl)-3- (4H-1,2,4-triazol-4-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 456.10
2.883.sup.a 122 ##STR00324## 8-(Cyclopropylamino)-6-((4-
((2-(dimethylamino)ethyl) amino)-3-(4H-1,2,4-triazol-
4-yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 444.10
2.800.sup.a 123 ##STR00325## 8-(Cyclopropylamino)-6-((4-
((2-methoxyethyl)amino)-3- (4H-1,2,4-triazol-4-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 431.10
3.561.sup.a 124 ##STR00326## 6-((3-Cyano-5- methoxyphenyl)amino)-8-
((2-methoxyethyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile
364.01 1.783.sup.c 125 ##STR00327## 6-((3-Cyano-5-
methoxyphenyl)amino)-8- ((5-methoxy-2-pyridinyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 413.02 1.983.sup.c 126 ##STR00328##
8-(Cyclopropylamino)-6-((4- (2-methoxyethoxy)-3-(4H-
1,2,4-triazol-4-yl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 432.00 3.666.sup.a 127 ##STR00329##
8-(Cyclopropylamino)-6-((4- (2-(dimethylamino)ethoxy)-
3-(4H-1,2,4-triazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 445.10 2.905.sup.a 128 ##STR00330##
8-(Cyclopropylamino)-6-((4- ((1-methyl-4-piperidinyl)
oxy)-3-(4H-1,2,4-triazol-4- yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 471.10 3.040.sup.a 129
##STR00331## 8-(Cyclopropylamino)-6-((4- ((3-(dimethylamino)propyl)
amino)-3-(4H-1,2,4-triazol- 4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 458.10 2.938.sup.a 130
##STR00332## 8-(Cyclopropylamino)-6-((3-
(4-methyl-1-piperazinyl)-5- (4H-1,2,4-triazol-4-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 456.10
2.405.sup.b 131 ##STR00333## 8-(Cyclopropylamino)-6-((3-
((2-(dimethylamino)ethyl) amino)-5-(4H-1,2,4-triazol-
4-yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 444.10
2.440.sup.b 132 ##STR00334## 8-(Cyclopropylamino)-6-((4-
((2-(dimethylamino)ethyl) (methyl)amino)-3-(4H-1,2,4-
triazol-4-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile
458.10 3.041.sup.a 133 ##STR00335## 8-(Cyclopropylamino)-6-((3-
(4-(2-hydroxyethyl)-1- piperazinyl)-5-(4H-1,2,4-
triazol-4-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile
486.10 2.437.sup.b 134 ##STR00336## 8-(Cyclopropylamino)-6-((3-
(2-(dimethylamino)ethoxy)- 5-(4H-1,2,4-triazol-4-
yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 445.10
2.468.sup.b 135 ##STR00337## 8-(Cyclopropylamino)-6-((4-
((2-methoxyethyl)(methyl) amino)-3-(4H-1,2,4-triazol-
4-yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 445.10
3.791.sup.a 136 ##STR00338## 8-(Cyclopropylamino)-6-((3-
methoxy-5-(1H-1,2,4-triazol- 1-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 387.98 1.803.sup.c 137
##STR00339## 8-(Cyclopropylamino)-6-((3- (1H-1,2,4-triazol-1-yl)-4-
(trifluoromethoxy)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 441.91 1.793.sup.c 138 ##STR00340##
8-(Cyclobutylamino)-6-((3- methoxy-5-(4H-1,2,4-triazol-
4-yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 402.1
1.76.sup.c 139 ##STR00341## 8-(Cyclopropylamino)-6-((4-
((2-(1-pyrrolidinyl)ethyl) amino)-3-(4H-1,2,4-triazol-
4-yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 470.10
2.851.sup.a 140 ##STR00342## 8-(Cyclopropylamino)-6-((4-
(3-(dimethylamino) propoxy)-3-(4H-1,2,4- triazol-4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 459.00 2.920.sup.a 141
##STR00343## 8-(Cyclopropylamino)-6-((3-
(4-hydroxy-1-piperidinyl)-5- (4H-1,2,4-triazol-4-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 457.00
2.545.sup.b 142 ##STR00344## 8-(Cyclopropylamino)-6-((3-
(3aR,7aS)-2-oxohexahydro [1,3]oxazolo[5,4-c]pyridin-
5(2H)-yl)-5-(4H-1,2,4- triazol-4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 498.00 2.753.sup.b 143
##STR00345## 8-(Cyclopropylamino)-6-((4-
(2-(1-pyrrolidinyl)ethoxy)-3- (4H-1,2,4-triazol-4-yl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 471.00
2.846.sup.a 144 ##STR00346## 6-((4-(4-amino-1-
piperidinyl)-3-(4H-1,2,4- triazol-4-yl)phenyl)amino)
8-(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile
456.10 3.053.sup.c 145 ##STR00347## 8-(Cyclopropylamino)-6-((3-
(1H-1,2,4-triazol-1-yl)-3- pyridinyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 358.92 1.533.sup.c 146
##STR00348## 8-(Cyclopropylamino)-6-((3- (2-(dimethylamino)ethoxy)-
5-(1H-1,2,4-triazol-1-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 444.98 1.420.sup.c 147 ##STR00349##
8-Anilino-6-((3-(2- (dimethylamino)ethoxy)-5-
(1H-1,2,4-triazol-1-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 481.22 1.532.sup.c 148 ##STR00350##
8-(Cyclopropylamino)-6-((4- ((2-(4-morpholinyl)ethyl)
amino)-3-(1H-1,2,4-triazol- 1-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 486.22 1.310.sup.c 149
##STR00351## 8-(Cyclopropylamino)-6-((4- (4-(2-hydroxyethyl)-1-
piperazinyl)-3-(4H-1,2,4- triazol-4-yl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 486.10 2.825.sup.c 150
##STR00352## 8-(Cyclopropylamino)-6-((4- (2-(4-morpholinyl)ethoxy)-
3-(4H-1,2,4-triazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 487.10 2.836.sup.a
151 ##STR00353## 8-(Cyclopropylamino)-6-((4- ((3-morpholinylmethyl)
amino)-3-(4H-1,2,4-triazol- 4-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 472.00 2.910.sup.a 152
##STR00354## 8-(Cyclobutylamino)-6-((3- (4-methyl-1-piperazinyl)-5-
(4H-1,2,4-triazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 470.3 1.45.sup.c 153 ##STR00355##
8-(Cyclopropylamino)-6-((4- (2-(methylamino)ethoxy)-3-
(4H-1,2,4-triazol-4-yl) phenyl)amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 431.00 2.798.sup.a 154 ##STR00356##
8-(Cyclopropylamino)-6-((3- (4-hydroxy-1-piperidinyl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 390.10
2.243.sup.b 155 ##STR00357## 8-(Cyclopropylamino)-6-((3-
methyl-5-(1H-1,2,4-triazol- 1-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 372.14 1.808.sup.c 156
##STR00358## 6-((3-Chloro-5-(1H-1,2,4- triazol-1-yl)phenyl)amino)-
8-(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile
392.05 1.910.sup.c 157 ##STR00359## 8-(Cyclopropylamino)-6-((3-
(1H-1,2,4-triazol-1-yl)-5- (2,2,2-trifluoroethoxy)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 456.12
1.928.sup.c 158 ##STR00360## 8-(Cyclopropylamino)-6-((4-
(tetrahydro-2H-pran-4- ylamino)-3-(1H-1,2,4-
triazol-1-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile
457.15 1.623.sup.c 159 ##STR00361## 8-(Cyclopropylamino)-6-((3-
(hydroxymethyl)-5-(1H- 1,2,4-triazol-1-yl)phenyl)
amino)imidazo[1,2- b]pyridazine-3-carbonitrile 388.13 1.533.sup.c
160 ##STR00362## 8-(Cyclopropylamino)-6-((2-
methoxy-5-(1H-1,2,4-triazol- 1-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 388.00 3.083.sup.b 161
##STR00363## 6-((3-Cyano-5- (trifluoromethyl)phenyl) amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 384
3.430.sup.b 162 ##STR00364## 8-(Cyclopropylamino)-6-((2-
methyl-5-(1H-1,2,4-triazol- 1-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 372.20 1.72.sup.c 163
##STR00365## 8-(Cyclopropylamino)-6-((4-
fluoro-3-(1H-1,2,4-triazol-1- yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 376.09 1.68.sup.c 164
##STR00366## 8-(Cyclopropylamino)-6- ((1,4-dimethyl-2-oxo-1,2-
dihydro-7-quinolinyl)amino) imidazo[1,2-b]pyridazine-3-
carbonitrile 386.00 4.170.sup.a 165 ##STR00367##
8-(Cyclobutylamino)-6-((3- (1H-1,2,4-triazol-1-yl)-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyriazine-3-carbonitrile 440.09 1.983.sup.c 166 ##STR00368##
8-Anilino-6-((4-((2- (dimethylamino)ethyl)
amino)-3-(4H-1,2,4-triazol- 4-yl)phenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 480.19 1.46.sup.c 167
##STR00369## 8-(Cyclopropylamino)-6-((5- (1H-1,2,4-triazol-1-yl)-2-
(trifluoromethoxy)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 441.99 1.91.sup.c 168 ##STR00370##
6-((4-Cyano-2-pyridinyl) amino)-8- (cyclopropylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 317.00 2.796.sup.b 169
##STR00371## 8-(Cyclopropylamino)-6-((3- (4H-1,2,4-triazol-4-yl)-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 425.90 3.073.sup.b 170 ##STR00372##
8-(Cyclopropylamino)-6-((2- fluoro-5-(1H-1,2,4-triazol-1-
yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 376.02
1.760.sup.c 171 ##STR00373## 3-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-N-(tetrahydro-2H- pyran-4-yl)-5-(1H-1,2,4-
triazol-1-yl)benzamide 485.14 1.705.sup.c 172 ##STR00374##
8-(Cyclopropylamino)-6-((3- fluoro-5-(1H-1,2,4-triazol-1-
yl)phenyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile 376.03
1.832.sup.c 173 ##STR00375## 8-(Cyclopropylamino)-6-
((3,5-di-1H-1,2,4-triazol-1- ylphenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 425.05 1.757.sup.c 174
##STR00376## 8-(Cyclopropylamino)-6-((3- (2-(methylamino)ethoxy)-5-
(1H-1,2,4-triazol-1-yl) phenyl)amino)imidazo[1,2-
b]pyridazin-3-carbonitrile 431.13 1.377.sup.c 175 ##STR00377##
8-Amino-6-((3-(1H-1,2,4- triazol-1-yl)-5- (trifluoromethyl)phenyl)
amino)imidazo[1,2- b]pyridazine-3-carbonitrile 385.99 1.75.sup.c
176 ##STR00378## N-(3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-5-(trifluoromethyl)
phenyl)methanesulfonamide 451.90 9.139.sup.h 177 ##STR00379##
Methyl (3-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-5-(tetrahydro-2H- pyran-4-
ylcarbamoyl)phenyl) carbamate 491.00 3.690.sup.a 178 ##STR00380##
3-Cyano-5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-N- methylbenzenesulfonamide 408.90
2.800.sup.b 179 ##STR00381## N-(3-Cyano-5-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)amino)
phenyl)methanesulfonamide 409.00 2.773.sup.b 180 ##STR00382##
3-Cyano-5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-N- ethylbenzenesulfonamide 422.90
2.925.sup.b 181 ##STR00383## 6-((3-Amino-4-fluorophenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 324.00
3.386.sup.a 182 ##STR00384## Methyl (3-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyriazin-6-yl)
amino)-5-(methylsulfonyl) phenyl)carbamate 442.00 3.561.sup.a 183
##STR00385## 3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-N-(2-(diethylamino)
ethyl)-5-(1H,1,2,4-triazol-1- yl)benzamide 500.19 1.410.sup.c 184
##STR00386## 6-((3-Chloro-5-cyanophenyl) amino)-8-
(cyclopropylamino) imidazo[1,2-b]pyridazine-3- carbonitrile 350.08
1.967.sup.c 185 ##STR00387## 3-Cyano-5-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-N-(tetrahydro-2H- pyran-4-yl) benzenesulfonamide 479.00
2.850.sup.b 186 ##STR00388## 6-((3-Cyano-5-((4-methyl-1-
piperazinyl)sulfonyl)phenyl) amino)-8- (cyclopropylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 478.00 2.661.sup.b 187
##STR00389## 3-Cyano-5-((3-cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl)amino) benzenesulfonamide 395.00 2.562.sup.b
188 ##STR00390## 3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-5-(methylsulfonyl) benzoic acid 413
2.626.sup.b 189 ##STR00391## 8-Anilino-6-((3-cyano-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 420.00 4.460.sup.a 190 ##STR00392##
6-((3-Cyano-5- (trifluoromethyl)phenyl) amino)-8-((2-hydroxyethyl)
amino)imidazo[1,2- b]pyridazine-3-carbonitrile 388.00 3.958.sup.a
191 ##STR00393## 6-((3-Cyano-5- (trifluoromethyl)phenyl)
amino)-8-((2-(4- morpholinyl)thyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 457.00 3.376.sup.a 192
##STR00394## 3-((3-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-5-(1H-1,2,4-triazol- 1-yl)benzamide
401.14 1.700.sup.c 193 ##STR00395## 8-Amino-6-((3-cyano-5-
(trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 344.00 0.900.sup.c 194 ##STR00396##
3-((3-Cyano-8- (cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-N-methyl-5-(1H- 1,2,4-triazol-1-yl)benzamide 415.13
1.975.sup.c 195 ##STR00397## 6-((3-Cyano-5-fluorophenyl)
amino)-8-(2-pyridinylamino) imidazo[1,2-b]pyridazine-3-
carbonitrile 371 3.423.sup.b 196 ##STR00398## 6-((3-Cyano-4-
methylphenyl)amino)-8-(2- pyridinylamino)imidazo[1,2-
b]pyridazine-3-carbonitrile 367 3.396.sup.b 197 ##STR00399##
8-Amino-6-((3-cyano-5- fluorophenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 294 2.831.sup.b 198 ##STR00400##
8-Amino-6-((3-cyano-4- methylphenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 290 2.813.sup.b 199
##STR00401## 6-((3-Cyano-5-fluorophenyl) amino)-8-((2-methoxyethyl)
amino)imidazo[1,2- b]pyridazine-3-carbonitrile 352 3.068.sup.b 200
##STR00402## 6-((3-Cyano-4- methylphenyl)amino)-8-((2-
methoxyethyl)amino) imidazo[1,2-b]pyridazine-3- carbonitrile 348
3.06.sup.b 201 ##STR00403## 6-((3-Cyano-5-fluorophenyl)
amino)-8-((2,2,2- trifluoroethyl)amino)imidazo [1,2-b]pyridazine-3-
carbonitrile 376.00 2.100.sup.c 202 ##STR00404## 6-((3-Cyano-5-
(trifluoromethyl)phenyl) amino)-8-((2,2,2-
trifluoroethyl)amino)imidazo [1,2-b]pyridazine-3- carbonitrile
426.20 1.000.sup.e 203 ##STR00405## 6-((3-Cyano-5-
(trifluoromethyl)phenyl) amino)-8-(cyclobutylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 398.10 2.270.sup.c 204
##STR00406## 8-Amino-6-((3-cyano-4- (trifluoromethoxy)phenyl)
amino)imidazo[1,2- b]pyridazine-3-carbonitrile 360 3.135.sup.b 205
##STR00407## Methyl (5-((8-amino-3- cyanoimidazo[1,2-
b]pyridazin-6-yl)amino)-2- methylphenyl)carbamate 338 2.377.sup.b
206 ##STR00408## 6-((3-Chloro-5- cyanophenyl)amino)-8-
(cyclobutylamino)imidazo[1, 2-b]pyridazine-3-carbonitrile 364.30
1.030.sup.e 207 ##STR00409## 8-Amino-6-((3-fluoro-5-(1H-
1,2,4-triazol-1-yl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 336.30 0.770.sup.e 208 ##STR00410##
8-(Cyclobutylamino)-6-((3- methoxy-5-(5-methyl-1H-
tetrazol-1-yl)phenyl)amino) imidazo[1,2-b]pyridazine-3-
carbonitrile 417.30 0.930.sup.e 209 ##STR00411##
8-(Cyclopropylamino)-6-((2- oxo-1,2,3,4-tetrahydro-7-
quinolinyl)amino)imidazo[1, 2-b]pyridazine-3-carbonitrile 360.14
1.69.sup.c 210 ##STR00412## Methyl (5-((3-cyano-8-((2-
methoxyethyl)amino) imidazo[1,2-b]pyridazin-6-
yl)amino)-2-methylphenyl) carbamate 396 2.715.sup.b 211
##STR00413## 6-((5-Cyano-2- methoxyphenyl)amino)-8-
(cyclobutylamino)imidazo[1, 2-b]pyridazine-3-carbonitrile 360.30
1.000.sup.e 212 ##STR00414## 6-((2-Chloro-5-cyanophenyl)
amino)-8-(cyclobutylamino) imidazo[1,2-b]pyridazine-3- carbonitrile
364.30 1.030.sup.e 213 ##STR00415## 6-((5-Cyano-2-
methoxyphenyl)amino)-8- (cyclopropylamino)imidazo
[1,2-b]pyridazine-3- carbonitrile 346.30 0.950.sup.e 214
##STR00416## 8-(Cyclopropylamino)-6-((3- (3-pyridinyl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 368.14 2.87.sup.g 215
##STR00417## 6-((3-Cyano-4- (trifluoromethoxy)phenyl)
amino)-8-((2-methoxyethyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 418 3.321.sup.b 216 ##STR00418##
8-(Cyclopropylamino)-6-((3- (4-pyridinyl)phenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 368.14 1.51.sup.c 217
##STR00419## 6-((3-Cyano-4- (trifluoromethoxy)phenyl)
amino)-8-(2-pyridinylamino) imidazo[1,2-b]pyridazine-3-
carbonitrile 437 3.633.sup.b
218 ##STR00420## 8-Amino-6-((4-methyl-2- oxo-1,2-dihydro-7-
quinolinyl)amino)imidazo[1, 2-b]pyridazine-3-carbonitrile 332
2.681.sup.b 219 ##STR00421## 8-Amino-6-((4-methyl-3-
oxo-3,4-dihydro-2H-1,4- benzoxazin-6-yl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 336 2.725.sup.b 220
##STR00422## 8-(Cyclopropylamino)-6-((4- methyl-3-oxo-3,4-dihydro-
2H-1,4-benzoxazin-6-yl) amino)imidazo[1,2-b]
pyridazine-3-carbonitrile 376 3.17.sup.b 221 ##STR00423##
6-((3-Cyano-4- methylphenyl)amino)-8- ((2,2,2-trifluorethyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 372.10 1.070.sup.e 222
##STR00424## 6-((3-Methoxy-5-(1H- tetrazol-1-yl)phenyl)amino)-
8-((2,2,2-trifluoroethyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 431.10 1.010.sup.e 223 ##STR00425##
8-(Cyclopropylamino)-6-((2- oxo-4-(trifluoromethyl)-1,2-
dihydro-7-quinolinyl)amino) imidazo[1,2-b]pyridazine-3-
carbonitrile 426.20 1.030.sup.e 224 ##STR00426## (5-((3-Cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-methylphenyl) acetic acid 363 2.993.sup.e 225 ##STR00427##
6-((2-Chloro-5-cyano-4- methylphenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 364
3.296.sup.e 226 ##STR00428## 8-Amino-6-((2-chloro-5-
cyano-4-methylphenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 324 3.873.sup.e 227 ##STR00429##
8-Amino-6-((2-chloro-5- cyanophenyl)amino)imidazo
[1,2-b]pyridazine-3- carbonitrile 310 2.678.sup.e 228 ##STR00430##
8-Amino-6-((5-cyano-2- methoxyphenyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 306 2.613.sup.e 229
##STR00431## 6-((5-Cyano-2- (trifluoromethyl)phenyl) amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 384.20
1.290.sup.e 230 ##STR00432## 6-((5-Cyano-2-
(trifluoromethyl)phenyl) amino)-8-((2,2,2- trifluoroethyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 426.10 1.280.sup.e 231
##STR00433## 6-((3-Cyano-4- (trifluoromethyl)phenyl)
amino)-8-((2,2,2- trifluoroethyl)amino)imidazo [1,2-b]pyridazine-3-
carbonitrile 426.10 1.090.sup.e 232 ##STR00434## 6-((3-Cyano-4-
(trifluoromethyl)phenyl) amino)-8- (cyclopropylamino)imidazo
[1,2-b]pyridazine-3- carbonitrile 384.12 2.970.sup.c 233
##STR00435## 6-((2-Chloro-5-cyano-4- methylphenyl)amino)-8-(2-
pyridinylamino)imidazo[1,2- b]pyridazine-3-carbonitrile 401
3.228.sup.b 234 ##STR00436## 6-((5-Cyano-3-fluoro-2-
methoxyphenyl)amino)-8- ((2,2,2-trifluoroethyl)amino)
imidazo[1,2-b]pyridazine-3- carbonitrile 406.20 1.030.sup.e 235
##STR00437## N-(5-((5-Cyano-8- (cyclopropylamino)imidazo
[1,2-b]pyridazin-6-yl) amino)-2-ethylphenyl) methanesulfonamide 412
2.58.sup.b 236 ##STR00438## 8-Amino-6-((3-(4H-1,2,4-
triazol-4-yl)-5- (trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 386 2.46.sup.b 237 ##STR00439##
6-((5-Cyano-2- (trifluoromethoxy)phenyl) amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 400.20
1.150.sup.e 238 ##STR00440## 6-((5-Cyano-2-(2-(4-
morpholinyl)ethoxy)phenyl) amino)-8- (cyclopropylamino)
imidazo[1,2-b]pyridazine-3- carbonitrile 445.30 0.870.sup.e 239
##STR00441## 6-((5-Cyano-3-fluoro-2- methoxyphenyl)amino)-8-
(cyclopropylamino)imidazao [1,2-b]pyridazine-3- carbonitrile 364.20
0.970.sup.e 240 ##STR00442## 6-((4-Chloro-3- cyanophenyl)amino)-8-
(cyclopropylamino)imidazo [1,2-b]pyridazine-3- carbonitrile 350.90
1.91.sup.c 241 ##STR00443## 8-Amino-6-((5-Cyano-2-
(trifluoromethyl)phenyl) amino)imidazo[1,2-
b]pyridazine-3-carbonitrile 344.18 3.09.sup.g 242 ##STR00444##
8-(Cyclopropylamino)-6-((2- methoxy-5-(4-pyridinyl)
phenyl)amino)imidazo[1,2- b]pyridazine-3-carbonitrile 398.22
1.59.sup.c 243 ##STR00445## N-(4-Chloro-5-((3-cyano-8-
(cyclopropylamino)imidazo [1,2-b]pyridazin-6-yl)
amino)-2-methylphenyl) methanesulonamide 432 2.67.sup.b *HPLC
conditions .sup.aYMC S5 ODS 4.6 .times. 50 mm, 10-90% aqueous
methanol containing 0.2% H.sub.3PO.sub.4, 4 min. gradient,
monitored at 220 nm .sup.bCHROMOLITH .RTM. column 4.6 .times. 50 mm
eluting with 10-90% aqueous methanol over 4 min. containing 0.1%
TFA, 4 mL/min, monitoring at 220 nm. .sup.cPHENOMENEX .RTM. Luna 5
micron C18 4.6 .times. 30 mm, 0 to 100 B in 2 min. with 1 min. hold
time, flow rate = 5 mL/min., detection at 254 nm, Solvent A: 10%
methanol/90% water/0.1% TFA; Solvent B: 10% water/90% methanol/0.1%
TFA .sup.dYMC S5 ODS, 4.6 .times. 50 mm. 1 mL/min., 0-100%
Water-Methanol 0.2% H.sub.3PO.sub.4, gradient over 15 min.
.sup.eBEH C18 2.1 .times. 50 mm, 1.7 u, 0 to 100 B in 1 min. with
0.5 min. hold time, flow rate = 1 mL/min., detection at 254 nm,
Solvent A: 100% water/0.1% TFA; Solvent B: 100% ACN1/0.1% TFA
.sup.fColumn: PHENOMENEX .RTM. Luna C18 4.6 .times. 30 mm 3 u,
A10-90% aqueous methanol containing 0.1% TFA in 2 min; 4 mL/min
flow .sup.gWaters Sunfire C18 4.6 .times. 150 mm 5 micron. 1
mL/min., 0-100% Water-Methanol 0.2% H.sub.3PO.sub.4, gradient over
4 min. .sup.hSunfire-S5-C18 4.6 .times. 50 mm (4 min. grad) 10-90%
aqueous methanol over 4 min. containing 0.1% TFA, 4 mL/min.,
monitoring at 220 nm. .sup.iPHENOMENEX .RTM. Luna 4.6 .times. 50 mm
S10 Solvent A = 5% ACN-95% H20-10 mM NH4Ac, Solvent B = 95% ACN-5%
H20-10 mM NH4Ac, flow rate = 4 mL/min., detection at 220 nm,
gradient over 4 min. .sup.jPHENOMENEX .RTM. Luna 3.0 .times. 50 mm
S10, 10-900% Water-Methanol 0.1% TFA, gradient over 2 min.,
monitoring at 254 nm.
Example 244
8-(Cyclopropylamino)-6-((4-(diethylamino)phenyl)amino)imidazo[1,2-b]pyrida-
zine-3-carbonitrile
##STR00446##
[0652] 244A:
8-(Cyclopropyl(4-methoxybenzyl)amino)-6-(4-(diethylamino)phenylamino)imid-
azo[1,2-b]pyridazine-3-carbonitrile
##STR00447##
[0654] A microwave tube was charged with 1G (30 mg, 0.085 mmol),
N.sup.1,N.sup.1-diethylbenzene-1,4-diamine (139 mg, 0.85 mmol), and
NMP (1 mL). The mixture was irradiated in a microwave for three
cycles of 15 min. (300 W), 120.degree. C. The crude reaction
mixture was dissolved in a small amount of MeOH and purified by
reversed phase HPLC (YMC ODS-A 5 um 30.times.250 mm, 10-90% aqueous
methanol containing 0.1% TFA, 25 mL/min., 30 min. gradient,
monitored at 220 nm) to afford 244A, (5 mg, 9.0% yield). HPLC:
Rt=3.896 min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=482.1 [M+H].sup.+.
Example 244
8-(Cyclopropylamino)-6-((4-(diethylamino)phenyl)amino)imidazo[1,2-b]pyrida-
zine-3-carbonitrile
##STR00448##
[0656] A solution of 244A (5 mg, 10.38 .mu.mol) in DCM (1 mL) was
treated with TFA (1 mL, 12.9 mmol) and stirred at room temperature
for three hours. The reaction mixture was concentrated and
dissolved in a small amount of MeOH and purified by reversed phase
HPLC (YMC ODS-A 5 um 30.times.250 mm, 10-90% aqueous methanol
containing 0.1% TFA, 25 mL/min., 20 min. gradient, monitored at 220
nm) to give Example 244, (1.2 mg, 22.12% yield). HPLC: Rt=3.178
min. (YMC S5 ODS 4.6.times.50 mm, 10-90% aqueous methanol
containing 0.2% H.sub.3PO.sub.4, 4 min. gradient, monitored at 220
nm). MS (ES): m/z=362.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 11.09-11.33 (1H, m), 9.70 (1H, s), 8.15
(1H, s), 7.82-8.05 (2H, m), 7.51-7.67 (2H, m), 6.24 (1H, s), 1.01
(6H, t, J=6.80 Hz), 0.72-0.86 (2H, m, J=5.54 Hz), 0.53-0.72 (2H, m,
J=2.77 Hz).
Example 245
8-(Cyclopropylamino)-6-((3-((2-(dimethylamino)ethyl)amino)-5-(4H-1,2,4-tri-
azol-4-yl)phenyl)amino)imidazo[1,2-b]pyridazine-3-carbonitrile
##STR00449##
[0658] A mixture of Example 36 (30 mg, 0.090 mmol) and
1-methylpiperazine (100 mL) in NMP (1 mL) was heated in a microwave
at 160.degree. C. for 1 hour and 15 min. The reaction mixture was
purified by prep HPLC. The fractions were concentrated, diluted
with saturated aqueous NaHCO.sub.3 and extracted with EtOAc. The
organic phase was dried with Na.sub.2SO.sub.4, filtered,
concentrated, and purified by flash chromatography, silica gel (4
g, stepwise gradient from 100% dichloromethane to 10%
methanol/dichloromethane) to give Example 245 (8.0 mg, 21% yield)
as a white solid. HPLC: Rt=2.608 min. (CHROMOLITH.RTM. column 4
6.times.50 mm eluting with 10-90% aqueous methanol over 4 min.
containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS (ES):
m/z=414 [M+H].sup.+.
Example 246
6-((3-Cyano-5-(4-morpholinyl)phenyl)amino)-8-(cyclopropylamino)imidazo[1,2-
-b]pyridazine-3-carbonitrile
##STR00450##
[0660] Example 246 was prepared from Example 36 and morpholine
following the procedure employed for the preparation of Example
245. HPLC: Rt=3.466 min. (CHROMOLITH.RTM. column 4 6.times.50 mm
eluting with 10-90% aqueous methanol over 4 min. containing 0.1%
TFA, 4 mL/min., monitoring at 220 nm). MS (ES): m/z=401
[M+H].sup.+.
Example 247
6-((3-Cyano-4-(4-morpholinyl)phenyl)amino)-8-(cyclopropylamino)imidazo[1,2-
-b]pyridazine-3-carbonitrile
##STR00451##
[0662] Example 247 was prepared from Example 25 and morpholine
following the procedure employed for the preparation of Example
245. HPLC: Rt=3.188 min. (CHROMOLITH.RTM. column 4 6.times.50 mm
eluting with 10-90% aqueous methanol over 4 min. containing 0.1%
TFA, 4 mL/min., monitoring at 220 nm). MS (ES): m/z=401
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 9.52
(1H, s), 8.21 (1H, d, J=2.77 Hz), 8.14 (1H, s), 7.93 (1H, s), 7.77
(1H, dd, J=8.94, 2.64 Hz), 7.20 (1H, d, J=9.07 Hz), 6.18 (1H, s),
3.70-3.82 (4H, m), 3.03-3.11 (4H, m), 2.51-2.59 (1H, m), 0.76-0.86
(2H, m), 0.62-0.71 (2H, m).
Example 248
6-((3-Cyano-4-(4-methyl-1-piperazinyl)phenyl)amino)-8-(cyclopropylamino)im-
idazo[1,2-b]pyridazine-3-carbonitrile
##STR00452##
[0664] Example 248 was prepared from Example 25 and
1-methylpiperazine following the procedure employed for the
preparation of Example 245. HPLC: Rt=3.188 min. (CHROMOLITH.RTM.
column 4 6.times.50 mm eluting with 10-90% aqueous methanol over 4
min. containing 0.1% TFA, 4 mL/min., monitoring at 220 nm). MS
(ES): m/z=401 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 9.47 (1H, s), 8.19 (1H, d, J=2.77 Hz), 8.13 (1H, s),
7.92 (1H, s), 7.74 (1H, dd, J=9.06, 2.52 Hz), 7.18 (1H, d, J=9.06
Hz), 6.17 (1H, s), 3.01-3.13 (4H, m), 2.42-2.60 (5H, m), 2.25 (3H,
s), 0.74-0.87 (2H, m), 0.61-0.71 (2H, m).
Example 249
N-(3-((3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)phen-
yl)sulfamide
##STR00453##
[0666] Sulfamoyl chloride (0.017 mL, 0.034 mmol; 2M solution in
MeCN) was added to an ice-cold solution of 3A (0.0073 g, 0.017
mmol) and DIEA (6.59 .mu.L, 0.038 mmol) in DCM (0.5 mL) under
nitrogen. The resulting solution was stirred for 30 min. The
reaction was quenched with water and partitioned between water and
DCM, whereupon a precipitate formed. The reaction mixture was
filtered, and the filtrate was concentrated. The residue was
dissolved in DCM (0.2 mL) and treated with triethylsilane (10.9
.mu.L, 0.069 mmol) and TFA (0.2 mL) and stirred at room temperature
for 20 min. Volatiles were removed via a stream of nitrogen, and
the solid was dissolved in DMF and purified via preparatory HPLC
using an YMC ODS C-18 column (30.times.250 mm), 0%-100% B. Solvent
B: (90% MeOH, 10% H.sub.2O, 0.1% TFA). Solvent A: (10% MeOH, 90%
H.sub.2O, 0.1% TFA). Gradient, start % B=0, final % B=100, gradient
time 180 min. (total run time 200 min.), flow rate 25 mL/min.
(monitoring at 254 nm). The appropriate fractions were concentrated
in vacuo, and the remaining residue was suspended in 2 mL 1:1
MeCN/1N HCl and lyophilized overnight, furnishing Example 249
(0.002 g, 28% yield) as a light yellow solid. HPLC: Rt=3.390 min.
(YMC S50DS-A column (4.6.times.50 mm) 0%-100% B. Solvent B: (90%
MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4). Solvent A: (10% MeOH,
90% H.sub.2O, 0.2% H.sub.3PO.sub.4). Gradient, start % B=0, final %
B=100, gradient time 4 min., hold at 100% 1 min., flow rate 4
mL/min.). MS (ES): m/z=385.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.99 (1H, s), 7.57 (1H, s), 7.44 (1H, d,
J=1.76 Hz), 7.23 (1H, d, J=8.06 Hz), 6.84 (1H, d, J=1.51 Hz), 6.36
(1H, s), 3.68-3.74 (1H, m), 2.86 (1H, s), 2.62 (1H, s), 1.82-1.89
(1H, m), 1.39 (1H, s), 1.27-1.34 (1H, m), 0.85-0.94 (2H, m), 0.67
(2H, s).
Example 250
1-(3-((3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)phen-
yl)-3-methylurea
##STR00454##
[0668] To a solution of 3A (0.065 g, 0.153 mmol) in DCM (1 mL) at
0.degree. C. was added methylisocyanate (9.15 mg, 0.16 mmol). The
reaction was slowly warmed to 22.degree. C. and stirred overnight.
The reaction mixture was filtered, and the solid was washed with
cold DCM. The solid was then dissolved in THF and concentrated in
vacuo, revealing a light tan solid, which was dissolved in a
solution containing 1:1 TFA/DCM and 0.1 mL triethylsilane. The
mixture was stirred at 22.degree. C. for 30 min. The volatiles were
removed via a stream of nitrogen, and the residue was taken up in
EtOAc/DCM, whereupon a precipitate formed. The solid was filtered
and washed with DCM and dried overnight. The resulting solid was
taken up in 1N HCl (2 mL) and lyophilized overnight, furnishing
Example 250 (0.041 g, 67% yield) as a white solid. HPLC: Rt=3.573
min. (YMC S50DS-A column (4.6.times.50 mm) 0%-100% B. Solvent B:
(90% MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4). Solvent A: (10%
MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4). Gradient, start % B=0,
final % B=100, gradient time 4 min., hold at 100% 1 min., flow rate
4 mL/min.). MS (ES): m/z=363.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.24 (1H, s), 8.45 (1H, s), 8.11 (1H, s),
7.81 (1H, s), 7.62 (1H, dd, J=8.06, 1.26 Hz), 7.50 (1H, d, J=1.76
Hz), 7.12 (1H, t, J=8.18 Hz), 6.82-6.92 (1H, m), 6.29 (1H, s),
5.95-6.13 (1H, m), 2.60-2.67 (3H, m), 2.43-2.55 (1H, m), 0.73-0.83
(2H, m), 0.58-0.69 (2H, m).
Example 251
N-(5-((3-Cyano-8-((5-hydroxy-2-pyridinyl)amino)imidazo[1,2-b]pyridazin-6-y-
l)amino)-2-methylphenyl)acetamide
##STR00455##
[0670] To a suspension of Example 5 (65 mg, 0.15 mmol) in DCM (4
mL) was added BBr.sub.3 (1.0 M solution, 1.52 mL, 1.52 mmol)
dropwise at room temperature under nitrogen, and the resulting
suspension stirred at ambient temperature for 1 hour. An additional
amount of BBr.sub.3 (1.0 M solution, 0.5 mL, 0.5 mmol) was added
and the mixture was stirred at ambient temperature for 18 hours.
The reaction was quenched with water, and neutralized to pH 8 with
1 N NaOH. The resulting mixture was stirred at ambient temperature
for 40 minutes, and the solid was collected by filtration, rinsed
with water and air dried. The residue was purified by reverse phase
HPLC, and lyophilized with 1.0 N HCl to give Example 251, (34.5 mg,
0.083 mmol, 54.8% yield). HPLC: Rt=3.428 min. (YMC S5 ODS
(4.6.times.50 mm) 0%-100% B. Solvent B: (90% MeOH, 10% H.sub.2O,
0.2% H.sub.3PO.sub.4). Solvent A: (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4). Gradient, start % B=0, final % B=100, gradient
time 4 min., hold at 100% 1 min., flow rate 4 mL/min.). MS (ES):
m/z=415.0 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 9.74 (1H, s), 9.37 (1H, s), 9.20 (1H, s), 8.16 (1H, s), 7.95
(1H, s), 7.91 (1H, d, J=2.76 Hz), 7.59-7.67 (2H, m), 7.32 (1H, d,
J=9.04 Hz), 7.19 (1H, dd, J=8.78, 3.01 Hz), 7.07 (1H, d, J=8.28
Hz), 6.88-6.95 (1H, m).
Example 252
N-(5-((3-Cyano-8-((5-(2-hydroxyethoxy)-2-pyridinyl)amino)imidazo[1,2-b]pyr-
idazin-6-yl)amino)-2-methylphenyl)acetamide
##STR00456##
[0672] To a solution of Example 251 (15 mg, 0.036 mmol) in DMF (0.5
mL) was added 2-bromoethanol (0.013 mL, 0.18 mmol), followed by
K.sub.2CO.sub.3 (20.01 mg, 0.145 mmol), and the resulting
suspension was stirred at 100.degree. C. overnight. The insoluble
material was filtered off, and the mother liquor was purified by
reverse phase HPLC. The appropriate fractions were concentrated.
The residue was dissolved in a small amount of CH.sub.3CN, diluted
with 0.5 N HCl, and lyophilized to yield Example 252 (6.86 mg,
0.012 mmol, 33.2%). HPLC: Rt=3.481 min. (YMC S5 ODS column
(4.6.times.50 mm) 0%-100% B. Solvent B: (90% MeOH, 10% H.sub.2O,
0.2% H.sub.3PO.sub.4). Solvent A: (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4). Gradient, start % B=0, final % B=100, gradient
time 4 min., hold at 100% 1 min., flow rate 4 mL/min.). MS (ES):
m/z=459.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 9.94 (1H, s), 9.49 (1H, s), 9.29 (1H, s), 8.25 (1H, s),
8.05-8.12 (2H, m), 7.71 (2H, s), 7.50 (2H, d, J=1.76 Hz), 7.15 (1H,
d, J=8.28 Hz), 4.06-4.10 (2H, m), 3.74 (2H, t, J=4.89 Hz), 3.51
(1H, s), 2.17 (3H, s), 2.07 (3H, s).
Example 253
3-(6-(3-Acetamido-4-methylphenylamino)-3-cyanoimidazo[1,2-b]pyridazin-8-yl-
amino)-N-(2-(dimethylamino)ethyl)benzamide
##STR00457##
[0673] 253A: tert-Butyl 3-(4-methoxybenzylamino)benzoate
##STR00458##
[0675] 253A was prepared from 4-methoxybenzaldehyde and tert-butyl
3-aminobenzoate following the procedure as described in 4A. HPLC:
Rt=3.82 min. (PHENOMENEX.RTM. Luna C18 4.6.times.30 mm 3u, A10-90%
aqueous methanol containing 0.1% TFA in 2 min; 4 mL/min flow). MS
(ES): m/z=314.0 [M+H].sup.+.
253B: tert-Butyl
3-((6-chloro-3-cyanoimidazo[1,2-b]pyridazin-8-yl)(4-methoxybenzyl)amino)b-
enzoate
##STR00459##
[0677] 253B was prepared from 253A and a mixture of 1F following
the procedure as described in 1G. HPLC: Rt=4.99 min.
(PHENOMENEX.RTM. Luna C18 4.6.times.30 mm 3u, A10-90% aqueous
methanol containing 0.1% TFA in 2 min; 4 mL/min flow). MS (ES):
m/z=490.1 [M+H].sup.+.
253C:
346-Chloro-3-cyanoimidazo[1,2-b]pyridazin-8-yl)(4-methoxybenzyl)amin-
o)benzoic acid
##STR00460##
[0679] A solution of 253B (100 mg, 0.20 mmol) in acetonitrile (5
mL) was treated with iodine (15.54 mg, 0.061 mmol) and water (50
.mu.L, 2.78 mmol). The reaction mixture was stirred at 80.degree.
C. for 8 hours. The reaction mixture was diluted with ethyl
acetate, and washed with water. The aqueous layer was extracted
with ethyl acetate (4.times.20 mL). The pooled organic phase was
dried over Na.sub.2SO.sub.4 and concentrated. The residue was
triturated with DCM and filtered. The filtrate was concentrated,
dissolved in DCM, and purified by flash chromatography, silica
column (12 g, gradient elution from hexanes-ethyl acetate in 15
min.). The appropriate fraction was concentrated under reduced
pressure and dried in vacuo to yield 253C (57.5 mg, 64.9% yield) as
a yellow solid. HPLC: Rt=4.23 min. (PHENOMENEX.RTM. Luna C18
4.6.times.30 mm 3u, A10-90% aqueous methanol containing 0.1% TFA in
2 min; 4 mL/min flow). MS (ES): m/z=434.0 [M+H].sup.+.
253D:
3-((6-Chloro-3-cyanoimidazo[1,2-b]pyridazin-8-yl)(4-methoxybenzyl)am-
ino)-N-(2-(dimethylamino)ethyl)benzamide
##STR00461##
[0681] A stirred solution of 253C (55 mg, 0.127 mmol) in DMF (1.0
mL) was treated with N.sup.1,N.sup.1-dimethylethane-1,2-diamine
(0.021 mL, 0.190 mmol), BOP (72.9 mg, 0.165 mmol) and TEA (0.035
mL, 0.254 mmol), and the reaction mixture was stirred at ambient
temperature for 1 hour. The reaction mixture was concentrated,
triturated with water, and the resulting white solid was collected
by filtration to yield 253D (60.0 mg, 93.7% yield). HPLC: Rt=3.47
min. (PHENOMENEX.RTM. Luna C18 4.6.times.30 mm 3u, A10-90% aqueous
methanol containing 0.1% TFA in 2 min; 4 mL/min flow). MS (ES):
m/z=504.1 [M+H].sup.+.
Example 253
3-(6-(3-Acetamido-4-methylphenylamino)-3-cyanoimidazo[1,2-b]pyridazin-8-yl-
amino)-N-(2-(dimethylamino)ethyl)benzamide
##STR00462##
[0683] Example 253 was prepared from 253D and
N-(5-amino-2-methylphenyl)acetamide following the procedure as
described in Example 6. HPLC: Rt=3.110 min. (YMC S5 ODS
(4.6.times.50 mm) 0%-100% B. Solvent B: (90% MeOH, 10% H.sub.2O,
0.2% H.sub.3PO.sub.4). Solvent A: (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4). Gradient, start % B=0, final % B=100, gradient
time 4 min., hold at 100% 1 min., flow rate 4 mL/min.). MS (ES):
m/z=512.2 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
ppm 10.04 (1H, br. s.), 9.52-9.58 (2H, m), 9.21 (1H, s), 8.94 (1H,
t, J=5.52 Hz), 8.18 (1H, s), 7.87 (1H, s), 7.59-7.63 (2H, m),
7.44-7.54 (2H, m), 7.06 (1H, d, J=8.28 Hz), 6.81-6.85 (1H, m), 3.59
(3H, q, J=5.69 Hz), 3.24 (2H, q, J=5.86 Hz), 2.73-2.84 (6H, m),
2.08 (3H, s), 1.98 (3H, s).
Example 254
3-((3-Cyano-6-((3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)phenyl)amino)imidaz-
o[1,2-b]pyridazin-8-yl)amino)-N-methyl-N-(1-methyl-3-pyrrolidinyl)benzamid-
e
##STR00463##
[0684] 254A:
3-((6-Chloro-3-cyanoimidazo[1,2-b]pyridazin-8-yl)(4-methoxybenzyl)amino)--
N-methyl-N-(1-methylpyrrolidin-3-yl)benzamide
##STR00464##
[0686] A stirred solution of 253C (500 mg, 1.152 mmol) in DMF (1
mL) was treated with N,1-dimethylpyrrolidin-3-amine (0.217 mL, 1.73
mmol), BOP (663 mg, 1.5 mmol) and TEA (0.32 mL, 2.30 mmol), and the
reaction mixture was stirred at room temperature for 1 hour. The
reaction mixture was triturated with water, and the solid was
collected by filtration and dried in vacuo to obtain 254A (337 mg,
0.636 mmol, 55.2% yield) as a light grey solid. HPLC: Rt=1.56 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 0 to 100 B in 2
min. with 1 min. hold time, flow rate=5 mL/min., detection at 254
nm, Solvent A: 10% methanol/90% water/0.1% TFA; solvent B: 10%
water/90% methanol/0.1% TFA). MS (ES): m/z=531.97 [M+H].sup.+.
Example 254
3-((3-Cyano-6-((3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)phenyl)amino)imidaz-
o[1,2-b]pyridazin-8-yl)amino)-N-methyl-N-(1-methyl-3-pyrrolidinyl)benzamid-
e
##STR00465##
[0688] Example 254 was prepared from 254A and
3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)aniline by utilizing the
procedure as described in Example 6. HPLC: Rt=1.53 min.
(PHENOMENEX.RTM. Luna 5 micron C18 4.6.times.30 mm, 0 to 100 B in 2
min. with 1 min. hold time, flow rate=5 mL/min., detection at 254
nm, Solvent A: 10% methanol/90% water/0.1% TFA; Solvent B: 10%
water/90% methanol/0.1% TFA). MS (ES): m/z=579.13 [M+H].sup.+.
Example 255
3-((3-Cyano-6-((3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)phenyl)amino)imidaz-
o[1,2-b]pyridazin-8-yl)amino)-N-(2-(dimethylamino)ethyl)benzamide
##STR00466##
[0690] Example 255 was prepared from 253D and
3-methoxy-5-(5-methyl-1H-tetrazol-1-yl)aniline following the
procedure as described in Example 6. HPLC: Rt=3.11 min. (YMC S5 ODS
4.6.times.50 mm, 10-90% aqueous methanol containing 0.2%
H.sub.3PO.sub.4, 4 min. gradient, monitored at 220 nm). MS (ES):
m/z=512.2 [M+H].sup.+.
Example 256
2-(5-((3-Cyano-8-(cyclopropylamino)imidazo[1,2-b]pyridazin-6-yl)amino)-2-m-
ethylphenyl)acetamide
##STR00467##
[0692] A mixture of 1G (50 mg, 0.14 mmol),
2-(5-amino-2-methylphenyl)acetic acid (46.7 mg, 0.17 mmol),
Pd.sub.2(dba).sub.3 (12.9 mg, 0.014 mmol), xantphos (16.4 mg, 0.028
mmol), copper (I) iodide (13.5 mg, 0.071 mmol) and Cs.sub.2CO.sub.3
(184 mg, 0.56 mmol) in DMA (1 mL) was purged with nitrogen and
heated at 125.degree. C. After 5 hours, the reaction mixture was
diluted with 10% methanol/chloroform and filtered through a short
silica gel column washing with 10% methanol/dichloromethane wash.
The filtrate was concentrated and purified by reverse phase HPLC.
The fractions were concentrated and dissolved in DCM (0.5 mL) and
treated with (2,4-dimethoxyphenyl)methanamine (31.2 mg, 0.19 mmol),
TEA (0.043 m, 0.31 mmol) and HATU (47.3 mg, 0.12 mmol). The
reaction mixture was at room temperature for 30 minutes,
concentrated, and then dissolved in DCM (0.5 mL), and treated with
triethylsilane (0.2 mL) and TFA (1 mL) and heated at 60.degree. C.
for 40 min. The reaction mixture was concentrated and purified
using reverse phase HPLC to isolate Example 256 (6.2 mg, 12% yield)
as a white solid. HPLC: Rt=2.77 min. (BEH C18 2.1.times.50 mm,
1.7u, 0 to 100 B in 1 min. with 0.5 min. hold time, flow rate=1
mL/min., detection at 254 nm, Solvent A:100% water/0.1% TFA;
Solvent B: 100% ACN1/0.1% TFA). MS (ES): m/z=362 [M+H].sup.+.
* * * * *